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Mitochondrial dynamics in demyelinated axons in a
cerebellar slice culture system
Axonal degeneration is the major cause of disability in progressive
multiple sclerosis (MS). It has been shown that in MS and relevant disease
models, demyelinated axons harbor an increased number of mitochondria,
which is reflected in bigger stationary sites of mitochondria, increased
mitochondrial activity and increased transport speed of mitochondria. This
axonal response of mitochondria to demyelination (ARMD) is protective, as
there is an increase in energy demand due to the redistribution of sodium
channels along the axon following demyelination. However, it remains to be
determined how this ARMD is mounted and how mitochondrial dynamics
are involved. By using in vivo and in vitro systems we are determined to
elucidate the transport and fusion dynamics of the ARMD and where these
additional mitochondria come from. Using a cerebellar slice culture system
with lysolecithin induced demyelination, we show that the increase in
mitochondrial occupancy of the axon already occurs at 24 hours after
demyelination and plateaus around 3 to 4 days after demyelination. At 24
hours, there was a steep increase in the mitochondrial numbers inside the
axon, which is then followed by an increase in mitochondrial size over the
following days. All parameters decrease again over the following days, but
remain elevated compared to baseline even 12 days after demyelination. To
determine the source of these additional mitochondria and to assess the
fusion dynamics within the axon, we used a lentivirus expressing a
mitochondrial targeted photoconvertible dye (mEOS2) to label
mitochondria in Purkinje cells. The mitochondria that are labelled green in
the Purkinje cell axons are then photoconverted to red by illuminating the
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initial part of the axon with a 405-nm laser and imaged over the following
20 minutes to determine the transport and fusion dynamics. This showed an
increased number of mitochondria moving from the cell body into the axon,
as well as an increase in retrograde transport of mitochondria in the
demyelinated compared to the myelinated axons. Furthermore the size of
newly transported mitochondria and their speed was increased in the
anterograde direction. Furthermore, the fusion rate of newly transported
mitochondria with stationary converted mitochondria was increased in the
demyelinated axons compared to myelinated control. These changes can
also be observed in unmyelinated axons, as well as axons of cerebellar slices
of the dysmyelinating shiverer mutant with or without lysolecithin
treatment. The manipulation of mitochondrial dynamics after
demyelination with the fission inhibitor mdivi-1 and the ATPase inhibitor
oligomycin both showed an increasing or decreasing effect on the
mitochondrial parameters after demyelination respectively. The effect on
the axonal health after demyelination was detrimental with both of these
treatments. Increasing mitochondrial biogenesis with pioglitazone
increased axonal mitochondrial parameters, as well as ameliorated axonal
damage after demyelination with lysolecithin. As the neuronal cell bodies in
MS harbour mitochondrial DNA deletions, which affects their physiology,
including energy production efficiency, another aim of this thesis was to
model this deficiency in vitro. As it was not possible to model these
mitochondrial defects in vitro within the experiments of this thesis, the
characterization of a mitochondrial mutant in vivo model was done as a




Multiple sclerosis (MS) is an incurable disease of the central nervous
system affecting around 2.5 million people worldwide. MS usually presents
first in young adults, disrupting their lives and future outlooks, with
symptoms like numbness, weakness in the limb, vertigo or blurred vision.
During the relapsing stage of the disease, these symptoms may improve and
worsen again, but once the disease gets to the progressive stage, typically a
continuous worsening of symptoms is observed. While there are therapies
available that modify the relapsing-remitting stage of the disease, there are
no therapies approved that stop the continuous degeneration of the nerve
cells and their processes, which can be found from the beginning of
diagnosis and goes into high gear during the progressive stage of the
disease. It has been shown that the loss of axons, long processes of the nerve
cells that send output signals to other nerve cells, is the best correlator of
clinical disability in MS. These axons are surrounded by an insulating layer,
which enhances signal transduction efficiency along the axon and supports
the axon with nutrients, called myelin, that is lost during the process of
demyelination which is widespread in MS, both in the white matter where
the axons reside, as well as in the grey matter of the cell bodies. It was
shown previously in MS autopsy tissue and relevant disease models that
upon demyelination there is an increase of mitochondria, the powerhouses
of the cell, inside the demyelinated axons. This response to the loss of
myelin is protecting the axon from degeneration following demyelination,
which is caused by the increase in energy demand and subsequent
detrimental processes. Currently it is not known where these additional
mitochondria, that are found in the demyelinated axon, are coming from
and how the dynamics of this vital organelle develop in the axon after the
loss of myelin. Here we show that the dynamics of these mitochondria
change significantly after demyelination and that these mitochondria are
transported from the cell body into the axon and are bigger and faster than
mitochondria in the myelinated axons. We also show that this reaction of
mitochondria reaches a peak a few days after demyelination and lessens
again thereafter, without ever coming down to control levels. We also tried
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to manipulate this mitochondrial response to test the effect on axonal health
after demyelination and found that there was a significant amelioration
when enhancing mitochondrial production. Lastly we tried to model
mitochondrial deficiency, the reduced ability to generate energy, which is
widespread in MS nerve cells and determined effect of mitochondrial
deficiency on synapses, which have also been shown to be lost in MS.
In summary these experiments stress the importance of the nerve cell
bodies, which are still mostly intact in the progressive stage of this disease,
as they supply the much needed energy producing mitochondria into the
vulnerable demyelinated axon. More importantly we show that
manipulating mitochondrial dynamics, for example the production of new
mitochondria, is a treatment target to tackle the widespread axonal loss seen
in the progressive stage of MS and possibly could improve the clinical
outcome of this devastating disease.
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1.1.1 Disease course and etiology
Multiple sclerosis (MS), is an inflammatory disease of the central nervous
system (CNS) of unknown etiology and is the second most frequent cause of
disability in young adults (Noseworthy et al., 2000; Compston and Coles,
2002). The clinical manifestation of MS is very heterogenous, because it can
affect many different part of the CNS (Ghasemi, 2017). This heterogeneity is
also reflected in the pathological features of MS, as there are many different
cell types involved in the disease process (Popescu, Pirko, and Lucchinetti,
2013). For the diagnosis of MS the most important tool, apart from
neurological exams, is the magnetic-resonance-imaging (MRI) method, as it
allows for non-invasive imaging of the brain, although some lesions,
especially grey matter lesions, are not revealed by the MRI (McDonald et al.,
2001; Polman et al., 2011; Miller, 1995; Miller et al., 1998). As for the disease
course, officially there are still 3 different types of MS disease courses
recognized at the onset of disease, however there is an ongoing debate as to
whether classify the different subgroups of MS as one disease (Confavreux
and Vukusic, 2006; Lublin et al., 2014; Barnett et al., 2009). The 3 different
types mentioned are the relapsing-remitting (RRMS) type, which affects
around 85% of newly diagnosed patients (Confavreux and Vukusic, 2006;
Lublin et al., 2014; Dutta and Trapp, 2014). RRMS is characterized by
relapses, with disease worsening, and subsequent remission, where the
disease symptoms may improve again (Confavreux and Vukusic, 2006;
Lublin et al., 2014; Dutta and Trapp, 2014). The second type of MS is the
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primary-progressive MS (PPMS), which presents as a steady decline in
neurological symptoms without relapses or remission (Confavreux and
Vukusic, 2006; Lublin et al., 2014; Dutta and Trapp, 2014). The last type of
MS that affect newly diagnosed patients, is the so-called
relapsing-progressive MS (PRMS), which presents itself with relapses
without phases of remission and steady worsening of clinical symptoms
(Confavreux and Vukusic, 2006; Lublin et al., 2014). About 80% of the RRMS
cases will develop the secondary-progressive MS (SPMS) disease course
over 10-15 years, which judging from the clinical symptoms is similar to the
PPMS disease course (Confavreux and Vukusic, 2006; Lublin et al., 2014).
There are several therapies licensed for RRMS, that are mostly
immune-regulatory or immune-suppressive and are categorized in first-line
and escalation therapies (Polman et al., 2006; Wingerchuk and Carter, 2014;
Gold et al., 2012; Fox et al., 2012; Comi et al., 2009). On the other hand, with
the CD20 antibody Ocrelizumab there is only one therapy available for
PPMS, which was only licensed recently (Montalban et al., 2017). Another
compound possibly affecting disease progression in PMS is MD1003, which
is high dose biotin and showed improvement in EDSS in a subgroup of
patients during a Phase II trial (Tourbah et al., 2016).
In RRMS blood-brain-barrier (BBB) disruption is seen frequently,
especially during disease relapses, while the inflammatory processes taking
place in the progressive stage of the disease seem to be taking place behind
a closed BBB (Minagar and Alexander, 2003; Mahad, Trapp, and Lassmann,
2015). The genetics of MS are also very heterogenous, as no gene was
identified as being directly responsible for MS, but several
genome-wide-association-studies (GWAS) have revealed over 100 genes,
mostly immune-related genes like the HLA locus, associated with the
disease (Compston and Sawcer, 2002; Akesson et al., 2002; Sawcer et al.,
2002; Hafler et al., 2007; Allen et al., 1994). The fact that women are twice as
much affected compared to men, suggests that hormones might play an
important role in disease development, there are also therapies in
development that involve hormone related drug targets (Goldenberg, 2012;
Gold and Voskuhl, 2009). Also, environmental factors, such as sunlight and
subsequent Vitamin D production seem to play a role in the etiology of MS,
as people further away from the equator are more affected by the disease
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(Hayes, 2000; Holick, 2007). There is also the hypothesis that a virus might
be responsible for the development of multiple sclerosis, the main candidate
is the Epstein-Barr-virus, which belongs the family of herpes-viruses
(HHV-4) and also other members of the herpes viruses have been implicated
in MS etiology (Lipton et al., 2007; Warner and Carp, 1988). Another disease
triggering factor might be of bacterial origin, for example a bacterial toxin,
as the case of a woman with MS with Clostridium perfringens type B
infection demonstrated (Rumah et al., 2013). The mechanism for the
autoimmune response seen in MS, could be molecular mimicry, or the tissue
damage could be a result of the immune cells trying to destroy the infection
and damaging the surrounding neuronal tissue in the process (Olson et al.,
2001; Croxford, Olson, and Miller, 2002).
1.1.2 MS pathology
MS was considered a classical demyelinating disease, in which
inflammation plays the main role of destruction of the myelin surrounding
the axons (Love, 2006). While demyelination and inflammation are
important factors in the pathology of MS, other factors, such as neuronal
damage and astrogliosis are also considered pathological hallmarks of the
disease (Ferguson et al., 1997; Fawcett and Asher, 1999; Bitsch et al., 2000a;
Stichel and Muller, 1998; Popescu, Pirko, and Lucchinetti, 2013; Lassmann,
2013; Kutzelnigg and Lassmann, 2014). As mentioned above for many years
the focus in MS research was the demyelination occurring in the white
matter of the brain, because MS was long considered a disease affecting
mainly the white matter of the brain, but during the last decades the grey
matter (GM) damage, which plays a key role in MS progression, as there are
several kinds of GM lesions occurring, sometimes very early in the disease
course, came more into focus (Popescu and Lucchinetti, 2012a). These GM
lesions are recognized as leukocortical lesion, which expand in the GM as
well as in the WM, intracortical lesion, which like the name suggests are
found inside the GM and subpial lesion, which are the only lesion type
specific for MS (Popescu and Lucchinetti, 2012a; Bo et al., 2003). The
heterogeneity of the disease mentioned in the previous section, also extends
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to the pathology of MS lesions, as lesions are very heterogeneous between
MS patients (Lassmann, Bruck, and Lucchinetti, 2001; Metz et al., 2014).
MS lesion can be categorized into four distinct lesion patterns,
depending on the type of cells present within the lesion and the type of
myelin protein degradation products within the cells (Lassmann, Bruck, and
Lucchinetti, 2001). Furthermore the stage of the demyelinating lesion in MS
can be subdivided according to their stage, classical active lesion are
characterized by a substantial infiltration of macrophages that contain
myelin degradation products and these lesions can be further described
according to which myelin products are found within the macrophages,
with the minor myelin products being found early and the major myelin
products later during the lesion timecourse (Brück et al., 1995; Popescu and
Lucchinetti, 2012b; Bitsch et al., 2000a). Chronic active plaques, which are
mostly found in patients during the progressive phase of the disease, show
sharp lesion edges with a rim of macrophages around the inactive lesion
center (Brück et al., 1995; Popescu and Lucchinetti, 2012b; Bitsch et al.,
2000a). Finally chronic inactive lesion, which are completely demyelinated
and show a significant loss of axons and oligodendrocytes within the lesion,
while they only display minor infiltration by macrophages or other immune
cells (Brück et al., 1995; Popescu and Lucchinetti, 2012b; Bitsch et al., 2000a).
In some cases remyelinated shadow plaques can be found, displaying thin
myelin sheaths around the axon and only faint histochemical signal for
myelin (Brück et al., 1995; Popescu and Lucchinetti, 2012b; Bitsch et al.,
2000a).
Outside-in or inside-out
Although most of the lesions show lymphocyte infiltration either directly in
the lesion or nearby, a study that showed 12 RRMS patients autopsy cases,
who died shortly after the onset of a MS relapse suggested that the early MS
lesion does not contain infiltrating lymphocytes (Barnett and Prineas, 2004).
This finding fuelled the so-called inside-out hypothesis of MS, that the
oligodendrocytes die because of some intrinsic factor and the immune cells
infiltrate the brain as a reaction to the damage (Barnett and Prineas, 2004;
Prineas and Parratt, 2012; Tsunoda and Fujinami, 2002). The more
prominent theory to this date is the outside-in hypothesis of MS, which
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suggests that the infiltrating immune cells from the periphery into the brain
start the inflammatory reaction, possibly against an auto antigen resembling
one of the myelin proteins, and damaging the oligodendrocytes and axons
in the process (Lucchinetti et al., 2011; Guseo and Jellinger, 1975). Most of
the current MS therapies are targeting the immune mediated part of the
disease by either destroying, reducing, modifying immune cells or by
preventing the lymphocytes to enter the brain (Polman et al., 2006;
Wingerchuk and Carter, 2014; Gold et al., 2012; Fox et al., 2012; Comi et al.,
2009).
Modes of tissue damage
The direct correlation of T-Cells (CD8+) within the lesion with the extent of
axonal damage underlines the importance that the direct damage mediated
by immune cells plays in the destruction of tissue in MS, also the number of
macrophages within the lesion are correlated with tissue damage found
(Kuhlmann et al., 2002; Trapp et al., 1998). Another important mechanism,
also in great part mediated by the innate and adaptive immune system, is
oxidative damage, which is now recognized as a major driving factor of
tissue damage and mitochondrial injury (Kuhlmann et al., 2002; Haider
et al., 2011; Horssen et al., 2011; Dutta et al., 2006; Horssen et al., 2006).
Dysfunctional mitochondria are in turn a major source of reactive oxygen
species (ROS) and enhance the oxidative damage done by immune
mediated ROS and reactive nitrogen species (RNS) (Starkov, 2008; Orrenius,
2007). Since mitochondrial DNA is very vulnerable to oxidative damage,
mitochondrial DNA deletions are also enhanced, which amplifies the
number of dysfunctional mitochondria and leads to so-called virtual
hypoxia (Lu et al., 2000; Campbell et al., 2011; Campbell and Mahad, 2012;
Trapp and Stys, 2009). Although there are several animal models of MS, the
extent of oxidative damage in MS cases is not found in any of these models,
also mitochondrial DNA deletions were not observed (Trapp et al., 1998;
unpublished data from Mahad lab).
Another factor contributing to the degeneration of axons in multiple
sclerosis are changes in the demyelinated axon leading to an enhance
calcium concentration inside the axon (Waxman, 1992; Craner et al., 2004b;
Moll et al., 1991; Smith, 2007; Waxman, 2006). The axonal sodium channels
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used for the saltatory conduction of action potentials are normally mainly
concentrated around the node of Ranvier, these sodium channels have the
NaV1.6 subtype and are characterized by a low threshold and persistent
sodium current (Craner et al., 2004b). In the acutely demyelinated axon
potassium channels, that were hidden under the myelin are unmasked by
the process of demyelination and in addition the distribution of sodium
channels is sparse, which leads to a failure in action potential propagation
(Craner et al., 2004b; Waxman, 2006). To restore function of the axonal
conductivity, the sodium channels redistribute along the demyelinated
axon, which leads to an extensive expression of NaV1.6 and NaV1.2 sodium
channels, in addition to the unmasked potassium channels, along the axon
where the myelin was before (Craner et al., 2004b; Waxman, 2006). In
contrast to the NaV1.6 sodium channels, the NaV1.2 sodium channels
produce rapidly activating and inactivating sodium currents, which support
action potential conduction along the axon. As mentinoned above, the
NaV1.6 sodium channels produce a persistent sodium current, which leads
to higher concentration of sodium inside the demyelinated axon compared
to the myelinated axon (Craner et al., 2004b; Waxman, 2006). These NaV1.6
sodium channels are found to be co localized with Na+ − Ca2+-exchanger
(NCX) along the demyelinated axon (Craner et al., 2004a). The
accumulation of sodium inside the axon eventually leads to the reversal of
the Na+ − Ca2+-exchanger, which in turn leads to an increase in
intra-axonal accumulation of calcium (Stys et al., 1993; Stys, Waxman, and
Ransom, 1992). The accumulation of calcium inside the axon then triggers
several different signalling cascades leading to the activation of proteases
and lipases, which in turn induce axonal injury (Waxman, 2006; Kornek
et al., 2001). To pump the overload of sodium out of the axon, the Na+/K+
ATPase is used to get sodium out of the axon, while pumping potassium in,
this requires ATP to work and that means that functional mitochondria are
required to keep the ions balance favourable in order for the axon to survive
(Mohd, 2010; Albers and Siegel, 1998; Lores Arnaiz and Ordieres, 2014).
As mentioned in the beginning of the section, reactive oxygen and
nitrogen species, for example nitric oxide (NO), can trigger mitochondrial
damage, leading to dysfunctional mitochondria inside the axon
(Giovannoni et al., 1998; Smith and Lassmann, 2002). These dysfunctional
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mitochondria are not able to produce enough energy to pump the excess
sodium out of the axon, which leads to the above mentioned cascade
leading to the accumulation of intra-axonal calcium and finally axonal
injury (Coleman, 2005; Stys and Jiang, 2002; O’Hanlon et al., 2003; Xie and
Barrett, 1991).
1.2 Mitochondria
Mitochondria, which are one of the key organelles of every eukaryotic cell
and responsible for many life-maintaining functions, have once been a
single cell organism which was engulfed by another organism billion years
ago, a symbiosis between an aerobic bacterium and a primordial eukaryotic
cell (Wallace, 2005; Chan, 2006a; Cavalier-Smith, 2006). This small organelle
took over several functions from the host cell, giving it an evolutionary
advantage over other cells that did not contain mitochondria (Wallace, 2005;
Chan, 2006a; Cavalier-Smith, 2006). Besides being the power-house of most
cells, especially neurons with their high energy demand are in need of
massive amounts of adenosine triphosphate (ATP), mitochondria are
involved in many essential function, like calcium buffering, fatty acid
oxidation and apoptosis (Pinton et al., 2008; Friedman and Nunnari, 2014;
Wanders et al., 2010). Every mitochondria has its own genome containing
many copies of its 16kb sized circular mtDNA which encodes for just 37
genes, while most (900) of the genes that are needed for mitochondrial
function are encoded inside the nuclear DNA (Wallace, 2005; Chan, 2006a;
Cavalier-Smith, 2006; Iborra, Kimura, and Cook, 2004).
The proteins made from nuclear DNA have to be imported into the
mitochondria from the cytoplasm, of the 37 genes encoded by the
mitochondrial DNA, 13 are needed to make protein subunits of the
respiratory complexes I, III, IV and V, while complex II is totally encoded in
the nuclear DNA; see figure 1.1 (Wallace, 2005; Chan, 2006a; Cavalier-Smith,
2006; Iborra, Kimura, and Cook, 2004). Furthermore, there are 22
mitochondrial tRNAs and and 2 mitochondrial rRNAs, which are needed
for the translation of mtDNA (Wallace, 2005; Chan, 2006a; Cavalier-Smith,
2006; Iborra, Kimura, and Cook, 2004). The most important part of
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mitochondrial energy production is the mitochondrial respiratory chain,
which is made up of 5 complexes; see figure 1.1 (Rich and Maréchal, 2010).
FIGURE 1.1: Mitochondrial respiratory chain complexes and
their gene locations. All five complexes (I,II,III,IV,V) are
located in the inner mitochondrial membrane. The colour
code of the hexagons shows the location of the genes needed
for the assembly of each complex. White represents genes
encoded in the genomic DNA (Complex II is entirely nuclear
encoded), which have to be translated and imported into the
mitochondria. On the bottom is a schematic picture of the
mitochondrial DNA and the coding locations of the complexes.
Green=complex I; purple=complex III; yellow=complex IV;
blue=complex V. On the outer membrane sits porin, a
transmembrane protein on all mitochondria which can be
used as a mitochondrial marker in immunohistochemistry.
Complex II (SDH=succinate dehydrogenase) and complex
IV (COX=cytochrome c oxidase) activity are used in the
COX/SDH assay shown in the methods sections.
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These complexes - through a series of electron transfers – create an
electrochemical gradient between the matrix and the intermembrane space
(Rich and Maréchal, 2010). This electrochemical gradient is then used by the
ATP-Synthase (fifth complex of the respiratory chain) to generate ATP
(Jonckheere, Smeitink, and Rodenburg, 2012). Each of these complexes, with
the exception of complex II is at least partly encoded in the mitochondrial
DNA; see figure 1.1 (Iborra, Kimura, and Cook, 2004).
1.2.1 Mitochondrial turnover and dynamics
Since the mitochondria are needed for efficient energy production,
mitochondrial biogenesis and transport are important processes in coping
with the local energy demand in cells, this is even more important in
neurons with their polarized morphology and long axons (Schwarz, 2013;
Britt et al., 2016; Sheng, 2014). Adjustments to mitochondrial biogenesis and
transport allow the neuron to respond to changes in local energy demand
(Schwarz, 2013; Britt et al., 2016; Sheng, 2014). Because mitochondrial
proteins are encoded in both mitochondrial and nuclear genomes, proteins
made in the cytoplasm have to be imported into the mitochondria and
assemble with proteins synthesized in the mitochondria (Neupert, 1997;
Chacinska et al., 2009). Once the components are made the mitochondrion
may undergo fission and create a brand new mitochondrion, and the new
mitochondrion may get transported to some other part of the cell and may
fuse with other mitochondria (Chen and Chan, 2009b). The balance of
fusion and fission is an important factor determining mitochondrial
biogenesis, which makes mitochondrial biogenesis a very dynamic process
and challenging one to study (Chan, 2006a; Chen and Chan, 2009b). The
general assumption is that mitochondrial biogenesis occurs perinuclear, but
there is also evidence for axonal biogenesis (Amiri and Hollenbeck, 2008).
Severe defects in either mitochondrial fission or fusion results in embryonic
lethality in mice, pointing towards an essential part mitochondrial dynamics
of fusion and fission play in maintaining essential functions inside the cell
(Chen et al., 2003; Elgass et al., 2013; Wakabayashi et al., 2009).
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Mitochondrial fusion and fission
The fusion process allows for content mixing between the mitochondria in
the cell and the fission to isolate defective mitochondria as well as create
new functional mitochondria, that can be transported around the cell. This
creation of a mitochondrial network allows for a healthy mixing of the
mitochondrial population (Chan, 2012a; Chen et al., 2010). Apart from
content mixing, mitochondrial fusion has several other important functions,
among these respiratory chain complex activity and response to cellular
stress environments (Chan, 2012a; Westermann, 2012; Muster et al., 2010;
Cogliati et al., 2013; Youle and Bliek, 2012).
FIGURE 1.2: Mitochondrial fusion processes depicted in a
simplified graphical image, showing the mitochondrial fusion
proteins. The mitofusin (Mfn) shown in green are responsible
for the fusion of the outer mitochondrial membrane, while the
optic-atrophy-1 (OPA1) shown in orange mediates the fusion of
the inner mitochondrial membrane.
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This dynamic behaviour of mitochondria is associated with mtDNA
stability, mitochondrial protein function including respiratory chain
complex activity, apoptosis and mitophagy, as well as response to cellular
stress including increase in energy demand (Chan, 2012a; Westermann,
2012; Muster et al., 2010; Cogliati et al., 2013; Youle and Bliek, 2012; Chen
et al., 2010). The deletion of fusion mediators Mfn1, Mfn2 or OPA1 leads to
the death of mouse embryos in midgestation, further highlighting the
importance of mitochondrial fusion (Chen et al., 2003). Because
mitochondria are double membrane organelles, mitochondrial fusion has to
include fusion of the outer membrane as well as fusion of the inner
membrane between two fusing mitochondria (Chan, 2012a; Scott and Youle,
2010). Fusion of outer and inner membrane takes place more or less at the
same time after the mitochondria start to fuse (Chan, 2012a; Scott and Youle,
2010). The two GTPases Mitofusin 1 and 2 (Mfn1) and (Mfn2), which are
proteins embedded within the outer membrane of mitochondria, are
responsible for the fusion of the outer mitochondrial membrane in
mammals; see figure 1.2 (Chen et al., 2003). For the fusion of the inner
mitochondrial membrane another GTPase, named OPA1, is necessary; see
figure 1.2 (Song et al., 2007; Chan, 2012a). There is also evidence that the
mitofusins play a role in the contact between the mitochondria and the
endoplasmatic reticulum (ER), called the mitochondria associated
membranes (MAM), which have recently been implicated in multiple
sclerosis (Marchi, Patergnani, and Pinton, 2014; Haile et al., 2017b). OPA1
deficiency, which got its name optic-atrophy-1, because its mutation leads to
the most common form of optic atrophy, can lead to reduction in respiratory
chain efficiency, loss of cristae complexity and increased apoptosis, while
OPA1 conditional knockouts still retain the fusion of the inner
mitochondrial membrane, which points towards mitochondrial fusion being
a multistep process (Cogliati et al., 2013; Varanita et al., 2015; Song et al.,
2009; Frezza et al., 2006; Chan, 2012a). In contrast to the mitofusin proteins,
which are required on both mitochondria for the fusion of the outer
mitochondrial membrane to take place, OPA1 deficient mitochondria are
still able to fuse with OPA1 expressing mitochondria (Chan, 2012a). There
are eight different isoforms of OPA1, some short and some long splice
forms, a combination of short and long isoforms is required for
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mitochondria inner membrane fusion under normal conditions, but it has
been reported that under stress conditions the long isoforms are sufficient to
mediate mitochondrial fusion (Chan, 2012a; Tondera et al., 2009; Song et al.,
2007).
Opposing mitochondrial fusion, the process of mitochondrial fission is
just as necessary to keep a healthy balance of form and function within the
mitochondrial network (Chan, 2012a).
FIGURE 1.3: Mitochondrial fission processes depicted in a
simplified graphical image, showing the proteins responsible
for mitochondrial fission. The dynamin-related protein 1
(Drp1) shown in black is a GTPase mediating the constriction of
the mitochondrial membrane and subsequently mitochondrial
fission. Mitochondrial fission factor (Mff), shown in violet, and
mitochondrial fission 1 protein (FIS1), shown in brown, are
both potential candidates for interaction with Drp1.
Mitochondrial fission may also be involved in the mitochondrial
segregation process between the daughter cells after cell division (Chan,
2012a; Taguchi et al., 2007). Another GTPase, namely dynamin-related
protein 1 (DRP1), seems to be the key player mediating the fission process
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via a dynamin like constriction along the mitochondrial membrane; see
figure 1.3 (Chan, 2012a; Frank et al., 2001). Drp1 is located within the cytosol
and upon interaction with another key player mediates mitochondrial
fission, Fis1, Mff, MiD49 and MiD51 are all potential candidates for this
interaction with Drp1, with recent evidence pointing towards mitochondrial
fission factor (Mff) as being the interaction partner of Drp1, since its
knockdown leads to a reduction of Drp1 recruitment; see figure 1.3 (Liu and
Chan, 2015; Losón et al., 2013; Otera et al., 2010). Also, since Drp1 is
assembled on the mitochondrial outer membrane, it is not known which
proteins are responsible for the fission of the inner mitochondrial membrane
or if the same process is responsible for both membranes (Chan, 2012a).
Since Drp1 is needed for mitochondrial fission, deletion of Drp1 leads to
elongated mitochondria that collapse (Chan, 2012a; Smirnova et al., 2001;
Lee et al., 2004). Fission and fusion work opposing one another but also
work together in maintaining the right balance of shape, size and number of
mitochondria (Chan, 2012a). As mentioned above deletions of protein
responsible for either of this processes are embryonic lethal (Chen et al.,
2003; Elgass et al., 2013; Wakabayashi et al., 2009). That the deletion of OPA1
is as severe as the deletion of the mitofusins, points towards matrix mixing
as being an important part of mitochondrial fusion, but it has also been
reported that mitochondrial content mixing can occur when mitochondria
touch each other briefly without fusing completely, this phenomenon has
been named "kiss-and-run", which occurs frequently in a normal
functioning mitochondrial network (Song et al., 2009; Chan, 2012a; Liu et al.,
2009). This mixing of mitochondrial content is necessary because it
constantly homogenizes the content of the mitochondrial population, which
would otherwise become more and more heterogenized (Chan, 2012a; Chen,
Chomyn, and Chan, 2005).
Fusion also allows for complementation of mtDNA mutations, because
of this mitochondria can tolerate quite a high load of mutated mtDNA until
the phenotype presents itself (DiMauro and Schon, 2003; Nakada, Inoue,
and Hayashi, 2001). Loss of fusion diminishes mtDNA content, which
shows its importance for mtDNA stability (Chen et al., 2010; Chan, 2012a;
Chen, Chomyn, and Chan, 2005). Fusion is also depended on mitochondrial
membrane potential and mitochondria with low membrane potential
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cannot fuse and are subsequently degraded by mitophagy (Chan, 2012a;
Song et al., 2007; Twig et al., 2008; Legros et al., 2002). These two
mechanisms allow mitochondria that have some dysfunction to be rescued
by fusing with other functional mitochondria, while severely dysfunctional
mitochondria get singled out by fission and degraded by mitophagy (Chan,
2012a; Twig et al., 2008). Lack in fusion furthermore leads to defects in the
mitochondrial respiratory chain and diminishes the ability for stress
response (Chen et al., 2010; Chan, 2012a; Chen, Chomyn, and Chan, 2005;
Chen, McCaffery, and Chan, 2007; Chen, Liu, and Dorn, 2011).
Mitochondrial transport
Due to their distinct morphology with an axon up to one meter long
neurons in particular, but other cells as well, face the challenge to distribute
their mitochondria to sites where energy demand is high, like synapses or
nodes of ranvier, and where calcium buffering is needed (Schwarz, 2013;
Britt et al., 2016; Sheng, 2014; Lin and Sheng, 2015; Cai and Sheng, 2009;
Saxton and Hollenbeck, 2012; Sheng and Cai, 2012). To meet this challenge
neuron have a specialized transport system for mitochondria, which allows
mitochondria to be transported from the soma to the axon terminal via
anterograde transport along the microtubule network and from the axon
terminal to the soma retrogradely to the soma, mitochondria frequently
make pauses and change direction of movement (Schwarz, 2013; Britt et al.,
2016; Sheng, 2014; Lin and Sheng, 2015; Cai and Sheng, 2009; Saxton and
Hollenbeck, 2012; Sheng and Cai, 2012). In most neurons, approximately
30% of mitochondria are motile, while the vast majority remain stationary
throughout the cell, especially at places with high demand for energy or
Ca2+ buffering (Sun et al., 2013; Yi, Weaver, and Hajnóczky, 2004).
Transport of mitochondria is important to adjust to changes in energy
demand, to remove dysfunctional mitochondria and replace them with
fresh mitochondria (Lin and Sheng, 2015; Cai and Sheng, 2009; Saxton and
Hollenbeck, 2012; Sheng and Cai, 2012). Long distant transport relies on the
microtubule network, while the plus end of the microtubule in the axon
points towards the axon terminal and travel in this direction is mediated by
the kinesin motor family, therefore kinesins drive anterograde transport of
mitochondria; see figure 1.4 (Lin and Sheng, 2015; Cai and Sheng, 2009;
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Saxton and Hollenbeck, 2012; Sheng and Cai, 2012; Morris and Hollenbeck,
1995). For mitochondria the most important kinesin subtype, is the
kinesin-1 (KIF5), which has three isoforms: KIF5A, KIF5B and KIF5C
(Schwarz, 2013; Sheng, 2014; Pilling et al., 2006; Glater et al., 2006). While
KIF5B is expressed in every cell type, KIF5A and KIF5C is restricted to
neurons (Schwarz, 2013; Sheng, 2014). The kinesin transport requires ATP
hydrolysis for its function, this is mediated by the N-Terminus of the kinesin
motor protein, while the C-Terminus is responsible for cargo binding; see
figure 1.4 (Schwarz, 2013; Gilbert et al., 1995; Karcher, Deacon, and Gelfand,
2002; Marx, Hoenger, and Mandelkow, 2009). There are also two member of
the kinesin-3 family which seem to be involved in mitochondrial transport,
namely KIF1B-α and Kinesin-like-protein 6 (KLP6), but as opposed to the
kinesin-1 family their role in mitochondrial transport needs to be further
examined (Schwarz, 2013; Saxton and Hollenbeck, 2012).
FIGURE 1.4: Mitochondrial transport in the axon depicted in
a simplified graphical image, showing the proteins responsible
for axonal mitochondrial transport. The kinesin motor proteins
(green circles) are mediating anterograde transport along
the microtubules (long blue lines), while dynein (light blue
circles) mediates retrograde transport in the axon. There are
several adaptor proteins binding the mitochondria to the motor
proteins, with the TRAK (orange) proteins binding Miro1
(yellow), which is a calcium adapter protein and mediates
mitochondrial transport to energy demanding spots in the
axon. Dynactin (violet) is another adaptor protein connecting
the TRAK proteins to the dynein motor proteins. Syntaphilin
(red) acts as an anchor for mitochondria, which stops them in
their tracks and helps keeping mitochondria and places with
high energy demand.
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Dynein drives mitochondrial transport in the direction of the minus end
of the microtubule network, which in the axon is pointed toward the soma
and thus dynein mediates retrograde transport of mitochondria; see figure
1.4 (Schwarz, 2013; Saxton and Hollenbeck, 2012; Pilling et al., 2006).
Dynein contains multiple subunits, of which two heavy chains (DHC) are
catalytic subunits, furthermore there are intermediate chains (DIC), light
intermediate (DLIC) and light chains (DLC), which are responsible for ATP
hydrolysis or cargo binding (Schwarz, 2013; Saxton and Hollenbeck, 2012;
Roberts et al., 2013; Bhabha et al., 2016). Dynactin is also needed to bind to
the microtubule network as well as dynein and mediate retrograde
transport; see figure 1.4 (Schwarz, 2013; Saxton and Hollenbeck, 2012;
Drerup et al., 2017). Since mitochondria can move anterograde as well as
retrograde and dynein is attached to mitochondria moving in both
direction, it is likely that kinesins and dynein coordinate the transport of
mitochondria in concert (Schwarz, 2013; Saxton and Hollenbeck, 2012).
Mitochondria attach to the motorproteins only indirectly via specialized
adaptor proteins TRAK1 and TRAK2 in mammals, loss of either of these
proteins disturbs mitochondrial transport; see figure 1.4 (Schwarz, 2013;
Saxton and Hollenbeck, 2012; Brickley and Stephenson, 2011; Spronsen
et al., 2013). TRAK1 is responsible for axonal transport of mitochondria by
binding to both kinesins and dynein, while TRAK2 mainly mediates
dendritic transport (Schwarz, 2013; Saxton and Hollenbeck, 2012; Brickley
and Stephenson, 2011; Spronsen et al., 2013; Kimura and Murakami, 2014).
Another important protein for mitochondrial transport is the Rho
GTPase Miro, which is located at the outer mitochondrial membrane and
mediates binding of mitochondria to the TRAK1/2 proteins and therefore
attachment to the kinesin or dynein motor proteins; see figure 1.4 (Schwarz,
2013; Lin and Sheng, 2015; Saxton and Hollenbeck, 2012; Ahmad et al., 2014;
Las and Shirihai, 2014; Guo et al., 2005). Miro has four Ca2+ binding EF
hands, which mediate dissociation of mitochondria from the motor proteins
upon meeting increased calcium concentration, this directs mitochondrial
movement to sites where they are needed for the buffering of calcium (eg
synapses) (Lin and Sheng, 2015; Stephen et al., 2015b; Guo et al., 2005).
Syntabulin is another kinesin mitochondria adaptor protein, which binds
directly to the cargo binding site of the motor protein; see figure 1.4 (Cai,
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Gerwin, and Sheng, 2005; Lin and Sheng, 2015). Another important protein
that ensures mitochondria are present at sites with high energy demand, is
the mitochondrial anchor protein syntaphilin, which is an axon targeted
mitochondrial outer membrane protein; see figure 1.4 (Kang et al., 2008).
Syntaphilin mediates binding of the microtubules to to mitochondria, thus
bringing mitochondria to a stop (Kang et al., 2008). Deletion of syntaphilin
leads to robust increase in mitochondrial movement, while overexpression
abolishes mitochondrial transport in the axon (Kang et al., 2008; Sheng,
2014; Zhou et al., 2016). Syntaphilin is also required to halt mitochondrial
transport via the Miro-Ca2+ pathway, as was shown by using synphilin
knockout mice, in which activation of neurons, that normally activates
dissociation of Miro from the TRAK proteins and thus stops mitochondrial
transport, was not enough to stop mitochondria in neurons (Lin and Sheng,
2015; Chen and Sheng, 2013).
Mitochondrial changes in disease
Classical hereditary mitochondrial diseases result from mutations affecting
mitochondrial genes and mostly lead to respiratory deficiency within the 5
complexes of the respiratory chain (Chan, 2006a; Wallace, 2005; Dimauro
and Davidzon, 2005; DiMauro and Schon, 2003). There are now hundred of
point mutations or changes within DNA encoding for mitochondrial
proteins known, that lead to many different diseases, many of which affect
the CNS (Chan, 2006a). All of these classical mitochondrial disease are
maternally inherited, because the mitochondria are inherited from the
zygote and the mitochondria in the sperm are marked with ubiquitin and
targeted for degradation (Chan, 2006a; Wallace, 2005; Dimauro and
Davidzon, 2005; DiMauro and Schon, 2003). As there are many copies of
mitochondrial DNA within a single mitochondrion, the mutant DNA needs
to pass a certain threshold for the phenotype to present itself, in many of
individuals with mtDNA mutations there is still a mixture of wildtype
mitochondrial DNA and mutant mitochondrial DNA within each
mitochondrion, this state is called heteroplasmy (Chan, 2006a; Wallace,
2005; Dimauro and Davidzon, 2005; DiMauro and Schon, 2003; Hayashi
et al., 1991; Nakada et al., 2001; Chen et al., 2010). This is the reason why
most of the mitochondrial diseases progress with age, as there is an
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accumulation of mutant DNA within the mitochondria over time (Chan,
2006a).
Because neurons are particularly dependant on mitochondrial function,
they are one of the cells most easily affected by respiratory deficiency, but
most cells do not lose respiratory function until there is a high load of
mutated mtDNA, around 60%-90%, which is probably due to the dynamic
state of mitochondria, which allows for the mixture of mtDNA and wild
type via fusion with other healthy mitochondria, diluting mutated mtDNA
(Chan, 2006a; Hayashi et al., 1991; Nakada et al., 2001; Youle and Bliek, 2012;
Chen et al., 2010; Scott and Youle, 2010). Also constant mitophagy, the
degradation of defective mitochondria via the PINK1 and parkin pathway,
removes deficient mitochondria from the mitochondrial network (Bingo and
Sheng, 2016; McWilliams and Muqit, 2017; Whitworth and Pallanck, 2017).
In autopsy tissue of multiple sclerosis cases extensive neuronal damage can
be found, and the main correlate of disability is axonal loss, which in turn is
caused by inflammation, oxidative injury and demyelination of the axons
(Mahad, Trapp, and Lassmann, 2015; Peterson et al., 2001; Trapp et al., 1998).
Furthermore, it has been reported in several studies from independent
institutes, that there is a neuronal mitochondrial dysfunction within the
neurons, which in turn could lead to an energy deficiency in the neurons
and their axons and contribute to the neurodegeneration taking place in
multiple sclerosis (Dutta et al., 2006; Campbell et al., 2011; Broadwater et al.,
2011; Witte et al., 2013; Kim et al., 2010; Hares et al., 2014; Fischer et al., 2013;
Haile et al., 2017a). As reported in the section MS Pathology (1.1.2),
demyelination leads to an intra-axonal accumulation of sodium, which
needs to be pumped out of the axon by the Na+/K+ ATPase, which in turn
requires ATP and is down regulated in multiple sclerosis lesions (Mahad,
Trapp, and Lassmann, 2015; Mohd, 2010; Albers and Siegel, 1998;
Lores Arnaiz and Ordieres, 2014; Young et al., 2008).
The combination of increased energy demand with dysfunctional
mitochondria inside the axon leads to a state termed "virtual hypoxia" in the
axon, which eventually leads to calcium overload and death of the axon
(Trapp and Stys, 2009; Mahad, Trapp, and Lassmann, 2015). If the
respiratory deficient mitochondria within the neuronal cell bodies of MS
autopsy tissue reported previously, are transported to the axon to help with
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the increase in energy demand after demyelination, an additional load of
dysfunctional mitochondria would accumulate in the axon, leading to an
even further increase of ROS and tissue damage, without the adequate
energy production (Mahad, Trapp, and Lassmann, 2015). The accumulation
of mitochondria inside the axon after demyelination was already reported
previously, the question where these mitochondria come from is one of the
aims of this thesis (Mahad et al., 2009; Witte et al., 2009; Zambonin et al.,
2011; Ohno et al., 2011).
Mitochondrial changes in demyelinating diseases
Myelination of the axons not only allows for an increased speed in signal
conduction, but also accounts for an energy efficient way of signal
transmission (Mahad, Trapp, and Lassmann, 2015; Neishabouri and Faisal,
2011). As mentioned in section MS Pathology 1.1.2 in demyelinating
diseases, like MS, demyelination of axons leads to a redistribution of
NaV1.2 and NaV1.6 ion channels along the axon and increased sodium
influx into the axon (Craner et al., 2004b; Witte et al., 2014). To pump the
additional ions out of the cell, more ATP powered Na+/K+ exchangers are
needed, which increases the energy demand of the demyelinated axon
(Trapp and Stys, 2009; Mahad, Trapp, and Lassmann, 2015; Mohd, 2010;
Albers and Siegel, 1998; Lores Arnaiz and Ordieres, 2014). To cope with this
increased energy demand more mitochondria are needed at the
demyelinated site, which leads to an accumulation of mitochondria in the
demyelinated axon, as a compensatory mechanism (Mahad et al., 2009;
Witte et al., 2009; Zambonin et al., 2011; Ohno et al., 2011).
How this mitochondrial axonal response to demyelination (ARMD)
functions in detail, whether newly mitochondria are made on the site of
demyelination or transport from other sites of the cell is increased, is
currently unknown. ARMD means more mitochondria (biogenesis), more
mitochondrial activity, different morphology (more elongated through
fusion), faster mobile mitochondria (transport) (Mahad et al., 2009; Witte
et al., 2009; Zambonin et al., 2011; Ohno et al., 2011). The ARMD protects the
axons from degeneration following the increased energy demand and
increased oxidative damage after demyelination (Kiryu-Seo et al., 2010;
Ohno et al., 2014). It has also been reported that neurons in MS display a
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decrease in nuclear encoded mitochondrial genes, mitochondrial DNA
deletions and a reduction of complex IV activity (Campbell et al., 2011;
Dutta et al., 2006; Broadwater et al., 2011; Witte et al., 2013; Kim et al., 2010;
Hares et al., 2014; Fischer et al., 2013; Haile et al., 2017a). How the axonal
response of mitochondria to demyelination is impacted in neurons
harbouring mitochondrial respiratory chain defects has not been studied.
Preliminary data in the Mahad (unpublished) lab shows that in DRG
specific mitochondrial mutant mice there is a gradual decline in
mitochondrial content in myelinated axons. Upon demyelination
mitochondria deficient in respiratory chain enzymes appear in the
demyelinated axonal segment in mutants, contrasting the findings in
wild-type mice.
In summary, multiple sclerosis is characterized by inflammation,
demyelination, but also mitochondrial changes in the neuronal cell body,
namely deficiency of some respiratory chain subunits (Noseworthy et al.,
2000; Compston and Coles, 2002; Dutta et al., 2006; Campbell et al., 2011;
Broadwater et al., 2011; Witte et al., 2013; Kim et al., 2010; Hares et al., 2014;
Fischer et al., 2013; Haile et al., 2017a; Mahad, Trapp, and Lassmann, 2015).
In order to understand and model multiple sclerosis better, a disease model
needs to address these changes, while most models currently in use, only
reflect parts of the mentioned changes in multiple sclerosis, there are no
models that adequately model oxidative damage or mitochondrial
deficiency in the neurons (Schuh et al., 2014; Dutta et al., 2006; Campbell
et al., 2011; Broadwater et al., 2011; Witte et al., 2013; Kim et al., 2010; Hares
et al., 2014; Fischer et al., 2013; Haile et al., 2017a).
1.3 Hypothesis and Aim
1.3.1 Hypothesis
1. The axonal response of mitochondria to demyelination (ARMD), which
helps the axon to cope with the increased energy demand after
demyelination, is constituted by a) anterograde transport of mitochondria
from the cell body into the demyelinated axon, b) fusion of motile
mitochondria with the stationary mitochondria in the demyelinated axon
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and c) biogenesis of mitochondria in the neuronal cell body
2. The ARMD is perturbed in neurons with complex IV deficiency by the
lack of mitochondrial activity, reduction in mitochondrial numbers,
reduction in fusion and reduced anterograde transport of mitochondria.
1.3.2 Aim
During my PhD thesis, I will use in vitro and in vivo techniques to look at
fusion/fission dynamics and transport under basal and experimentally
demyelinated conditions. I will use a cerebellar slice culture system to
determine which mechanism drives the ARMD and where these additional
mitochondria come from. I will analyse demyelinated axons and compare
with them myelinated axons in mitochondrial mutant mice and controls to
determine whether the ARMD is perturbed in mitochondrial mutants.
Furthermore, I intend to test mitochondria targeted drugs as potential
therapeutic agents to prevent axon degeneration.
Specific aims
1. Determine the timecourse of ARMD in cerebellar slice cultures to find the
optimal time point for live imaging of mitochondria in the axon.
To determine the timecourse of the ARMD, cerebellar slice cultures will be
demyelinated by using lysolecithin and then stained with
immunohistochemistry at different timepoints after demyelination.
2. To assess the extent of transport and fusion dynamics in myelinated and
unmyelinated axons of wildtype neurons.
To determine mitochondrial dynamics in myelinated and unmyelinated
axons, I will tranduce purkinje-cells (PC) by using a lentivirus expressing a
photoconvertible dye with mitochondrial targeting sequence, as PC have
easy to follow axons and cerebellar slices are well established for
myelination experiments.
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3. To assess the extent of transport and fusion in demyelinated axons of
wildtype neurons.
The ARMD is constituted by several aspects (increased numbers, activity,
size and speed) and I will aim to identify the relative contribution of
transport and fusion by using cerebellar slice cultures with
lysolecithin-induced demyelination.
4. Manipulation of the ARMD using different compounds.
To assess the effect of blocking or enhancing certain aspects of the ARMD, I
will use different compounds to either block mitochondrial fission and
transport respectively, or enhance mitochondrial biogenesis.
5. To develop in vitro and in vivo systems to determine how the ARMD is
affected in neurons lacking complex IV activity.
I will aim to determine what effect the presence of these non-functional
mitochondria has on the ARMD using an in vivo and in vitro system.
Preliminary data indicates that mitochondrial complex IV deficiency occurs
in the cell body before it appears in the non-demyelinated axon and ARMD
is perturbed in transgenic mice lacking cytochrome-c oxidase in neuronal
cell body (COX10fl/fl − Thy1 − Cre − ERT2+− mutants). The optimal
timing for demyelinating the mutants is when there is no structural change
but sufficient complex IV deficiency. I will therefore use the in vivo system
(COX10fl/fl − Thy1 − Cre − ERT2+−) to determine which structural
changes the deficiency of complex IV causes and to determine the optimal
time point for demyelination. Because any observed change will be most
pronounced at the end stage, I will start there and work my way back to
earlier time points where there is no structural change apparent. I will check
for signs of inflammation, synapse loss, effects on cell body or dendrites
(axons have already been looked at in the Mahad lab). This in vivo data will
then be compared to the situation in the slice culture system by inducing
demyelination in a cerebellar brain slices derived from the
COX10fl/fl − Thy1− Cre−ERT2+− mice. In the slice culture system, I will
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manipulate mitochondrial fission/fusion, axonal transport and biogenesis
to assess their effect on the ARMD.
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Chapter 2
Timecourse of the ARMD
2.1 Introduction
2.1.1 Cerebellar slice culture and demyelinating agent
There are several recent publications about studying mitochondrial
dynamics in vivo and in vitro, while in vivo offers the obvious advantage of
seeing how the dynamics take place in the live animal, the possibility of
easy manipulation is a key advantage that lies within the in vitro approach,
especially in the organotypic brain slice culture which offers the best
similarity to the in vivo situation is one of the most widely used in vitro
techniques (Zambonin et al., 2011; Ohno et al., 2011; Kiryu-Seo et al., 2010;
Ohno et al., 2014; Misgeld et al., 2007; Misgeld, Nikic, and Kerschensteiner,
2007). Organotypic brain slice cultures have been used to study areas from
electrophysiology to assessing drug effects in a close to in vivo setting
(Humpel, 2015; Suter, Smith, and Dudek, 1999; Miki, Hirai, and Takahashi,
2013; Miron et al., 2010). Another area that has been studied by using
cerebellar brain slices is demyelination and remyelination and the most
widely used demyelinating agent is lysolecithin (Miron et al., 2010;
Birgbauer, Rao, and Webb, 2004; Zhang et al., 2011). Lysolecithin is, amongst
the most widely used demyelinating agents, the one that affects
mitochondrial function function the least, while also keeping the axons
intact (Birgbauer, Rao, and Webb, 2004; Zhang et al., 2011; Komai, Hunter,
and Takahashi, 1973; Keough, Jensen, and Yong, 2015; Jeffery and
Blakemore, 1995; Wallace et al., 2003; Yu et al., 2007).
Cerebellar slice culture was chosen, not only because there are a lot of
publications concerning demyelination, but also because the cerebellum has
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a very distinct morphology and only a few different types of neurons, and
the single output of the cerebellar cortex is coming from the purkinje cells,
which are positioned between the molecular layer and granule cell layer in
the cerebellar cortex (Sillitoe and Joyner, 2007; Mordel et al., 2013). The
purkinje cells are one of the biggest neurons in the brain and have an easy to
recognize morphology, because of their big dendritic tree (Kapfhammer,
2004). Furthermore, purkinje cells have easy to follow myelinated axons and
have been used in previous studies of demyelination in organotypic brain
slice culture (Miron et al., 2010; Birgbauer, Rao, and Webb, 2004; Zhang
et al., 2011). Both the dendritic tree and the axons are preserved if the
organotypic brain slices are cut in sagittal orientation (Miron et al., 2010;
Birgbauer, Rao, and Webb, 2004; Zhang et al., 2011). Last but not least, the
cerebellum is frequently affected in multiple sclerosis, often from the start of
the disease (Tornes, Conway, and Sheremata, 2014; Weier et al., 2015). All
these features make the cerebellum as well as the purkinje cell a reasonable
good model to study mitochondrial dynamics in demyelinated axons.
2.1.2 Axonal response of mitochondria to demyelination
(ARMD)
Previous studies have shown, that several mitochondrial parameters are
changed in demyelinated axons of MS patients compared to healthy
controls, this change has also been shown in animal models of the disease,
as well as in tissue culture (Mahad et al., 2009; Witte et al., 2009; Zambonin
et al., 2011; Ohno et al., 2011; Kiryu-Seo et al., 2010; Ohno et al., 2014). There
is an increase in mitochondrial numbers, size, activity and speed of motile
mitochondria in the demyelinated axon compared to the myelinated axon
(Mahad et al., 2009; Witte et al., 2009; Zambonin et al., 2011; Ohno et al.,
2011; Kiryu-Seo et al., 2010; Ohno et al., 2014). This ARMD, is an adaptive
mechanism to deal with the increase in energy demand in the demyelinated
axon, which is caused in part by the redistribution of sodium channels along
the axon after demyelination, which in term needs more Na+/K+ pump
activity to get rid of the excess sodium inside the axon (Craner et al., 2004b;
Witte et al., 2014; Trapp and Stys, 2009; Kiryu-Seo et al., 2010; Ohno et al.,
2014). The ARMD seems to be protective in the short term, as it was shown
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by demyelinating snph-KO mice, in which the ARMD is not mounted. This
lead to a higher number of alzheimer-precursor-protein (APP) positive
bulbs in the snph-KO compared to the control, which indicates a short-term
protective effect of the ARMD after demyelination (Ohno et al., 2014).
Another study has shown the long-term effect of crossing a snph-KO with a
shiverer mutant, which the authors claim to be a model for progressive
multiple sclerosis (Joshi et al., 2015). In this case the disruption of the
ARMD, by knocking out syntaphlin was protective, as the
shiverer-snph-double-KO had a better survival rate than the shiverer (Joshi
et al., 2015). The authors argue that over a long period, the mitochondria
which are stuck in the axon, are more and more damaged and are
subsequently damaging the axon via ROS and therefore argue that the
increased content of mitochondria is harmful after a prolonged period of
demyelination (Joshi et al., 2015).
2.1.3 Timecourse of the ARMD
While several studies described the different changes of mitochondrial
parameters in the axon occurring as a response to demyelination in MS, as
well as in different model systems, so far the timecourse of the ARMD and
how it is mounted was not described (Mahad et al., 2009; Witte et al., 2009;
Zambonin et al., 2011; Ohno et al., 2011; Kiryu-Seo et al., 2010; Ohno et al.,
2014). To study the timecourse of the ARMD, I used an in vitro slice culture
system with lysolecithin induced demyelination and
immunohistochemistry (IHC) staining at different timepoints after
demyelination. This approach also allowed me to determine the best time
point to perform live imaging of the mitochondrial dynamics, which is
shown in Chapter 4. The optimal time point for live imaging would be
when the response is still strong in terms of dynamics and many
mitochondria are transported to the axon.
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2.2 Materials and methods
2.2.1 Cerebellar brain slice culture
Animals
All procedures were performed according to the 1986 Animals Act
(scientific procedures) UK and were approved by the local ethics committee.
For all the experiments C57BL/6 mice were used. For the generation of
cerebellar organotypic slice cultures mice from P7 to P12 were used, because
slice generated at this age ensures a good survival of purkinje cells, while
already displaying many features of the adult structure of the cerebellum.
Dissection of the cerebellum
Every step was carried out on ice to minimize the tissue damage. For the
dissection of the cerebellum, P7 to P12 C57BL/6 mice were decapitated with
big scissors and placed into ice-cold dissection medium in a 60 mm petri dish.
Medium sized bow scissors were used to cut the skin above the mid line of
the skull. A curved forceps was used to pierce into the eyes to hold the head
in place. Using small bow scissors the skull was penetrated above the middle
of the mid line and cut along the mid line and to both sides of the skull. Using
a forceps the skull pieces were peeled back and removed as much as possible.
The connection between the cerebellum and the cerebrum was cut using a
scalpel knife to cut in between the cerebellum and the cerebrum. Finally a
curved spatula was used to remove the cerebellum and brain stem from the
skull and immerse it into the ice-cold dissection medium, while the rest of
the head was discarded. The whole dissection procedure was done in about
5 minutes.
Slicing with Leica VT1200S
The cerebellum with attached brain stem was then carried to the Leica
VT1200S Vibratome, while immersed in dissection medium inside a petri
dish placed in an icebox. For immobilizing the cerebellum on the magnetic
stage cyanoacrylate superglue with gel control was used, for this several
small drops of the superglue were placed in the middle of the magnetic
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stage. The cerebellum was then picked up using a curved spatula and
carefully placed sideways in the middle of the superglue drop to cut the
cerebellum into sagittal slices. Sagittal orientation allows for the best
preservation of purkinje cells, as their dendritic tree and the axon is
orientated along the sagittal plane, only the axons of the granule cells are
cut as they are orientated along the coronal plane. Before mounting the
magnetic stage back into the Vibratome, the superglue was allowed to dry
for a few seconds before immersion into the ice cold dissection medium
which filled the cutting chamber of the Vibratome. On the Vibratome
settings, the cutting thickness was set at 300µm, the cutting speed at 0.4µm
per second and the amplitude at 1.40mm. Using the automatic cutting
mode, the front end rear cutting points were chosen. The wilkinson razor
blade which was put in place before the procedure, was lowered as near as
possible to the top plane of the slice before starting the cutting.
Each cut slice was transferred to a 6 well plate sitting on ice filled with a
little of the ice cold dissection buffer, using a reversed broken glass pipette
with an attached rubber bulb. If the slice was too attached to the rest of the
brain, a forceps was used to sever the connection, without touching any
region of interest. After the cutting was finished, the slices from the 6 well
plate were transferred onto the Millicell R© cell culture inserts (PICM0RG50)
with 0.4µm poresize, which were placed in another six well plate containing
1ml of slice culture medium per well. This plate with the Millicell R© cell
culture inserts and slice culture medium were put in an incubator at 37 ◦C
with 5% CO2 at least 30 minutes before starting the slicing procedure. The
membranes of the cell culture inserts allow the slices to get access to oxygen
from the air above, while the slice culture medium supplies the slices with
nutrients from below through the membrane. For the transfer of the slices
the reversed broken glass pipette with attached rubber bulb was used.
Because the slices need access to air and contact with the membrane for
attachment, excess dissection medium from the membranes was carefully
removed using a 1000µl pipette with filter tips. Because the slices should
not be to close to each other, the slices were moved around until the were
placed roughly in the middle of the insert and far enough apart from each
other by sucking and releasing medium with the pipette without touching
the slices. The plate with the slices placed correctly was then put again into
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the incubator, until the next round of slicing. The plate was labelled with
date, mouse number and special procedures. After the last round of slicing
was finished, the plates were put again into the incubator at 37 ◦C with 5%
CO2 and the culture medium is changed one hour after slicing and
thereafter every 2 days.
Reagents and Media
Dissection medium (for 200ml medium)
196ml HBSS (Life technologies)
2ml 450g/L D-glucose (5mg/ml; Sigma)
2ml Antibiotic/Antimycotic (Life technologies)
Keep on ice before dissection
Culture medium (for 40ml medium)
20ml MEM (Life technologies)
10ml HBSS (Life technologies)
10ml heat inactivated horse serum ((Life technologies)
0.41ml D-Glucose (5mg/ml; Sigma)
0.41ml GlutaMAX (Life technologies)
0.41ml Antibiotic/Antimycotic (Life technologies)
2.2.2 Demyelination with lysolecithin
In the literature lysolecithin concentrations ranging from 0.25mg/ml to
0.5mg/ml are most widely reported concentrations with incubation times
reaching from 16 hours to 26 hours, with 0.5mg/ml for 17 hours being used
in most studies (Miron et al., 2010; Ohno et al., 2014; Liu et al., 2010;
Birgbauer, Rao, and Webb, 2004). Therefore for the demyelination of the
slices 0.5mg/ml lysolecithin was added to the slice culture medium for 17
hours before replacing it with normal medium. The slices were then stained
at several timepoints after demyelination to determine the timecourse of the
ARMD. For this the slices were fixed with paraformaldehyde (PFA), after
which antigen retrieval was performed, after which the slices were blocked
before incubating them with the primary and secondary antibody.
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2.2.3 Immunohistochemistry
For Immunohistochemistry slice culture tissue and frozen sections were
used, the slides were labelled according to which antibodies, dilution and
antigen-retrieval method would be used, and furthermore the date of the
beginning of the current staining was indicated. After fixation with 4%
paraformaldehyde (PFA) the slides or slices were washed and heat-induced
antigen retrieval was performed by using a microwave. After the antigen
retrieval step, the specimen were washed, before blocking with 2% NGS for
20 minutes on room temperature (RT). After the blocking step the primary
antibody solution was directly applied on the slides or slices.
Frozen section staining
The frozen tissue was cut into whole brain sections, so that the cerebellum
was readily observable. After cutting a piece of Whatman R© paper and
labelling it appropriately with date and type of tissue, a small drop of O.C.T.
TM compound (Tissue-Tek) was applied onto the paper. The tissue was put
into that drop and put on fast freeze in a Leica CM1950 cryostat with a
chamber temperature of −20 ◦C and the paper with the tissue on it was
frozen onto a metal chuck. The chuck with the tissue on it was then fixed in
the cutting chamber and the tissue was cut into 15µm thick sections. The cut
tissue was then put onto a coated glass slide, which was then labelled
accordingly and left on room temperature to dry for about 60 minutes,
before putting it into a −80 ◦C freezer for long term storage. Before the
staining the slides were incubated 60 minutes on room temperature and
then fixed in 4% PFA for 30 minutes. If needed the slides were blocked with
0.3% H2O2 in dH2O for 30 minutes on room temperatures before antigen
retrieval. For the frozen section a microwave was used to achieve antigen
retrieval. For this the appropriate buffer was heated in the microwave on
high setting until the solution began to boil, the slides were immersed into
this hot solution for 1 minute. Afterwards the slides were briefly washed
with dH2O before washing them 3 times for a minimum of 2 minutes with
TBS.
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Antibody application
After the antigen-retrieval step, a PAP pen was used to make a hydrophobic
circle around the sections for the following washing and incubation steps.
The slides were then washed at least 3 times for 2 minutes with tris-buffered-





































Before the application of the primary antibodies, the sections were
blocked for 20 minutes at room temperature using 2% normal goat serum
(NGS) in TBS buffer. The primary antibodies were then also diluted in 2%
NGS/TBS and after pipetting the antibody-solution on the sections the
slides were incubated either over night at 4 ◦C or for 1 hour and 30 minutes
at room temperature. After the incubation with the primary antibody, the
sections were washed at least 3 times for 2 minutes with TBS pH 7.6. The
secondary antibodies were also diluted in 2% NGS/TBS, applied on the
sections and incubated for 30 minutes at room temperature. For the double-
or triple-labelling of different epitopes, primary antibodies from different
species or different IgG subclasses were combined to prevent cross reaction
of the secondary antibodies. The slides were then incubated with
appropriate fluorescent secondary antibody diluted 1:200 in 2% NGS/TBS.
After washing the slides again with TBS they were finally the mounted with
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Vectashield mounting medium with DAPI (Vector) and put into a −20 ◦C
freezer before analysis. Imaging was performed with a Zeiss LSM 710
confocal laser-scanning microscope.
Slice culture staining
The slices and a piece of surrounding membrane were cut out of the slice
culture insert using a scalpel, the slices stayed attached to the membrane
through the whole staining procedure. Similar to the frozen sections the
slices were fixed in 4% PFA for 30 minutes before washing them with
distilled water. The antigen retrieval was achieved by microwaving a 1mM
EDTA (pH 8.0) solution until boiling and immersing the slices for 30
seconds. The transfer between different solutions was achieved by grabbing
the membrane surrounding the slices with a flat forceps. The slices were
then washed 3 times in TBS, by immersing them in a TBS filled well of a
24-well plate. After the washing steps, the slices were blocked for 20
minutes in another well filled with 2% NGS. During the blocking step, a wet
chamber was prepared and the glass slides which was later used for the
incubation of the slices with the different antibodies were labelled with slice
culture information, used antibodies and date. Furthermore two circles
were made on each glass slide by using a PAP pen, in which the antibody
solution would be applied for the staining. After the blocking with 2% NGS,
the primary antibody solution was slowly dropped into the PAP pen circles
on the slides and the slices were transferred into the solution by using the
flat forceps. The primary antibody was then incubated over night in the
cold room at 4 ◦C, while the slices were free floating in the antibody
solution. On the next day the slices were washed by removing the primary
antibody solution by using a 200µl pipette and applying TBS washing
solution with a pasteur pipette. The washing step was repeated 3 times,
before the secondary antibody solution, containing fluorescently labelled
antibodies was applied and incubated for 90 minutes at room temperature,
again the slices were free floating in the antibody solution to allow maximal
access through the entire thickness. After the secondary antibody step the
slices were washed again 3 times in TBS, after which a drop of Vectashield
with dapi was added on the slides, before putting on the glass coverslip and
nail polish to seal it. Before the Vectashield was added, the TBS washing
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solution was completely removed and the slices were checked for
orientation, by using the light reflection across the membranes and slices,
which revealed a different reflection pattern when the slices were in the
right orientation (top). The slides were then stored in the cold room at 4 ◦C
until imaging with the Leica LSM 710 confocal microscope.
Reagents and media
Citrate Buffer (pH 6.0)
1. Weigh out 1.47g citric acid per 500mL distilled water for a 15mM solution
2. Adjust to pH 6 using 0.1M Hydrochloric Acid or 0.1M Sodium Hydroxide
solution
EDTA (pH 8.0)
1. Weigh out 210mg EDTA per 500mL distilled water for a 1mM solution
2. Adjust to pH 8 using 0.1M Hydrochloric Acid or 0.1M Sodium Hydroxide
solution
PFA (4%)
1. Heat 500ml distilled water in a glass beaker to 65 ◦C using a microwave
and measuring the temperature using a thermometer between microwave
cycles.
2. Weight out 40g of paraformaldehyde powder in a large weighing boat
3. Add paraformaldehyde to warmed distilled water in fume cupboard
4. Use hot plate and magnetic stirrer to mix the solution
5. Add a few drops of 1M NaOH to the solution and leave it on the stirrer
until the solution has cleared
6. Add 500ml of Phosphate buffer pH 7.4
7. Adjust to pH 7.4 if needed using 0.1M Hydrochloric Acid or 0.1M Sodium
Hydroxide solution
8. Make 40ml aliquots and freeze at −20 ◦C and store the rest in the cold
room
Phosphate Buffer
1. Stock A: weight out 3.12g sodium dihydrogen orthophosphate and
dissolve it in 50ml distilled water for a 500mM solution
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2. Stock B: (500mM) weight out 14.15g disodium hydrogen orthophosphate
and dissolve it in 250ml distilled water for a 500mM solution
3. Buffer composition: 47.5ml Stock A + 202.5ml Stock B, adjust to pH 7.4
using 0.1M Hydrochloric Acid or 0.1M Sodium Hydroxide solution and
make up to 500ml with distilled water.
TBS-washing solution
Weigh out 300mg trizma base and 5g of NaCl per 500mL distilled water for
a 5mM solution
1. Adjust to pH 7.6 using 0.1M Hydrochloric Acid or 0.1M Sodium
Hydroxide solution
2.2.4 Confocal microscopy
The stained slices, as well as the frozen sections, were imaged using a Zeiss
LSM 710 confocal microscope with a 63x NA 1.4 oil immersion objective. The
microscope parameters were set to image Alexa fluor-488, Rhodamine-X-Red
and Alexa fluor-633. The filters were set to catch the appropriate wavelengths
and the laser power was at 6% for the green 35% for the red and 40% for the
deep red channel. The images were captured by taking a z-stack at 2x zoom,
a 1024x1024 pixel resolution and pixel dwell time of 1.06µs and saved as lsm
files. For each image every plane of the z-stack was exported separately as a
tif file for further analysis.
2.2.5 Image preparation
The tif files were then opened with photoshop to clean all non-axonal
mitochondria from the images. For this the foreground and background
colors were switched so that the white color rectangle is in the front and the
black one in the back. Then the green channel, which contained the
neurofilament staining for the axons, was selected, the colors were inverted
and the threshold was set to get good shaped axons without having too
much background. After the thresholding, the ’color range...’ option in the
panel ’select’ was used to mark the whole image frame outside the axons
that were selected by thresholding. After the selection was active, the blue
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channel, which was the COX-I staining for the mitochondria, was activated
and cut out to get rid of all non-axonal mitochondria. The cleared image
was then saved as a tif in a new folder. The images with non-axonal
mitochondria cleaned, were then opened in ImageJ (Fiji) and axons of a
minimum size were selected randomly, marked with the freehand selection
tool, cut out by using ctrl-x. The single axons were then copied into a new
image file, created with the shortcut ctrl+n, and saved as a new tif file into a
new folder.
2.2.6 Analysis of axonal mitochondrial parameters
To analyse the axonal mitochondrial parameters each single axon file was
then again opened with ImageJ and analysed using several macros. First the
macro was loaded via ’Plugins->Macro->Install...’ in ImageJ and the first
macro file named ’A1’ was selected. After the macro was loaded the first
image was added to ImageJ and the macro was started by pressing ’1’,
which separated the three color channels. For the macro to work each
channel was then thresholded, the threshold for the green channel
(neurofilament for the axons) was always set to 128 automatically, the blue
channel (COX-I for the mitochondria) was set automatically by using the
default threshold setting and the red channel (MBP for myelin) was not
used for analysis and thus closed. After threshold each of the used channels,
the green channel was selected and with the macro shortkey ’a’ the axonal
area was automatically measured and inserted into an excel file sheet. The
allocated axon number and the threshold for each channel was also inserted
into the same excel file sheet. Then the length of the axon was measured by
drawing a line along the axon, measured by pressing ’m’ and also inserted
into the excel file sheet. The green channel for the axon was then closed and
the blue channel for the mitochondria was activated. By pressing the macro
shortkey ’2’ the number of mitochondria and area sizes was measured by
using the ’Analyse particle...’ function of Fiji, which is integrated into the
macro and measures pixel sizes from 5-infinity pixels to exclude very small
particles. The results obtained from the measurements of the number of
mitochondria and area sizes was then inserted into the excel sheet on
another page, which automatically copied the number of mitochondria onto
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summary sheet. The excel sheet also calculated the total mitochondrial area,
which corresponded to the total measured area. The percentage of axonal
area occupied by mitochondria was automatically calculated on the first
sheet of the excel file sheet, by dividing the total mitochondrial area by the
total axonal area and multiplying it by 100. Finally the average size of one
mitochondrion was measured by dividing the total mitochondrial area by
the number of mitochondria. This calculations were done separately for
each axon, 40 axons per slice were done, and the average of each of the
mitochondrial parameters was calculated and used for statistical analysis
and graph creation in GraphPad Prism 6. In Graphpad Prism 6 ’Enter and
plot a single Y value’ was selected and the calculated averages for each slice
were inserted into the matrix. For creation of the graphs the dataset was
selected in the ’Graphs’ folder on the left and scatter plot from the ’Column’
tab was selected, which automatically created a scatter plot from the dataset
showing mean and error bars. For statistical analysis the ’Analyse’ function
was selected in the dataset matrix and ’Column analyses’ was selected to
compare two different datasets. Since the data is not expected to be
normally distributed the ’Mann-Whitney-U’ test was selected as a
non-parametric test. Multiple column comparison was done by using the
Kruskal-Wallis test. A p-value below 0.05 was regarded as being significant
and assigned a ’*’ in the graphs.
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2.3 Results
2.3.1 Comparison in vitro - in vivo
To check if the mitochondrial parameters (occupancy of the axons, number
of mitochondria and size of single mitochondria) in the in vitro slice culture
system is comparable to the in vivo situation, frozen sections from C57 mice
and cerebellar slices were immunostained. For this slices from P10 mice were
used and left in culture for 2 weeks before staining with Neurofilament (NF),
Myelin Basic Protein (MBP) and COXI antibodies to visualize axons, myelin
and mitochondria respectively. Also P24 frozen brain sections were stained
with the same antibodies to compare the mitochondrial parameters of the
axons in the brain sections to the mitochondrial parameters of the axons in
the cerebellar slices; see Figure 2.1.
FIGURE 2.1: Comparison of mitochondrial parameters in vivo
and in vitro, depicted by IHC staining for NF, MBP and COXI
in a cerebellar brain slice (A) and a cryosection of mouse
cerebellum (B), showing the overall similarity in appearance
as well as myelination. Scalebar=50µm; WM=white matter;
GM=grey matter
Overall there was robust myelination in the cerebellar slice culture after
two weeks in culture and in most slices several cerebellar foliae had healthy
axons; see figure 2.1. The overall occupancy of the axons by mitochondria
was very comparable between the slices and the in vivo situation, there was
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a slight trend to lower number of mitochondria in the slices and the size of
the single mitochondria showed a slight trend towards bigger mitochondria
in the slices compared to the in vivo sections, but no significant difference
was detected; see figure 2.2. This data indicates that the cerebellar slice
culture after two weeks in culture is very comparable to the in vivo situation
concerning myelination status and mitochondrial parameters inside the
axon.
FIGURE 2.2: Similarity of mitochondrial axonal parameters
between the cerebellar slice culture and cryosections of mouse
cerebellum. There was no significant difference between in vivo
and in vitro in the parameters measured. The slices from P10
mice have been in culture for two weeks. Each dot represents
one slice or frozen brain section from one mouse and includes
40 analysed axons
2.3.2 Demyelination with lysolecithin
For the timecourse of the ARMD 0.5mg/ml lysolecithin was added to the
slices after 1 week in culture for 17 hours as this is the most widely used
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concentration of lysolecithin in demyelination experiments using
organotypic brain slices. In my hands this concentration did not lead to
complete demyelination of the cerebellar slices, but since only fixed
immunohistochemistry stained slices were imaged for this chapter is was
possible to randomly select demyelinated axons during the imaging
process; see figure 2.3. After the lysolecithin was removed the slices were
left in culture for another 24 hours, which was then the 24 hour timepoint
after demyelination. The other timepoints were chosen accordingly 48, 72,
96, 120 and 144 hours after demyelination. The control slices were
myelinated slices without lysolecithin after 1 or 2 weeks in culture.
FIGURE 2.3: Demyelination of cerebellar slices cultures with
lysolecithin using 0.5mg/ml lysolecithin for 17h. (A) Control
after 1 week in culture stained for NF and MBP. (B) Lysolecithin
added after 6 days in culture and stained the day after for NF
and MBP. Scalebar=50µm
This procedure resulted in sufficient demyelination in the cerebellar
slices, so that is was possible to find at least 40 axons per slice that were
demyelinated; see figure 2.3. The demylinated axons were then cut out in
ImageJ and non-axonal mitochondria were cleared in Photoshop. The
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mitochondrial occupancy, number and size was then analysed by using an
ImageJ macro.
2.3.3 Timecourse of the ARMD
At all timepoints after demyelination with lysolecithin that were observed,
the mitochondrial parameters were changed significantly compared to the
myelinated control axons; see figure 2.4. The AMRD was mounted quick,
with all parameters changed already after 24 hours, while some reaching the
peak after 72 hours after demyelination.
FIGURE 2.4: Impact of demyelination with lysolecithin
on mitochondrial parameters in the axons, showing the
comparison of control (A) and lysolecithin treated slices (B)
after IHC staining for NF, MBP and COXI. Scalebar=5µm
Mitochondrial occupancy
The percentage of mitochondrial occupancy of the axons increased sharply
24 hours after demyelination and continued to increase until it plateaued
around 72 hours after lysolecithin treatment; see figure 2.5.
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FIGURE 2.5: Impact of demyelination on the mitochondrial
occupancy of the axons, depicting the mitochondrial occupancy
of the axons (in percent) at different timepoints after
demyelination. The multiple group comparison with the
Kruskal-Wallis test showed a significant difference with a p-
value <0.0001. Each dot represents one slice from one mouse
and includes 40 analysed axons
The mitochondrial occupancy was still up 7 to 12 days after
demyelination compared to baseline, but not as high as the peak at 72 hours
after demyelination; see figure 2.5. At around 1 week after demyelination,
remyelination starts to begin, but this was not sufficiently analysed in this
thesis.
Mitochondrial size and numbers
The number of mitochondria in the axons increased even faster with the
plateau already reached after 24 hours, with a slight increase at 72 hours
after lysolecithin treatment; see figure 2.6. In contrast to the mitochondrial
numbers, the size of the single mitochondria slowly increased over the
timecourse, reaching the peak size at 96 hours after demyelination; see
figure 2.6. All timepoints showed a significant increase in the size of the
average single mitochondrion compared to the myelinated control.
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FIGURE 2.6: Top: Impact of demyelination on the
mitochondrial size, depicting the size of single mitochondria in
the axons (in µm2) at different timepoints after demyelination.
The multiple group comparison with the Kruskal-Wallis test
showed a significant difference with a p-value of 0.0001.
Bottom: Impact of demyelination on the mitochondrial
numbers in the axons, depicting the mitochondrial numbers in
the axons (per µm2) at different timepoints after demyelination.
The multiple group comparison with the Kruskal-Wallis test
showed a significant difference with a p-value of 0.0004. Each
dot represents one slice from one mouse and includes 40
analysed axons.
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2.4 Discussion
2.4.1 The ARMD in cerebellar slice culture
This chapter showed that it is possible to get in vitro cerebellar slice cultures,
that are comparable to the in vivo situation in terms of myelination, as well
as mitochondrial parameters. Furthermore, we showed that the ARMD,
which is readily observed in demyelinated axons in multiple sclerosis, can
be modelled in this in vitro cerebellar slice culture model by using
lysolecithin as a demyelinating agent.
Although all the parameters of the AMRD (increase in mitochondrial
numbers, size, activity and speed in the demyelinated axon) have already
been shown in multiple sclerosis and relevant disease models by using
immunohistochemistry stainings of appropriate tissue sections, the
timecourse of this ARMD has not been studied in detail yet (Mahad et al.,
2009; Witte et al., 2009; Zambonin et al., 2011; Ohno et al., 2011; Kiryu-Seo
et al., 2010; Ohno et al., 2014).
Here we show the ARMD timecourse over several days after
demyelination, at several different timepoints. Already at 24 hours after
demyelination the numbers of mitochondria in the axons was significantly
higher than in myelinated control axons, this indicates a very fast response
by transporting the mitochondria, presumably from the cell body, to the
demyelinated axon. Over the following days the number of mitochondria in
the axon remained increased. The size of the single mitochondria in the
demyelinated axon increased steadily at every timepoint checked until
reaching a peak at 4 days after demyelination. This indicates that
mitochondrial fusion within the demyelinated axon is increased the days
following demyelination.
The percentage of mitochondrial occupancy of the demyelinated axon
reflects both of these mitochondrial parameters, as it increases quickly after
24 hours hours, where there is mostly transport of additional mitochondria
into the demyelinated axon and increases steadily until reaching a peak at 4
days after demyelination, coinciding with the peak in mitochondrial size
(fusion). This data shows that transport of additional mitochondria,
presumably from the cell body, and mitochondrial fusion within the
demyelinated axon are both important parameters for mounting the ARMD.
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The mitochondrial occupancy going down after 7 to 12 days, could be a
consequence of remyelination taking place, as remyelination typically starts
one week after demyelination and is reported to be quite robust 14 days
after. This change in mitochondrial occupancy also has been reported in
multiple sclerosis autopsy cases, as the mitochondrial occupancy of
remyelinated axon is reduced in comparison to demyelinated axons, but
still elevated compared to the myelinated axon (Zambonin et al., 2011).
This ARMD is a consistent and robust reaction to demyelination of
axons, which could be a response to the increased energy demand within
the demyelinated axon, as a redistribution of sodium channels has been
reported along demyelinated axons. This leads to an increased amount of
sodium in the axon, which has to be transported out of the axon by the
Na+/K+ ATPase (Craner et al., 2004b; Witte et al., 2014; Trapp and Stys,
2009; Mahad, Trapp, and Lassmann, 2015; Mohd, 2010; Albers and Siegel,
1998; Lores Arnaiz and Ordieres, 2014). There are several possibilities how
this increased mitochondrial occupancy of the axon is mediated: Firstly,
increased mitochondrial biogenesis in the perinuclear region of the cell and
subsequent transport to the axon and fusion of newly transported
mitochondria with the stationary mitochondria within the axon. Secondly,
there could be increased transport from the soma to the axon without
enhanced biogenesis, but this option would deplete mitochondrial content
over time. The third option would be mitochondrial biogenesis in the axon,
at the site where they are needed. Although there have been reports of
mitochondrial biogenesis of mitochondria in the axon, this was shown only
in developing regenerative stages of neurons, if axonal biogenesis of
mitochondria in mature neurons takes place has yet to be shown (Amiri and
Hollenbeck, 2008).
2.4.2 Optimal timepoint for live imaging mitochondrial
dynamics
Besides determining the timecourse of the ARMD, which has been
discussed in the previous section, this experiment was also used to find the
optimal timepoint for performing live imaging of mEOS2 transduced
purkinje cells (PC) to determine the mitochondrial dynamics in
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demyelinated axons of PC in cerebellar slices cultures. To effectively
perform live imaging on mitochondrial dynamics after demyelination, the
different parameters of the ARMD should be at or near the peak.
Because our main goal for the mitochondrial dynamics experiment was
to determine where these additional mitochondria in the demyelinated axon
come from, it was important that the mitochondrial transport rate in the
axon was at the peak. Since the 24h timepoint after demyelination already
showed the peak in mitochondria numbers, indicating the peak in transport
of mitochondria to the axon, it was decided the best timepoint for live
imaging the mitochondrial dynamics was directly after the lysolecithin was
removed from the medium.
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Chapter 3
Mitochondrial dynamics in the
myelinated axon
3.1 Introduction
3.1.1 Mitochondrial imaging in vivo
To study mitochondrial dynamics with live imaging, several mitochondrial
proteins, as well as genetic models of mitochondrial targeted fluorescent
proteins or transduction with a virus encoding a mitochondrial targeted
fluorescent protein are the most widely used options (Zhou et al., 2016;
Misgeld et al., 2007; Misgeld, Nikic, and Kerschensteiner, 2007).
Mitochondrial dyes have the advantage of not needing any elaborate
preparation, they are added to the tissue and stain the mitochondria after a
short incubation period (Chazotte, 2011; Mitra and Lippincott-Schwartz,
2011). The most widely used mitochondrial dyes are cationic fluorophores,
which means that their import into the mitochondria is dependant on
membrane potential (Chazotte, 2011; Mitra and Lippincott-Schwartz, 2011;
Kholmukhamedov, Justin M. Schwartz, and John J. Lemasters, 2014). One of
the first mitochondrial targeted dyes was the Mitotracker, which is available
in different fluorescent colors and stains all mitochondria in live tissue and,
due to forming a covalent bond, is retained in the mitochondria even after
the membrane is depolarized (Kholmukhamedov, Justin M. Schwartz, and
John J. Lemasters, 2014). On the other hand dyes like TMRE, which do not
form covalent bonds, are lost after the mitochondrial membrane is
depolarized and therefore only labels mitochondria with intact membrane
potential, while depolarized mitochondria are not labelled or will loose
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labelling upon depolarization (Kholmukhamedov, Justin M. Schwartz, and
John J. Lemasters, 2014). The main disadvantage of the mitochondrial dyes
is they will stain mitochondria across all of the cell types in the tissue, so it is
not possible to follow mitochondrial dynamics in a cell type of interest
(Chazotte, 2011; Mitra and Lippincott-Schwartz, 2011; Kholmukhamedov,
Justin M. Schwartz, and John J. Lemasters, 2014).
While the genetic models have the advantage of being independent of
mitochondrial membrane potential and expressing the fluorophore only in
the cells which express the selected promoter in a very reliable manner, it is
very time and resource consuming to make a suitable genetic model. There
are several publications of both in vivo and in vitro experiments using
genetic models (Zhou et al., 2016; Misgeld et al., 2007; Misgeld, Nikic, and
Kerschensteiner, 2007). Furthermore, it is possible to combine genetic
labelling of mitochondria with mitochondrial dyes, for example Zhou et al
(2016) looked at the effect of different manipulations on mitochondrial
membrane potential and used a combination genetic labelling of all
mitochondria (GFP-Mito) with TMRE, which is dependant on
mitochondrial membrane potential (Zhou et al., 2016). This way
mitochondria with intact membrane potential can be differentiated from
mitochondria with depolarized membrane potential (Zhou et al., 2016).
The second possibilty of labelling only a subpopulation of cells is to use
viral mediated transduction; see figure 3.1 (Zhou et al., 2016). There are
several different virus types available for transducing cells in vivo and in
vitro, with the most widely used being the lentiviruses and
Adeno-associated viruses (AAV) (Kiryu-Seo et al., 2010; Ohno et al., 2014;
Zhou et al., 2016; Stephen et al., 2015a). Both lentiviruses and AAV have
been used previuosly in vitro to look at mitochondrial dynamics (Kiryu-Seo
et al., 2010; Ohno et al., 2014; Zhou et al., 2016; Stephen et al., 2015a).
Furthermore lentiviral constructs have been used previously to transduct
PC in cerebellar slices and image mitochondrial dynamics (Kiryu-Seo et al.,
2010; Ohno et al., 2014).
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FIGURE 3.1: Lentiviral transduction of a target cell, depicting
the HEK293T cells containing the packaging plasmid, transfer
plasmid and envelope plasmid and the completely assembled
lentivirus infecting the target cell, reverse transcribing
the lentiviral RNA and integrating it into the target cell
genome. Adapted from the short review Lentiviral vector
production and cell transduction from Invivogen http :
//www.invivogen.com/docs/Insight201004.pdf
Lentiviral vectors are single-stranded RNA plasmids derived from the
HIV-1 virus. Lentiviruses belong to the family of retroviruses, which means
that they are reverse transcribed from RNA into cDNA and inserted into the
host genome for stable expression; see figure 3.1 (Escors and Breckpot, 2010;
Sakuma, Barry, and Ikeda, 2012). Envelope proteins from several different
viruses are available in combination with the usage of lentivirus, which
allows for the infection of dividing as well as non-dividing cells (Cronin,
Zhang, and Reiser, 2005). A lentiviral vector needs to contain several
different protein coding sequences, which are spread across several
plasmids, to allow the vector to transduce a target cell and integrate its
genetic material into the host genome; see figure 3.1 (Kim et al., 2012;
Durand and Cimarelli, 2011; Wollebo, Woldemichaele, and White, 2014). For
the integration into the host genome, the lentivirus needs a packaging
sequence (HIV-1 psi packaging signal), which is usually on the packaging
plasmid, and long terminal repeats (HIV-1 5’LTR and 3’LTR), which are
placed along the gene of interest on the transfer plasmid; see figure 3.1 (Kim
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et al., 2012; Durand and Cimarelli, 2011; Wollebo, Woldemichaele, and
White, 2014).
FIGURE 3.2: mEOS2 construct, depicting the transfer plasmid
containing the mEOS2 (in orange) protein with attached
mitochondrial targeting sequence (in pink). Original graphic
supplied by Pamela Brown and slightly modified for this thesis
In the 3rd generation lentiviruses, the packaging plasmid is split into two
packaging plasmid, encoding GAG (coding for the lentiviral core) and POL
(codes for the reverse transcriptase) on one plasmid and REV (regulates
viral protein expression) on another; see figure 3.1 (Dull et al., 1998; Cribbs
et al., 2013). As mentioned above, envelope proteins from many different
viruses are available to combine with lentiviruses, the envelope protein is
located on the envelope plasmid (Cronin, Zhang, and Reiser, 2005; Dull
et al., 1998; ; Cribbs et al., 2013). These plasmids are transfected into HEK
293T cells, which are left to grow for a few days with media changes in
between (Cribbs et al., 2013; Merten, Hebben, and Bovolenta, 2016; ; Wang
and McManus, 2009). The supernatant at harvest timepoint is collected and
centrifuged to concentrate the virus and finally stored at −80 ◦C (Cribbs
et al., 2013; Merten, Hebben, and Bovolenta, 2016; ; Wang and McManus,
2009). It is possible to integrate genes up to a size of 10kb into the transfer
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plasmid, but with increase in size there is also a drop in viral titer, which
leads to a lower transduction rate of cells (Holehonnur et al., 2015).
3.1.2 Visualizing mitochondrial dynamics in myelinated
axons with mitochondrial targeted mEOS2
To determine the transport and fusion dynamics in the myelinated and
unmyelinated PC axons, a lentivirus containing a construct with the
photoconvertible protein mEOS2 with attached mitochondrial targeting
sequence was used; see figure 3.2.
FIGURE 3.3: Spectrum of the mEOS2 protein, showing
excitation spectrum of the unconverted green and
converted red protein on the left and the emission
spectra of both the unconverted and converted state
of mEOS2 on the right. Graphic from: http://zeiss-
campus.magnet.fsu.edu/articles/probes/highlighterfps.html
The mEOS2 is a monomeric protein derived from the coral lobophyllia
hemprichii, which emits green light when excited with the 488nm laser; see
figure 3.3 (McKinney et al., 2009). This photoconvertible protein can be
irreversibly converted to a red emission spectrum by illuminating the
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structure of interest with UV light; see figure 3.3 (McKinney et al., 2009).
The emission spectrum of mEOS2 is very different between the unconverted
green and converted red state, so that there is very little overlap between the
two states, which allows for a good separation during imaging; see figure
3.3 (McKinney et al., 2009). There are several versions of the EOS protein
available, with the monomeric version being the most widely used for
protein labelling since its small size allows fusion proteins with single
molecules; see figure 3.2 (McKinney et al., 2009). The advantage of mEOS2
is that it allows for maturation of the fluorescent protein at 37 ◦C, which is
optimal when imaging cerebellar slices from mice (McKinney et al., 2009).
One of the main advantages of using photoconvertible proteins is that it is
possible to create two distinct mitochondrial populations according to their
conversion status, unconverted green mitochondria and converted red
mitochondria. This allows to more accurately follow mitochondria from one
population (eg unconverted green) through another population of
mitochondria (eg converted red). Another key advantage of differently
labelled mitochondria is the ability to visualize and quantify mitochondrial
fusion (Pham, McCaffery, and Chan, 2013; Owens and Walcott, 2012). There
are both genetic models of photocovertible proteins available, as well as
lentiviral construct expressing these photoconvertible proteins after
transduction and both have been used to study mitochondrial fusion in
different tissues both in vivo and in vitro, for example skeletal muscle and
motor neurons in cell culture (Pham, McCaffery, and Chan, 2013; Owens
and Walcott, 2012; Owens and Edelman, 2015).
3.2 Materials and methods
Animals
All procedures were performed according to the 1986 Animals Act
(scientific procedures) UK and were approved by the local ethics committee.
For all the experiments C57BL/6 mice were used. For the generation of
cerebellar organotypic slice cultures mice from P7 to P12 were used, because
slice generated at this age ensures a good survival of purkinje cells, while
already displaying many features of the adult structure of the cerebellum.
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3.2.1 Cerebellar brain slice culture
For the slicing protocol see methods section in chapter 2.
Injection using a Picospritzer III R©
During the incubation of the plate with membranes, the Picospritzer III R©
from Parker was assembled and prepared. Glass capillaries (Harvard
Apparatus, 1.5 OD x 1.86 ID x 75 L) were pulled and broken to a diameter
between 3µm and 15µm by using a glass capillary puller model PP-830 by
NARISHIGE Japan and breaking the needle tip with a Micro Forge MF-830
by NARISHIGE Japan. For the injection the plate with slices culture inserts
was placed on a stereo microscope, besides which a metal plate with
magnetic stand and attached micro-manipulator was placed. The needle
was then fixed to the appropriate device of the Picospritzer III R©, which was
then in turn fixed onto the micro-manipulator. The concentrated virus
solution was kept in −80 ◦C in 20µl aliquots for long term storage and was
defrosted on ice just before injection of the slices. To each aliquot 0.5µl of
Fast Green (FG) solution (1%) was added. The solution was then picked up
with a pipette which had a long thin metal tip and transferred to the glass
needle. The needle was then placed in a roughly 45◦ angle as close to the
slice as possible. Using the micro-manipulator the needle was then
manoeuvred to the purkinje cell layer (PCL) and the foot petal was used to
inject the viral solution into the PCL, using a pressure of 12 psi and varying
injection duration times (10-60ms) depending on the needle thickness. The
applied pressure, needle thickness and injection duration times were each
determined by trying many different combinations of these parameters in
test experiments. For each slice 5-10 injection were made, visible by a
distribution of the FG dye. After injection, the slices were put back into the
incubator and after 2-3 hours the medium was changed, to prevent any
possible detrimental effects of the FG dye on the PCs.
3.2.2 Media, reagents and devices
For the slice culture reagents see methods section in chapter 2.
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3.2.3 Determine myelination status by using spectral
confocal reflectance microscopy (SCoRe)
To determine the myelination status of the axons I used the spectral confocal
reflectance microscopy (SCoRe) technique, which is a label free imaging
method for myelin; see figure 3.4 (Schain, Hill, and Grutzendler, 2014).
FIGURE 3.4: ScoRe technique depicting a myelinated (left
panel) and demyelinated (right panel) mEOS2 positive axon.
The white rectangle shows the area which was converted and
used for live imaging. Scalebar=20µm
Since the lipid rich myelin has such a high refractive index, which leads
to a specific reflectance pattern when illuminated with different lasers (each
laser has its own pattern), it is possible to visualize it while live imaging by
collecting the reflectance of the laser with a very narrow collection spectrum
in and around the lasers excitation wavelength; see figure 3.4 (Schain, Hill,
and Grutzendler, 2014). The SCoRe imaging technique requires only very
low laser power to create the characteristic reflectance pattern, so it does not
excite any fluorescent proteins since the laser power is not high enough
(Schain, Hill, and Grutzendler, 2014). The SCoRe image was taken in the
same region and z-dimension as the fluorescent image of the mEOS2
positive cell, to allow overlapping of the two images; see figure 3.4.
3.2.4 Live imaging and conversion of mEOS2
The slices were imaged 14 days after the transduction with the lentivirus
containing the mEOS2 construct. The lentivirus used for this study was
supplied by Pamela Brown at the SURF facility of the University of
Edinburgh, who cloned and created the construct. For live imaging of
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mitochondria in the cerebellar brain slices an upright Zeiss LSM 880
airyscanner with a Zeiss 20x water dipping objective (NA 1.0) was used.
The CO2 independent Hibernate A was used as a live imaging solution and
the slices were imaged in a heating chamber maintained at 37 ◦C. To convert
the mEOS2 positive mitochondria from the basal green fluorescence to red
fluorescence, selected parts of the neurons were illuminated with a 405nm
laser with 3% laser power for 10 to 60 seconds, depending on the structure
that was converted. The cell body required longer exposure time than the
axon to be converted. To determine if the newly transported green
mitochondria come from the cell body, a 50µm segment adjacent to AIS was
converted using the 405nm laser at 3% laser power for around 20 seconds.
After the conversion a 85µm segment was imaged, using a 20x water
dipping objective from Zeiss (NA 1.0), every minute for 20 minutes. Newly
incoming mitochondria were counted visually and on the kymograph,
while their size was measured in ImageJ when they first appeared in the
axon.
3.2.5 Analysis of movement and fusion
For the analysis of newly transported unconverted green mitochondria into
the ROI each axon image series was manually analysed, for that each image
of the series was checked for any new green mitochondria appearing either
from the cell body direction or from the distal part of the axon.
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FIGURE 3.5: Newly transported mitochondria displaying
only green fluorescence. Depicted is a timelapse image
series showing several stationary red mitochondria with some
green residue and newly transported mitochondria with green
fluorescence only. Scalebar=10µm
For each mitochondrion appearing, the direction of movement was noted,
as well as the area of the mitochondrion was measured when it first appeared
in the ROI.
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FIGURE 3.6: Fusion dynamics within a myelinated axon, shown
in a timelapse image series with fusion data for 5 stationary
red mitochondria within the ROI, increasing sharply in green
fluorescence (bar graphs) after fusion events and loosing green
fluorescence (bar graphs) after a fission event. Scalebar=10µm
The newly transported mitochondria could be distinguished, because
they displayed green fluorescence only, as opposed to the converted
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mitochondria already present within the ROI, which were mostly red with
some green residue inside. To calculate fusion of newly incoming
unconverted (green) mitochondria with the stationary converted (red)
mitochondria within the region of interest, an ImageJ macro to calculate the
proportion of green in red fluorescence at different timepoints after
conversion, corrected for the baseline green fluorescence right after
conversion, was used. For this the baseline image was imported into ImageJ
the channels were split into green and red, the red channel was thresholded
using the default threshold and the green threshold was set to the same
value. The first part of the macro was activated by pressing ’2’ on the red
channel, which measured the area of the red mitochondria in the ROI by
using the ’particle analysis’ function of ImageJ. The second part of the
macro was activated, after the two color channels were merged by using the
’Image->Color->Merge Channels...’ option in Imagej, by pressing the macro
shortcut ’3’, which calculated the green area inside the red area.
This process was done for the earliest timepoint after conversion and the
20 minute timepoint, and the baseline green in red percentage (earliest
timepoint after conversion) was then substracted from the percentage of
green in red at the 20 minute timepoint to calculate the increase in green
inside red fluorescence, which represents the amount of fusion that took
place during the imaging process, minus the amount of fission during that
time. The green in red fluorescence increased sharply after fusion of an
incoming green mitochondria with a stationary red mitochondria within the
ROI, and decreased again after a fission event; see figure 3.6.
3.2.6 Kymograph generation and analysis of mitochondrial
speed
Kymographs of the timelapse images were generated by using the ImageJ
plugin KymographClear2.0, roughly this is done by performing a
Z-projection of the hyperstack and registering the stack to the first image.
Via the selected line tool the axon is traced, subsequently straightened by
the macro and the width in pixels is selected, which was 20 pixels for these
experiments. The linearized stack is then resliced and finally a z-projection
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of the resliced image generates the kymograph (Pham and Chan, 2014;
Mangeo, Prevo, and Peterman, 2016).
FIGURE 3.7: Kymograph of a myelinated axon showing
the tracing of individual movements of mitochondria in the
kymograph, which were subsequently used for the calculation
of the mitochondrial movement speed.
Mitochondrial speeds were subsequently measured by using the
Kymotoolbox Imagej plugin (designed by Fabrice Cordelieres), this was
done by tracing the single lines in the kymographs with the segmented line
tool and calculating the speed with the “analyze kymo” function of the
Kymotoolbox plugin, which calculates the displacement amount of a traced
particle over time; see figure 3.7 (Mangeo, Prevo, and Peterman, 2016; Zala
et al., 2013). Since the ROI was only imaged every minute, it was not
possible to measure ’real’ mitochondrial movement speed, but rather a
relative speed, which can be compared between different axons. The
mitochondrial number, entering from anterograde or retrograde direction,
was represented by the number and slope direction of tracks in the
kymograph.
3.2.7 Immunohistochemistry
For Immunohistochemistry protocol see methods section in chapter 2.
Antibody application
For Immunohistochemistry protocol see methods section in chapter 2.
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3.3 Results
3.3.1 Validation of SCoRe technique
To validate if the SCoRe technique really shows the myelin reflectance
pattern it was used in combination with IHC antibody staining against
MBP; see figure 3.8. Since this technique also works on fixed brain sections,
PFA fixed brain sections were stained with NF (for axons) and MBP (for
myelin) and subsequently imaged on a Zeiss LSM 710 confocal microscope
to visualize axons and their myelin; see figure 3.8. On the same region the
SCoRe technique was then applied by changing the confocal microscope
settings and the resulting SCoRe imaging was then overlapped with the
IHC staining from before; see figure 3.8.
FIGURE 3.8: Validation of SCoRe technique. (A) IHC staining
for NF and MBP to validate the SCoRe technique. (B)
SCoRe image of same area as in (A). White arrow=myelinated
axon which can also be seen in the SCoRe image. Red
arrow=demyelinated axon, which is missing from the SCoRe
image on the right. Scalebar=10µm
3.3.2 Stability of mEOS2 protein and viability of cerebellar
slices
To test the stability of the converted mEOS2 protein and the slice culture
viability, cerebellar slices were injected with the Picospritzer III R© to get
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mEOS2 positive cells, at this point it was not important which cell type
would be transduced, as this was just to evaluate the stability of the
converted protein in general, as well as the slice viability.
FIGURE 3.9: Stability of mEOS2 protein, shown in several
different fluorescence images before, directly conversion after
and 1 week after conversion. (A) Fluorescent images of cells
before conversion displaying only green fluorescence. (B) After
conversion mEOS2 is displaying only red fluorescence. (C) The
same region 1 week after conversion with the red fluorescence
being still stable, while a lot of new green mitochondria
appeared over time. Scalebar=40µm
After 2 weeks in culture a complete field of view was converted using
the UV laser on the confocal microscope and the same region was observed
1 week after conversion; see figure 3.9. The red converted protein was still
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observable and seemed to be stable even one week after conversion, while
the converted cells were still alive and overall the slice culture appeared to
be intact; see figure 3.9. Apart from the converted cells from the week
before, many other cells that started expressing mEOS2 after the conversion
and were visible by harbouring only unconverted green mEOS inside their
mitochondria; see figure 3.9. An issue of the mEOS2 protein is the bleaching
after laser exposure, which is quite significant after imaging every 30
seconds over 30 minutes, with the green being strongly affected by
photobleaching and the red being relatively stable over this time frame.
Because of this issue the imaging was limited to 20 minutes with 1 z-stack
imaging per minute, to reduce the bleaching of the green.
3.3.3 Transduction of PC
To transduce cells within the cerebellar slice culture 5µl of the lentiviral
solution containing the mEOS2 construct was pipetted on top of the slices
right after the slicing procedure. This only lead to a transduction of cells on
the outer rim of the cerebellar slices, while all the inner parts, including the
PCL were not transduced at all. To get the lentiviral solution into the deeper
layers of the cerebellar slice culture a pressure controlled Picospritzer III R©
system was used.
To image the transport and fusion dynamics in myelinated and
unmyelinated axons in cerebellar PC, several different optimization steps
were necessary to get mEOS2 positive PC in the cerebellar brain slices. The
first step was to test several different viral envelope proteins, among them
the WE, MLV-AMPHO and MLV-ecotrophic (murine leukemia virus),
Rabies, MOK (Mokola virus) and the widely used VSV-G (Vesicular
stomatitis virus glycoprotein) envelope proteins to test which of these give
the best neuronal transduction efficiency; see figure 3.10. Indeed the VSV-G
envelope protein resulted in the greatest number of positive cells, which
was the reason for using this envelope for all future experiments; see figure
3.10.
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FIGURE 3.10: Lentivirus with different envelope proteins,
showing transfected cells in green at different magnifications.
Scalebar=20µm for WE, MOK, Rabies and MLV-AMPHO and
Scalebar=40µm for MLV-ecotrophic and VSV-G
But, as revealed by IHC staining for calbindin, which in the cerebellum is
specifically expressed in the PC, it did not result in any positive PC; see
figure 3.11. Also, all the other envelope proteins did not transduce any
cerebellar PC, while giving a lot less positive transduced cells overall. Since
non of the envelope proteins lead to a transduction of PC in the cerebellar
brains slices, an intense literature research was performed to find possible
reasons. The japan based group lead by Hirokazu Hirai reported that a
shorter (after 40 hours) harvest of lentivirus lead to a better transduction of
PC in vivo and later showed in another publication that the reason behind
this was the change in pH over time and the subsequent change in cathepsin
K expression, as this was responsible for the switch from the
neuron-preferential transduction at the earlier harvest timepoint (after 40
hours) to a glia-preferential transduction at the later harvest timepoint (after
64 hours) and this effect could be reversed by treating the HEK cells with
cathepsin K inhibitor before harvesting the virus (Torashima et al., 2006;
Goenawan and Hirai, 2012).
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FIGURE 3.11: Lenti-CMV-mEOS2 not able to transduce
purkinje cells in cerebellar slices. mEOS2 (green) transfected
slices stained for PC (calbindin) in red showing no overlap
between the two. Scalebar=left 40µm right 50µm
This treatment with cathepsin-K inhibitor leads to a stronger
transduction of neurons, as opposed to mostly glial cell transduction by
lentivirus without cathepsin K inhibitor (Goenawan and Hirai, 2012). The
treatment of the HEK cells with cathepsin K inhibitor still did not lead to
transduction of PC in the cerebellar slices, but it did show mEOS2 positive
neuronal cells in dorsal root ganglion (DRG) culture. Some more literature
research showed some reports that stated that the CMV promoter, which is
the promoter driving the mEOS2 construct, is not effective in some in vitro
experiments and it was hypothesized that the CMV is silenced in the PC in
vitro (Li et al., 2010; Kumar et al., 2015). It was shown by Wheeler et al that
the CMV promoter is activated by neuronal depolarization and that this can
be mimicked by adding forskolin, therefore forskolin was added to the
medium one day after slicing and renewed two days later (Wheeler and
Cooper, 2001). Around 12 to 14 days after the slicing procedure and adding
forskolin, mEOS2 positive purkinje cells could be found in the slices; see
figure 3.12.
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FIGURE 3.12: Transduction with mEOS2 in cerebellar purkinje
cells and conversion with 405nm laser. mEOS2 positive PC
unconverted (A) and with converted cell body (B). The inlets
showing a magnification of the cell body before (A) and after
(B) conversion with the 405nm laser. Scalebar=40µm
Two different structures were converted to determine the mitochondrial
dynamics in the axons of cerebellar PC, namely the cell body and the axon,
which both lead to the axonal mitochondria fluorescing differently from
mitochondria in the cell body; see figure 3.12. The conversion of the cell
body resulted in the cells dying 1 day later. This could be a result of damage
to the DNA by the strong UV illumination, because of the big number of
mitochondria in the cell body it needed longer UV illumination than other
structures of the cell.
In contrast to the conversion of the cell body, converting the axon lead to
cells with converted axonal mitochondria that were still healthy 2 days after
the conversion with UV laser. The ROI for the conversion with the 405nm
laser was chosen so that the mitochondria in the axon are converted as
complete as possible, while minimizing the conversion of the mitochondria
in the cell body; see figure 3.13. This was achieved by converting the first
part of the axon just after the AIS, as there was a spill-over conversion
outside the ROI. This lead to the axonal mitochondria in the ROI being red,
while the cell body mitochondria and the axonal mitochondria outside the
ROI were mostly green fluorescent; see figure 3.13.
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FIGURE 3.13: Conversion of mEOS2 in purkinje cells,
depicted in fluorescence images showing a converted PC. The
mitochondria in the cell body are still mostly green (arrow),
while the mitochondria in the ROI (box) are fully converted to
red fluorescence. Scalebar=10µm
3.3.4 Mitochondrial dynamics of newly transported
mitochondria
Mitochondrial movement in myelinated and unmyelinated axons
To check the dynamics of mitochondrial movement in the myelinated and
unmyelinated axon, slices were injected with a lentivirus containing the
mEOS2-construct and were imaged 14 days later; see figure 3.14. In the
unconverted cell body and axon, all mitochondria displayed green
fluorescence and only minor background red fluorescence was visible before
conversion; see figure 3.13. Axons with sufficient positive SCoRe reflection
in the field of view were counted as myelinated, whereas axon without any
myelin in the field of view were counted as unmyelinated. Axons with
uncertain SCoRe reflection were not included.
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FIGURE 3.14: Fluorescence image of a pre conversion mEOS2
positive PC, showing that all mitochondria in the cell body and
axon are green fluorescing before conversion and only minor
red background fluorescence is visible. The arrows mark the
cell body in the green and red channel images. Scalebar=20µm
Since the axonal mitochondria in the ROI were all converted to red and
all mitochondria outside the ROI (including the cell body and axon) were
unconverted green fluorescent, newly transported green mitochondria
could readily be observed and counted; see figure 3.15. Fusion of the newly
transported green mitochondria with the converted red mitochondria in the
axon lead to yellow fluorescent mitochondria in the ROI. This enabled the
analysis of mitochondrial movement and fusion in the ROI. Overall there
was a trend of more newly transported green mitochondria entering the
converted part of the axon in the unmyelinated compared to the myelinated
axon from the anterograde direction and significantly more newly
transported mitochondria entering from the retrograde direction; see figure
3.16.
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FIGURE 3.15: Mitochondrial transport dynamics in myelinated
and unmyelinated axons. Depiction of a converted segment of
a myelinated (A) and unmyelinated (B) axon, showing newly
transported green mitochondria moving into the converted
part (white arrows). The continuous box represents the
converted part of the axon, while the dashed box indicates the
ROI for imaging. Scalebar=20µm for low magnification and
10µm for high magnification images
The size of the newly transported mitochondria was significantly bigger
in the anterograde direction and in the retrograde direction in the
unmyelinated compared to the myelinated axons; see figure 3.16.
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FIGURE 3.16: Mitochondrial transport dynamics in myelinated
and unmyelinated axons, showing the number of newly
transported green mitochondria into the converted axon and
their respective sizes. There was a significant increase in
number of newly transported mitochondria in the retrograde
direction and a significant increase in size of newly transported
mitochondria moving in the anterograde and retrograde
direction in the unmyelinated compared to the myelinated
axon. Each dot represents the average of all mitochondria from
one axon; the total n-number for the myelinated axons is 16
slices from 12 different mice and for the unmyelinated 8 slices
from 6 different mice. **=p-value <0.01; *=p-value <0.05
Mitochondrial speed in the myelinated axon
Kymographs of the timelapse images, every minute imaged was included,
were generated with the ImageJ plugin KymographClear2.0 and
mitochondrial speeds were subsequently measured by using the
Kymotoolbox Imagej plugin (designed by Fabrice Cordelieres), this was
done by tracing the single lines in the kymographs with the segmented line
tool and calculating the speed with the “analyze kymo” tool; see figure 3.17
(Mangeo, Prevo, and Peterman, 2016; Zala et al., 2013). The anterogradely
moving newly transported mitochondria displayed a significantly greater
speed in the unmyelinated axons compared to the myelinated axons, while
the retrograde moving speed of newly transported mitochondria showed a
trend towards an increase in the unmyelinated compared to the myelinated
axons, which might become significant with higher n-numbers; see figure
3.18.
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FIGURE 3.17: Kymographs of a myelinated (top panel) and
unmyelinated (bottom panel) axon, the black arrows pointing
in the anterograde direction. The left panels shows the
movement of newly transported green mitochondria, while the
right panels show converted red mitochondria within the axon
of myelinated (top) and unmyelinated (bottom) axons.
FIGURE 3.18: Mitochondrial movement speed in the
unmyelinated and myelinated axons. There was a significant
increase of mitochondrial anterograde movement speed in
the unmyelinated compared to the myelinated axon. Each
dot represents the average of all mitochondria from one axon;
the total n-number for the myelinated axons is 16 slices from
12 different mice and for the unmyelinated 8 slices from 6
different mice. *=p-value <0.05
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Mitochondrial fusion in the myelinated and unmyelinated axon
To determine the fusion rate of newly transported green mitochondria with
the stationary red mitochondria inside the axon, the percentage of green in
red fluorescence in the ROI was determined at different timepoints after
conversion and corrected for the baseline green in red fluorescence.
FIGURE 3.19: Mitochondrial fusion event, depicted in a
timelapse image series, which shows a fusion event and
subsequent increase in green fluorescence in the stationary red
mitochondria over 3 minutes. Scalebar=8µm
FIGURE 3.20: Fusion of newly transported mitochondira with
the stationary converted mitochondria within the ROI. There
was a significant increase of mitochondrial fusion, as well as
significantly more newly transported green mitochondria that
have not (yet) fused with the converted mitochondria in the
unmyelinated compared to the myelinated axon. Each dot
represents the average of all mitochondria from one axon; the
total n-number for the myelinated axons is 16 slices from 12
different mice and for the unmyelinated 8 slices from 6 different
mice. *=p-value <0.05
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FIGURE 3.21: Mitochondrial fusion and fission dynamics,
depicted in a timelapse series which shows a sharp increase
in the green in red fluorescence (bar graphs) after a fusion
event and decreasing (bar graphs) after a fission event over the
imaged time in a myelinated axon. Scalebar=8µm
The green in red fluorescence increased sharply after fusion of an
incoming green mitochondria with a stationary red mitochondria within the
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ROI, and decreased again after a fission event. In some instances it was also
possible to observe single fusion events; see figure 3.19.
FIGURE 3.22: Mitochondrial fusion and fission dynamics,
depicted in a timelapse series which shows a sharp increase
in the green in red fluorescence (bar graphs) after a fusion
event and decreasing (bar graphs) after a fission event over the
imaged time in an unmyelinated axon. Scalebar=10µm
The analysis showed an increase in mitochondrial fusion in the
unmyelinated axon compared to the myelinated axon, while most of the
newly incoming mitochondria did not fuse with the stationary red
mitochondrial pool over the imaged time; see figure 3.20. The
measurements for the fusion data were done at the end of the imaging
process by determining the green in red fluorescence and correcting it for
the baseline green in red fluorescence. The fusion and fission events
Chapter 3. Mitochondrial dynamics in the myelinated axon 74
however are very dynamic processes and during the imaging time several
fusion/fission events can take place, so the fusion data effectively
underestimates the fusion events taking place during that time. Green in red
fluorescence increases sharply after a fusion event and decreases after a
fission event; see figure 3.21. Apart from the overall greater increase of
green in red fluorescence over the imaged time, the single fusion and fission
events also displayed a higher dynamic in the unmyelinated compared to
the myelinated axon; see figure 3.22.
3.3.5 Mitochondrial dynamics of converted mitochondria
Mitochondrial movement in myelinated and unmyelinated axons
To determine the movement of mitochondria already present in the
myelinated and unmyelinated axons of PC, the red converted mitochondria
were analysed for anterograde/retrograde movement and size of
mitochondria. Overall there was no significant difference in the number of
converted moving mitochondria between the myelinated and
unmyelinated; see figure 3.23. Furthermore, the average size of the moving
converted mitochondria did not differ between the two conditions.
FIGURE 3.23: Dynamics of converted mitochondria within the
ROI, depicting the number of moving converted mitochondria
on the left and the average size of these moving converted
mitochondria (in µm2) per axon on the right. Each dot
represents the average of all mitochondria from one axon.
There was no significant difference in both parameters between
the unmyelinated and myelinated axon; the total n-number for
the myelinated axons is 5 slices from 5 different mice and for
the unmyelinated 5 slices from 4 different mice.
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Mitochondrial speed in the myelinated and unmyelinated axon
While most of the converted mitochondria did not move great distances, the
speed of the ones moving was analysed in myelinated and unmyelinated
axons. To measure the speed of the unconverted red mitochondria, the
according lines in the red kymographs were traced and speed was
calculated by using the Kymotoolbox ’analyse kymo’ function. The speed of
mitochondria in myelinated axons did not differ significantly from the
speed of mitochondria in the unmyelinated axons, neither in anterograde,
nor retrograde direction; see figure 3.24.
FIGURE 3.24: Mitochondrial movement speed of the converted
mitochondria within the ROI, showing no significant difference
in mitochondrial movement between the myelinated and
unmyelinated axons. Each dot represents the average of
all mitochondria from one axon; the total n-number for the
myelinated axons is 5 slices from 5 different mice and for the
unmyelinated 5 slices from 4 different mice.
Chapter 3. Mitochondrial dynamics in the myelinated axon 76
3.4 Discussion
3.4.1 Transduction of PC in cerebellar slices and conversion
of mEOS2 protein
To analyse the mitochondrial transport and fusion dynamics in the
myelinated and unmyelinated axon, the green to red photoconvertible
protein mEOS2 was used for live imaging of PC axon in cerebellar slices
(McKinney et al., 2009). As discussed in the introduction, the mEOS2
protein can be irreversibly converted from the unconverted green to the
converted red state and as shown in Figure 3.9 the converted state remains
stable at least a week in culture (McKinney et al., 2009). Furthermore, the
protein does not seem have a toxic effect on the cells, leaving them growing
even 3 weeks after transduction with the lentivirus expressing the
photoconvertible protein, which also shows that the lentivirus is not
harming the cerebellar slices to a significant extent. The transduction of PC
in the cerebellar slices was a major challenge during this project, as several
different steps are necessary to get mEOS2 positive PC by using the
lentiviral construct with CMV promoter. Firstly it was necessary to use a
pressure controlled system, like the Picospritzer III R© to get the viral
solution into the deeper layers of the slices, as pipetting the solution on top
only leads to transduction of cells in the outer rim of the cerebellar slices.
An optimization of pressure strength, duration of injection and needle
thickness was done and the tracer dye FG was used to give visual feedback
during injections. The test series of several different viral envelope
glycoproteins, showed that the widely used VSV-G envelope protein is the
most suitable one to get a high transduction rate in the cerebellar slices
(Cronin, Zhang, and Reiser, 2005). By using a shorter harvest timepoint, 40
hours after the setting up of the HEK293T cell culture instead of 64 hours,
and by adding the Cathepsin K Inhibitor to the HEK293T cell culture, the
transduction of neurons with the lentivirus containing the mEOS2 construct
was increased (Torashima et al., 2006; Goenawan and Hirai, 2012). This
could be observed in DRG culture, were the transduction of DRG was much
more efficient with the short 40 hour harvest and the Cathepsin K Inhibitor
treatment compared to the 64 hours harvest without Cathepsin K Inhibitor.
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The activation of the activity dependant CMV promoter, was achieved
by depolarizing the PC by adding forskolin to the slice culture medium
(Wheeler and Cooper, 2001). Using this method mEOS2 positive PC can be
observed in culture 12-14 days after the injection of the lentivirus. It is
possible to photoconvert single structures of a cell by illuminating a region
of interest with UV laser, this ROI can be very small, even conversion of
single mitochondria is possible if neighbouring mitochondria are not too
close. If converting bigger structures, the conversion gradient has to be
taken into consideration, as illuminating a ROI for complete
photoconversion, will results in a partial conversion of the adjacent
structures, structures further away will not be converted. Another
important finding is that strong illumination of the cell body leads to the
cells degeneration within 24 hours, one reason for this could be extensive
DNA damage due to the long exposure to the UV laser. The conversion of
the axonal mitochondria, adjacent to the AIS to prevent conversion of the
cell body mitochondria, did not lead to the degeneration of the PC even
after 48 hours. The SCoRe technique proved to be a valuable tool by
revealing the myelination status of the axons during live imaging (Schain,
Hill, and Grutzendler, 2014).
3.4.2 Mitochondrial dynamics in myelinated and
unmyelinated axons
The mitochondrial movement dynamics in myelinated and unmyelinated
axons were measured by manual counting and kymograph analysis. The
manual analysis also allowed to measure the size of any incoming
mitochondrion. Despite having some residual green fluorescence in
myelinated axons, there was not much mitochondrial movement observed
compared to the unmyelinated axons. This phenomenon of residual green
within the converted part of the axon was observed in both myelinated and
unmyelinated axons, but since only completely green mitochondria were
counted as being newly transported, it is still clear that this set of
mitochondria is coming in from the cell body or distal part of the axon
respectively. The movement analysis showed a trend toward more
mitochondria moving into the ROI from the anterograde direction and a
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significant increase in retrograde movement in the unmyelinated axons
compared to the myelinated axons. This increased mitochondrial transport,
could be due to an increase in energy demand in the unmyelinated
compared to the myelinated axon, possibly due to more sodium channels
being placed along the unmyelinated axon, leading to increased sodium
influx and demand the more ATP driven Na+/K+ ATPase activity to get rid
of excess sodium (Craner et al., 2004b; Witte et al., 2014; Mahad, Trapp, and
Lassmann, 2015; Mohd, 2010; Albers and Siegel, 1998; Lores Arnaiz and
Ordieres, 2014). Concerning the size, significantly bigger mitochondria were
entering from the distal axonal part via retrograde transport and as well as
from the cell body direction via anterograde transport in the unmyelinated
axon opposed to the myelinated axon. In this system it is not possible
distinguish between unmyelinated and demyelinated axon, so it is entirely
possible that some of these axons were demyelinated following the slicing
procedure or other stress factors during the in vitro culture process.
Interestingly, there was quite a spread of numbers of mitochondria moving
in either direction, especially in the anterograde direction, in the
unmyelinated axons. So it could be speculated that some of these axons
really were unmyelinated from the start, while others have been
demyelinated after being already myelinated, and that these two
populations of axons have a distinct mitochondrial transport profile.
When determining the rate of mitochondrial fusion of the newly
transported unconverted (green) mitochondria with the stationary
converted (red) mitochondria within the ROI, by measuring the increase of
the green inside red fluorescence from the timepoint after conversion to the
20 minute timepoint, a significant increase of fusion was observed in the
unmyelinated axons compared to the myelinated axons. As with the
transport, the increase in fusion, could be an adaptive mechanism to an
increase in energy demand in the unmyelinated, or possibly demyelinated
axons, as bigger mitochondria produce ATP more efficiently. Most
importantly the observations made in the mitochondrial transport and
fusion dynamics in the myelinated axon set the baseline for further
experiments in the which the cerebellar slices were treated with a
demyelinating agent and made it possible to assess any effect demyelination
might have on mitochondrial dynamics in PC axons in cerebellar slices.
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Chapter 4
Mitochondrial dynamics in the
demyelinated axon
4.1 Introduction
4.1.1 Live imaging of mitochondria in demyelinated axons
Mitochondrial pathology has been implicated in axon degeneration in
multiple sclerosis and relevant disease models. It has also been reported
that mitochondrial damage, without demyelination, is sufficient to lead to
axonal death, showing the importance of mitochondrial function in disease
(Dutta et al., 2006; Campbell et al., 2011; Campbell and Mahad, 2012; Mahad
et al., 2009; Mahad, Trapp, and Lassmann, 2015; Nikić et al., 2011; Sorbara
et al., 2014). There have been already several studies that involved live
imaging of mitochondrial dynamics in axons either in vivo or in vitro (Ohno
et al., 2011; Kiryu-Seo et al., 2010; Misgeld et al., 2007; Misgeld, Nikic, and
Kerschensteiner, 2007). Misgeld et al developed two mouse lines that
express either CFP (Thy1-mitoCFP) or YFP (nse-mitoYFP) under the control
of the neuron specific Thy1 or nse promoter respectively, both targeted to
mitochondria by a mitochondrial targeting sequence (Misgeld et al., 2007;
Misgeld, Nikic, and Kerschensteiner, 2007). These mouse lines can be used
to image mitochondrial dynamics both in vivo or in acutely explanted
nervous tissue. The labelling by mitoCFP or mitoYFP seems to leave
mitochondrial physiology mostly intact, as Misgeld et al show that the
mitochondria are still co-stained by membrane potential-sensitive
mitochondrial dyes (Misgeld et al., 2007; Misgeld, Nikic, and
Kerschensteiner, 2007). The authors also checked for mitochondrial changes
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after the transection of intercostal nerves in vivo and reported that already
by 3 hours after transection the distal axonal segment showed 2-3 fold
reduction in mitochondrial anterograde transport and more than 20-fold
after 6 hours (Misgeld et al., 2007). In contrast to the distal axon, the
proximal part of the axon showed an increase in anterograde transport by
12 hours after the injury, which was maintained at 24 and 48 hours, before
declining over the following weeks (Misgeld et al., 2007). This increase in
anterograde transport could be a sign of injury response, which contributes
to regeneration (Misgeld et al., 2007).
Several publications on mitochondrial dynamics in myelinated and
demyelinated axons were made by the Trapp Group from Cleveland and the
Mahad Group. In the first publication the Trapp group used an in vitro rat
DRG myelinating culture and infected it with a mito-DsRed2 expressing
lentivirus to follow any changes in mitochondrial dynamics via live
imaging. They found an increase in size of the mitochondrial stationary
sites after demyelination with lysolecithin, as well as an increase in
mitochondrial transport speed (Kiryu-Seo et al., 2010). These changes
returned to baseline after remyelination of the DRG axons. However they
did not look at the number of stationary sites or moving mitochondria in the
remyelinated axon, which was checked by Zambonin et al and they
reported an increase in the number of stationary sites in remyelinated axon
(Zambonin et al., 2011). Kiryu-Seo et al furthermore reported that
lysolecithin had no apparent effect on unmyelinated axons, so the changes
after demyelination can be attributed to the loss of myelin rather than an
effect of lysolecithin on mitochondria (Kiryu-Seo et al., 2010). In the second
publication the Trapp group used cerebellar slice culture to look at the
difference of mitochondrial stationary sites and transport in the
nodal/paranodal and juxtaparanodal/internodal axoplasm and reported
juxtaparanodel/internodal increase of mitochondrial stationary sites and
activity dependant modulation of mitochondrial motility (Ohno et al., 2011).
These effects were not observed in slices of the md-mutant, which lacks
compact myelin and subsequently does not form paranodal specializations
(Ohno et al., 2011). In the third publication from the Trapp group, again a
cerebellar slice culture system was used, both from wild-type and
syntaphilin-KO mice to look at the difference in the ARMD and the effect on
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axonal health (Ohno et al., 2014). They reported that the ARMD is not
mounted in the syntaphilin-KO, namely that there is no increase in
mitochondrial stationary sites, but an increase in the number and speed of
motile mitochondria in the KO compared to the wildtype (Ohno et al., 2014).
FIGURE 4.1: Method for the conversion of mitochondria
within different cellular compartments. Left: conversion of
cell body and movement of converted red mitochondria into
the axon where fusion with stationary unconverted green
mitochondria gives rise to yellow mitochondria in the axon.
Right: conversion of axon and movement of newly transported
unconverted green mitochondria into the axon where fusion
with stationary converted red mitochondria gives rise to yellow
mitochondria in the axon.
Furthermore, they showed that there is a significant increase in
Alzheimer-precursor-protein (APP) positive axons in the KO, which
indicates increase degeneration of axons in the KO (Ohno et al., 2014). This
finding points towards a protective effect of the ARMD in the short term.
(Ohno et al., 2014). Although these studies provide insight into the changes
of mitochondrial parameters after demyelination, none of the mentioned
studies looked at the fusion dynamics of the ARMD, nor was it determined
where these additional mitochondria come from. To study the dynamics of
the ARMD in more detail, namely to determine were the additional
mitochondria that are responsible to mount the ARMD come from and to
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assess the fusion dynamics in the demyelinated PC axons, cerebellar slices
were transduced by injecting the mEOS2 containing lentivirus into the PCL
of the slices by using the Picospritzer III R©. By using the photoconvertible
protein mEOS2, it is possible to convert a subset of mEOS2 (green in basal
state) expressing mitochondria (red in converted state) and determine the
rate of fusion with non-converted green mitochondria, by assessing the
green in red fluorescence; see figure 4.1 (McKinney et al., 2009).
Furthermore, by converting the first part of the axon adjacent to the AIS it
can be determined from which direction newly transported (unconverted
green) mitochondria come into the converted (red) segment of the axon; see
figure 4.1.
4.2 Materials and methods
Animals
All procedures were performed according to the 1986 Animals Act
(scientific procedures) UK and were approved by the local ethics committee.
For all the experiments C57BL/6 mice were used. For the generation of
cerebellar organotypic slice cultures mice from P7 to P12 were used, because
slice generated at this age ensures a good survival of purkinje cells, while
already displaying many features of the adult structure of the cerebellum.
4.2.1 Demyelination with lysolecithin
To determine the fusion and transport dynamics of mitochondria in
demyelinated axons, lysolecithin (L-α-Lysophosphatidylcholine powder
from egg yolk; L4129 Sigma) was used as the demyelinating agent, as
Lysolecithin has, as mentioned in chapter 2, the least effect on mitochondria
among the most widely used demyelination agents (Birgbauer, Rao, and
Webb, 2004; Zhang et al., 2011; Komai, Hunter, and Takahashi, 1973;
Keough, Jensen, and Yong, 2015; Jeffery and Blakemore, 1995; Wallace et al.,
2003; Yu et al., 2007). Right before the demyelination timepoint, the
L-α-Lysophosphatidylcholine powder was dissolved in slice culture
medium to the appropriate concentration, heated in the 37 ◦C water bath
and mixed by using a Vortex Genie R©. After the lysolecithin was completely
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dissolved, 800µl of the lysolecithin solution was added to each well of a six
well plate and the membranes with the slices on top were transferred from
the previous six well plate into the lysolecithin containing plate by using a
forceps. To find out the optimal concentration of lysolecithin to ensure
complete demyelination, while keeping the morphology of the axons intact,
several different lysolecithin dilutions were tested. The most widely used
concentration, which was also used in chapter 2, 0.5mg/ml lysolecithin left
on for 17 hours did not lead to significant demyelination (Birgbauer, Rao,
and Webb, 2004). Alternatively 0.5mg/ml was left on for 24 hours,
0.75mg/ml was tested for 17 hours and 24 hours, as well as 1mg/ml for 17
hours and 24 hours and 2mg/ml for 17 hours.
4.2.2 Determining mitochondrial dynamics in the
demyelinated axon
In chapter 2 the timecourse of the ARMD was determined by examining the
mitochondrial parameters at different timepoints after demyelination.
FIGURE 4.2: ScoRe technique depicting a myelinated (left
panel) and demyelinated (right panel) mEOS2 positive axon.
The white rectangle shows the area which was converted
and used for the subsequent live imaging experiment.
Scalebar=20µm
Furthermore, as the analysis in chapter 2 showed, that the ARMD is
mounted very fast after demyelination and this suggests that it would be
possible to observe any changes in mitochondrial dynamics soon after
demyelination with lysolecithin. Because of these findings, the first part of
the axon near to the cell body was converted by using UV laser and imaged
every minute over 20 minutes, right after the lysolecithin was removed from
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the slice culture. Like in chapter 3, SCoRe was used to determine the
myelination status of the axons; see figure 4.2. Mitochondrial movement
direction, size and numbers, as well as mitochondrial speed and fusion
dynamics were determined. Like in chapter 3, the fusion of newly
transported unconverted (green) mitochondria with the converted (red)
mitochondria into the ROI was determined by measuring the increase of
green in red fluorescence over the imaged time, this was corrected for the
baseline fluorescence right after conversion. For the mitochondrial transport
of unconverted green into the converted red ROI two different methods
were used. The first method, as used in chapter 3, was to determine the
newly transported unconverted green mitochondria by manual analysis and
to measure the size of each of these mitochondria. The second method,
which also allowed to compare the relative transport speed between
different axons, was to create kymograph by using the KymographClear 2.0
Plugin for Imagej and to use the kymotoolbox plugin function to measure
the number and speed of green mitochondria being transported within the
ROI (Wallace et al., 2003; Zala et al., 2013). For the analysis of speed the
’analyse kymo’ function of the kymotoolbox plugin was used and, after the
individual tracks were traced by using the ’segmented line’ tool, the
movement speed of traced mitochondria was calculated. Since the ROI was
only imaged every minute, it was not possible to measure ’real’
mitochondrial movement speed, but rather a relative speed, which can be
compared between different axons. The mitochondrial number, entering
from anterograde or retrograde direction, was represented by the number of
tracks in the kymograph.
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4.3 Results
4.3.1 Determination of the myelination extent in cerebellar
slices
Since the lentiviral transduction of PC in organotypic brain slices of the
cerebellum is quite sparse and random, it was important to determine the
myelination ratio in the cerebellar slices.
FIGURE 4.3: Amount of myelinated and unmyelinated axons
within cerebellar slices. Fluorescent image showing myelinated
and unmyelinated axons with IHC staining for NF and MBP in
cerebellar slices. The arrow depicting some of the myelinated
axons, while the arrowheads point at unmyelinated axons.
Scalebar=15µm
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For this the slices were left in culture for 14 days, the same amount of
time as they would be in culture for demyelination and live imaging, and
stained with IHC for NF and MBP to determine the amount of myelinated
axons; see figure 4.3. Axons with sufficient continuous myelination in the
field of view were counted as myelinated, whereas axons without myelin or
with very little myelin in the field were counted as being unmyelinated; see
figure 4.3. The ratio of unmyelinated to myelinated axons was 1:5, which
amounts to about 80% of axons being myelinated after 2 weeks in culture;
see figure 4.4. Another possibility would be that those axons were actually
demyelinated by an unknown process at some time point during or after the
slicing procedure.
FIGURE 4.4: Proportion of myelinated axons in cerebellar
slices after 14 days in culture, showing that about 20% of
axons on cerebellar slices were either unmyelinated after 2
weeks in culture or demyelinated at some time after the slicing
procedure by an unknown factor. Each dot represents one slice
from one mouse and includes at least 40 analysed axons
4.3.2 Determination of the optimal lysolecithin
concentration
The dose of 0.5mg/ml lysolecithin for 17h turned out not to be sufficient to
demyelinate most of the axons in the slices, despite being suitable for IHC
staining analysis, like used in chapter 2, since only demyelinated axons can
be selected for analysis, it was not sufficient for live imaging as there is no
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guarantee that the mEOS2 positive cells were demyelinated. Therefore, a
lysolecithin concentration experiment was done, testing different
concentrations of lysolecithin left on for different amount of times, to check
which concentration gives enough demyelination and still leaves the axons
healthy and intact. 24 hours after removing lysolecithin, the slices were
fixed and stained for NF and MBP.
FIGURE 4.5: Effect of different lysolecithin concentrations
on demyelination efficiency and axonal health. The aim
was to determine the optimal concentration which leads to
nearly complete demyelination, while still keeping the axonal
integrity intact. 2mg/ml lysolecithin lead to a deterioration
of the axonal health, which can be seen as extensive beading
of the NF stained axons. 0.5mg/ml lysolecithin did not lead
to sufficient demyelination, while 0.75mg/ml and 1mg/ml
lysolecithin lead to enough demyelination with the axonal
integrity still being intact. Scalebar=30µm
As mentioned before and shown in 4.5 the most widely used
concentration of 0.5mg/ml lysolecithin, even when left on for 24 hours, did
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not lead to sufficient demyelination; see figure 4.5. The next higher
concentration 0.75mg/ml already prompted a better demyelination ratio at
17 hours exposure time, while the 24 hour exposure lead to an even better
demyelination efficiency, with the axonal integrity still intact; see figure 4.5.
The 1mg/ml concentration lead to sufficient demyelination both after 17
hours and 24 hours of lysolecithin treatment with normal axonal
morphology. Finally, the 2mg/ml concentration, which was only used for 17
hours, did demyelinate the axons completely, but also seemed to have a
detrimental effect on the axonal health, as their morphology was clearly
affected; see figure 4.5. The most fitting concentration and timing, which
was subsequently used in all live imaging experiments, was 0.75mg/ml
lysolecithin left on for 24h, because it was the lowest concentration that
showed an overall good demyelination efficiency, while still keeping the
axons intact; see figure 4.5.
4.3.3 Mitochondrial dynamics of newly transported
mitochondria
Direction of movement, number and size of newly transported
mitochondria
As in Chapter 3, the part of the axon adjacent to the AIS was converted and
imaged every minute over 20 minutes, to determine the difference in
mitochondrial transport and fusion dynamics between the myelinated and
demyelinated axons; see figure 4.6. Each newly transported green
mitochondrion was counted and the direction was noted, also the size of
each newly transported mitochondrion was calculated by using ImageJ; see
figure 4.6. Furthermore, the rate of fusion was calculated by the fraction of
green reappearing in the stationary red mitochondria over the imaged time.
Axons with sufficient positive SCoRe reflection in the field of view were
counted as myelinated, whereas axon without any myelin in the field of
view were counted as demyelinated. Axons with only minimal SCoRe
reflection were not included, which was a rare finding, because the
lysolecithin concentration used was determined as being high enough for
nearly complete demyelination of axons in the slices.
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FIGURE 4.6: Mitochondrial transport and fusion dynamics
in demyelinated axons, showing a converted segment of a
myelinated (A) and demyelinated (B) axon, showing newly
transported green mitochondria moving into the converted
part (white arrows). The continuous box represents the
converted part of the axon, while the dashed box indicates the
ROI for imaging. Scalebar=20µm for low magnification and
10µm for high magnification images.
Overall there were significantly more new green mitochondria being
transported into the demyelinated axon compared to the myelinated axon.
This mirrored the observation made in the unmyelinated axons compared to
the myelinated axons as shown in chapter 3.
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FIGURE 4.7: Mitochondrial transport dynamics in
demyelinated axons depicting the number of newly
transported green mitochondria and total area of incoming
mitochondria into the converted axon. There were significantly
more newly transported mitochondria moving in the
anterograde and retrograde direction in terms of numbers
and total area in the demyelinated compared to the myelinated
axon. Each dot represents the average of all mitochondria from
one axon; the total n-number for the myelinated axons is 16
slices from 12 different mice and for the demyelinated 18 slices
from 13 different mice. *=p-value <0.05 ;**=p-value <0.01;
****=p-value <0.0001
FIGURE 4.8: Mitochondrial transport dynamics in
demyelinated axons depicting depicting the sizes of newly
transported green mitochondria into the converted axon. Left:
average sizes in µm2; Right: sizes of single mitochondria
in µm2. There were significantly bigger newly transported
mitochondria moving in the anterograde direction, measured
as average and single sizes, in the demyelinated compared
to the myelinated axon. Each dot represents the average of
all mitochondria from one axon; the total n-number for the
myelinated axons is 16 slices from 12 different mice and for
the demyelinated 18 slices from 13 different mice. ***=p-value
<0.001; ****=p-value <0.0001
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This change was observed in both directions, while there were
significantly more mitochondria coming in from the anterograde direction
as compared to the retrograde direction in the demyelinated axon (not
shown); see figure 4.7. The significant increase in transported mitochondria
was reflected both in numbers as well as in total area. The size of the newly
transported green mitochondria was significantly greater in the anterograde
moving mitochondria of demyelinated axons compared to myelinated
axons, both the average sizes of mitochondria per axon and all single sizes
of all mitochondria; see figure 4.8. The size of retrograde moving
mitochondria did not differ between the two conditions.
Fusion of newly transported mitochondria with post-conversion
mitochondria
To determine the fusion rate of the newly transported green mitochondria
with the converted red mitochondria within the ROI, an Imagej macro was
used to calculate the green inside red ratio for each image-series and
corrected for the baseline green fluorescence.
FIGURE 4.9: Mitochondrial fusion dynamics depicting the
fusion of newly transported mitochondria with the converted
mitochondria in the axon. There was significantly more fusion
of mitochondria, as well as significantly more green only
mitochondria in the demyelinated compared to the myelinated
axon. Each dot represents the average of all mitochondria from
one axon; the total n-number for the myelinated axons is 16
slices from 12 different mice and for the demyelinated 18 slices
from 13 different mice. **=p-value <0.01
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FIGURE 4.10: Mitochondrial fusion dynamics of a myelinated
axon depicting a timeseries showing the fusion and fission
dynamics over the imaged time in a myelinated axon, sharply
increasing the green in red fluorescence after a fusion event and
decreasing after a fission event. Scalebar=10µm
Overall there was significantly more fusion taking place in the
demyelinated axon compared to the myelinated axon, although the majority
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of the newly transported mitochondria did not (yet) fuse with the converted
stationary mitochondrial sites in the axon; see figure 4.9.
FIGURE 4.11: Mitochondrial fusion dynamics of a
demyelinated axon depicting a timeseries showing the
fusion and fission dynamics over the imaged time in a
demyelinated axon, sharply increasing the green in red
fluorescence after a fusion event and decreasing after a fission
event. Scalebar=10µm
As the data for the fusion was determined by measuring the green in red
fluorescence at the end of the timelapse imaging and correcting it for the
green in red fluorescence at baseline, it underestimates the fusion events
taking place during that time. This is because there are many fusion and
fission events in between that increase the green in red fluorescence or
decrease it again respectively; see figure 4.10. The fusion dynamics were not
only increased when measuring the total green in red fluorescence at the
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end of the imaging process, but also the number of single fusion and fission
events seemed to be increased in the demyelinated compared to the
myelinated axon when looking at fusion/fission events in a single axons,
although this would need further analysis; see figure 4.11.
Mitochondrial speed in the demyelinated axon
For calculating the mitochondrial movement speed, kymographs of the
timelapse images were generated by using the KymographClear2.0 ImageJ
plugin, while every minute imaged was included. The Kymotoolbox Imagej
plugin was then used to calculate the mitochondrial speed by tracing the
single lines in the kymographs with the segmented line tool and using the
“analyze kymo” function; see figure 4.12 (Mangeo, Prevo, and Peterman,
2016; Zala et al., 2013).
FIGURE 4.12: Kymographs of moving mitochondria within
a myelinated (top panel) and demyelinated (bottom panel)
axon, the black arrows pointing in the anterograde direction.
The left panels shows the movement of newly transported
green mitochondria, while the right panels show converted red
mitochondria within the axons.
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FIGURE 4.13: Mitochondrial movement speed in demyelinated
axons, showing significantly faster anterograde movement of
newly transported mitochondria in the demyelinated axons
compared to myelinated axons. The movement speed in
retrograde direction did not show any statistical difference
between the demyelinated and myelinated axons. Each dot
represents the average of all mitochondria from one axon;
the total n-number for the myelinated axons is 16 slices from
12 different mice and for the demyelinated 18 slices from 13
different mice. **=p-value <0.01
The speed of the newly transported mitochondria moving in anterograde
direction was significantly greater in the demyelinated axon compared to the
myelinated axon, while the retrograde speed of movement was not different
between the two conditions; see figure 4.13.
4.3.4 Mitochondrial dynamics of converted mitochondria
Mitochondrial movement in myelinated and demyelinated axons
To check the dynamics of the mitochondria already present in the axon at
the time of conversion, the movement directionality and respective sizes of
the converted red moving mitochondria was measured. There was no
significant difference between the myelinated and the demyelinated axons
in terms of number or average size of the converted moving mitochondria;
see figure 4.14. However only the size of the moving converted
mitochondria was measured and as there were many stationary red
mitochondria with bigger size in the ROI, which were not taken into
account in this analysis.
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FIGURE 4.14: Mitochondrial dynamics of the converted
mitochondria within the ROI, showing the number and
directionality of moving mitochondria and their respective
average sizes in both myelinated and demyelinated axons.
There was no significant difference in the parameters measured
between the myelinated and demyelinated axon. Each dot
represents the average of all mitochondria from one axon; the
total n-number for the myelinated axons is 5 slices from 5
different mice and for the demyelinated 5 slices from 4 different
mice.
Mitochondrial speed in the myelinated axon
To measure the speed of the converted mitochondria within the ROI, lines
were traced on the kymographs created for the red converted mitochondria
and the speed was calculated with the ’analyse kymo’ function of the
kymotoolbox plugin in ImageJ (Mangeo, Prevo, and Peterman, 2016; Zala
et al., 2013). The speed of the converted mitochondria was not different
between the myelinated and demyelinated axons, neither in anterograde
nor retrograde direction; see figure 4.15. As mentioned above only the
moving converted red mitochondria were taken into account during this
analysis and slight movement of the stationary red mitochondria, which
represents the biggest part of the converted red mitochondria, were not
analysed. Overall the speed of the converted red mitochondria was similar
to the unconverted green mitochondria in the myelinated axons, while the
anterograde transport in demyelinated axons showed a trend towards
decreased speed in the transport of converted mitochondria.
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FIGURE 4.15: Mitochondrial movement speed of post
conversion mitochondria in demyelinated and myelinated
axons. No significance difference between myelinated and
demyelinated axons was detected, neither in anterograde or
retrograde movement speed. Each dot represents the average
of all mitochondria from one axon; the total n-number for the
myelinated axons is 5 slices from 5 different mice and for the
unmyelinated 5 slices from 4 different mice.
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4.3.5 Cerebellar slice culture of the shiverer mutant
To determine if the greater number of mitochondria moving into the
demyelinated axon is a direct effect of the lysolecithin treatment rather than
demyelination, slices of the shiverer mutant were used to examine the effect
of lysolecithin on dysmyelinated axons; see figure 4.16 (Chernoff, 1981). The
dynamics of newly transported mitochondria coming into the ROI in the
shiverer mutant was similar to the demyelinated and unmyelinated
wild-type slices, with significantly increased anterograde transport of
mitochondria compared to the myelinated slices; see figure 4.17.
FIGURE 4.16: Mitochondrial dynamics in the shiverer mutant
with and without lysolecithin treatment. Timeseries of axons
in shiverer mutant slices with (D) and without (C) lysolecithin,
compared with myelinated (A) and demyelinated (B) axons of
wildtype slices. Scalebar=10µm
Chapter 4. Mitochondrial dynamics in the demyelinated axon 99
FIGURE 4.17: Mitochondrial transport in the shiverer slices
without lysolecithin treatment compared to wildtype slices
in different conditions, showing an increase in anterograde
moving newly transported mitochondria compared to the
myelinated wildtype, while the retrograde transport was not
different to the myelinated control. Each dot represents the
average of all mitochondria from one axon; the total n-number
for the shiverer axons without lysolecithin treatment is 5 slices
from 3 different mice.****=p-value < 0.0001; *=p-value < 0.05
FIGURE 4.18: Mitochondrial average sizes in the shiverer slices
without lysolecithin treatment compared to wildtype slices in
different conditions. There was a statistical significant increase
in mitochondrial size in anterograde moving mitochondria in
the shiverer mutant compared to the myelinated control. Each
dot represents the average of all mitochondria from one axon;
the total n-number for the shiverer axons without lysolecithin
treatment is 5 slices from 3 different mice. ***=p-value < 0.001;
**=p-value < 0.01; *=p-value < 0.05
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The retrograde transport number of newly transported mitochondria
however was not increased in the shiverer compared to myelinated control;
see figure 4.17. There was a statistical significant increase in mitochondrial
sizes of the anterograde moving mitochondria in the shiverer compared to
myelinated control, while the retrograde moving mitochondria did not
differ in size between the two conditions; see figure 4.18. However the
transport between the shiverer slices with and without lysolecithin treatment
was not significantly different, as both displayed increased anterograde
transport, with a slight decreasing trend in the lysolecithin treated slices; see
figure 4.19.
FIGURE 4.19: Mitochondrial dynamics in the shiverer mutant
with and without lysolecithin treatment, showing the number
of newly transported mitochondria on the left and their
respective average sizes on the right. There was no significant
difference between the shiverer mutant with and without
lysolecithin treatment, neither in number or size of newly
transported mitochondria. Each dot represents the average of
all mitochondria from one axon; the total n-number for the
shiverer axons without lysolecithin treatment is 5 slices from 3
different mice and for the shiverer with lysolecithin treatment 8
slices from 6 different mice.
To determine the speed of moving mitochondria in the shiverer mutant,
kymographs were created with the Kymoclear 2.0 ImageJ plugin; see figure
4.20 (Mangeo, Prevo, and Peterman, 2016). The speed was calculated by
tracing individual lines in the kymographs and using the ’analyse kymo’
function of the kymotoolbox ImageJ plugin; see figure 4.20 (Zala et al., 2013).
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FIGURE 4.20: Kymographs for axons of the shiverer mutant
without lysolecithin (top panel) and shiverer mutant with
lysolecithin (bottom panel) treatment, the black arrows
pointing in the anterograde direction. The left panels shows
the movement of newly transported green mitochondria, while
the right panels show converted red mitochondria within the
axons, showing significant movement in both conditions.
The mitochondrial movement speed in the anterograde direction was
similar to demyelinated and unmyelinated wild-type, with a statistical
significant increase of mitochondrial anterograde transport speed in the
shiverer compared to the wild-type axons; see figure 4.21. The analysis of the
mitochondrial speed in the shiverer mutant showed no significant different
between the shiverer slices with or without lysolecithin, although there was a
clear trend towards decreased anterograde and retrograde speed of newly
transported mitochondria in the shiverer slices with lysolecithin treatment;
see figure 4.22.
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FIGURE 4.21: Mitochondrial movement speed comparison
between the shiverer slices without lysolecithin treatment and
different wt conditions. There was a statistical significant
increase of mitochondrial transport speed in the anterograde
direction in the shiverer axons compared to myelinated control.
There was however no significant different in the retrograde
movement speed. Each dot represents the average of all
mitochondria from one axon; The total n-number for the
shiverer axons without lysolecithin treatment is 5 slices from 3
different mice. **=p-value < 0.01; *=p-value < 0.05
FIGURE 4.22: Movement speed of newly transported
mitochondria in the shiverer mutant with and without
lysolecithin treatment, showing no significant difference
in either anterograde or retrograde movement speed, but
with a trend towards decreased mitochondrial speed in
the shiverer with lysolecithin treatment compared to shiverer
without lysolecithin. Each dot represents the average of all
mitochondria from one axon; the total n-number for the shiverer
axons without lysolecithin treatment is 5 slices from 3 different
mice and for the shiverer with lysolecithin treatment 8 slices
from 6 different mice.
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FIGURE 4.23: Mitochondrial fusion in the shiverer axons
compared to wild-type axons in different conditions. There
was no statistical significant difference in mitochondrial fusion
between the myelinated control and the shiverer and neither
was there a statistical significant difference in the total green
area between the two conditions. Each dot represents the
average of all mitochondria from one axon; The total n-number
for the shiverer axons without lysolecithin treatment is 5 slices
from 3 different mice. **=p-value < 0.01; *=p-value < 0.05
FIGURE 4.24: Fusion dynamics of the shiverer mutant
with and without lysolecithin treatment, showing no
significant difference in fusion rate and both conditions
display surprisingly low fusion rates. Each dot represents the
average of all mitochondria from one axon; the total n-number
for the shiverer axons without lysolecithin treatment is 5 slices
from 3 different mice and for the shiverer with lysolecithin
treatment 8 slices from 6 different mice.
To analyse the fusion dynamics of the shiverer mutant slices, green in red
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fluorescence was measured at minute 20 and corrected for the baseline green-
in-red fluorescence at minute 0.
FIGURE 4.25: Fusion dynamics at the level of single fusion and
fission events, depicted by a timelapse image series showing
several stationary converted mitochondria in a shiverer mutant
without lysolecithin treatment, that display an increase and
decrease in green fluorescence after fusion and fission events
respectively. Scalebar=8µm
The comparison to the myelinated control showed no statistical
significant difference in the amount of mitochondrial fusion in the shiverer
slices also when comparing the total green area there was no significant
difference in the shiverer and myelinated axons; see figure 4.23. The
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comparison of shiverer with or without lysolecitiin treatment showed that
most of the mitochondria being transported to the converted region of the
axon, did not fuse with the converted stationary mitochondria and only
exhibited green fluorescence; see figure 4.24. When looking at the fusion
and fission dynamics in detail in single axons, it becomes clear that the
fusion data underestimates the number of fusion and fission events in the
shiverer axons without or with lysolecithin treatment; see figures 4.25 and
4.26.
FIGURE 4.26: Fusion dynamics at the level of single fusion
and fission events, depicted by a timelapse image series
showing several stationary converted mitochondria in a shiverer
mutant with lysolecithin treatment, that display an increase
and decrease in green fluorescence after fusion and fission
events respectively. Scalebar=8µm
This data set indicates that lysolecithin treatment does not increase
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mitochondrial transport, speed or fusion dynamics and the increase in
mitochondrial dynamics, seen after lysolecithin treatment of wildtype slices,
is an effect of the demyelination of the PC axons. There was however a
slight trend towards decrease in numbers and a trend towards decreased
mitochondrial transport speed in the lysolecithin treated shiverer slices
compared to the shiverer slices without lysolecithin treatment.
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4.4 Discussion
4.4.1 Mitochondrial dynamics in demyelinated axons
The timecourse experiment of the ARMD (Chapter 2) has shown that
already 24 hours after demyelination with lysolecithin there are significantly
more mitochondria in the demyelinated axon compared to the myelinated
axon, this is reflected in an increase in overall occupancy of the axon by
mitochondria and increased mitochondrial numbers. There is also an
increase in the area of single mitochondria, which increases even further 72
hours post demyelination. This increase in size indicates increased
mitochondrial fusion within the demyelinated axon. To assess the
mitochondrial dynamics in the demyelinated axon, mEOS2 positive PC
were demyelinated by using lysolecthin. To get sufficent demyelination of
PC axons, a lysolecithin concentration experiment was performed, since the
most widely used lysolecithin concentration did not result in complete
demyelination of the axons in the cerebellar slice culture. The relatively low
transduction rate of PC cells after injection with the lentivirus containing the
mEOS2 photoconvertible protein (roughly 1 positive cell per 3 slices) made
it necessary to ensure complete demyelination of the PC axons with
lysolecithin. A slightly higher concentration of 0.75mg/ml lysolecithin left
for 24 hours on the cerebellar slices, lead to sufficient demyelination while
still preserving the axonal structure. Subsequently only axons completely
without SCoRe signal in the field of view were counted as being
demyelinated, while axons with sufficient myelination in the field of view
were counted as being myelinated. However with the techniques used it
can not be ruled out that the rest of the axon is different from the observable
part, since some axons could not be imaged over the whole length.
The demyelinated, mEOS2 positive PC axons were then used to study
the mitochondrial transport and fusion dynamics in live cerebellar slices by
imaging every minute over 20 minutes and analysed for any changes in
mitochondria parameters. This analysis revealed an increase in
mitochondrial transport to the demyelinated axon, both from the
anterograde and retrograde direction. Since the converted axonal segment
was adjacent to the AIS, it can be assumed that the anterograde moving
green unconverted mitochondria are coming into the demyelinated axon
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from the unconverted cell body. Despite having some residual green
fluorescence in myelinated axons, there was not much movement observed
compared to the demyelinated axons. This phenomenon of residual green in
the ROI was observed in both myelinated and demyelinated axons that
were not fully converted, but since only completely green mitochondria
were counted as being newly transported, it is still clear that this set of
mitochondria is coming in from the cell body or distal part of the axon
respectively. The rate of anterograde transport into the observed region was
significantly higher than the rate of retrograde transport, so the increased
number of mitochondria in the axon and the overall increased occupancy of
the axon by mitochondria after demyelination, can be explained by a net
increase of anterograde transport. Mitochondrial fusion, which was
assessed by measuring the increase of green fluorescence within the
stationary red mitochondria, also was more frequent in the demyelinated
axon. This lead to an overall increase in the green to red ratio in the
demyelinated axon compared to the myelinated axon. This increased fusion
rate during the live imaging could explain the overall increase in size in the
ARMD timecourse experiment in chapter 2, as increased fusion leads to
bigger mitochondria. To assess mitochondrial movement speed in both
anterograde and retrograde direction, a kymograph of each axon was
generated and the kymograph tracks were analysed using different ImageJ
plugins (Mangeo, Prevo, and Peterman, 2016; Zala et al., 2013).
There was a significant increase in the speed of anterograde moving
newly transported mitochondria in the demyelinated axon, while the speed
of retrograde transport was not different between the demyelinated and
myelinated axons. This indicates an overall increase in anterograde speed,
which, like the increase in the number of mitochondria being transported in
the anterograde direction, eventually will lead to an accumulation of
mitochondria in the demyelinated axon over time. In summary the changes
in mitochondrial dynamics in the demyelinated axon, namely the increase
of anterograde movement, the faster speed of anterograde moving
mitochondria and the increased fusion rate of mitochondria within the
demyelinated axon compared to the myelinated axon are sufficient to
explain the increased mitochondrial content, which can be observed at
different timepoints after demyelination (see chapter 2).
Chapter 4. Mitochondrial dynamics in the demyelinated axon 109
4.4.2 Mitochondrial dynamics in the shiverer mutant
To determine if the increase in mitochondrial dynamics after demyelination
with lysolecithin is not an effect of lysolecithin, but of demyelination itself,
cerebellar brain slices of the dysmyelination shiverer mutant were used. Like
the wild-type slices, the shiverer slices were injected with the lentivirus just
after the slicing procedure and 2 weeks afterwards live imaging was
performed to determine changes in mitochondrial dynamics. Similar to the
demyelinated slices, the shiverer slices without lysolecithin treatment
showed an increase in anterograde transport and speed of anterograde
movement. In contrast to the demyelinated axons, the mitochondria in the
shiverer slices, retrograde transport was not higher than in the myelinated
slices.
TABLE 4.1: Change of mitochondrial dynamics between
the different conditions: ’+’ marks baseline. ’++’ marks a
statistical significant increase <2x compared to baseline. ’+++’
marks a statistical significant increase >2x. A=anterograde;
R=retrograde
Transport number Speed Size Fusion
A R A R A R
Myelinated + + + + + + +
Unmyelinated + ++ ++ + ++ ++ +++
Demyelinated +++ +++ ++ + ++ + +++
Shiverer without lysolecithin +++ + ++ + ++ + +
Shiverer with lysolecithin +++ + + + ++ + +
Furthermore, mitochondrial fusion events were also similar to
myelinated axons, which could be a explained by the longer time of
increased mitochondrial dynamics in the shiverer compared to the wild-type
demyelinated slices and fusion being already at the maximum and most of
the newly transported mitochondria just passing the stationary sites,
although this would result in bigger stationary sites compared to wild-type
demyelinated axons which was not observed, so the more likely explanation
is stronger bleaching of the green fluorescence during the shiverer
experiments. Between the shiverer slices with or without lysolecithin
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treatment, there was no significant difference in any of the mitochondrial
dynamics parameters measured, although there was a trend towards
decrease mitochondrial transport speed in the lysolecithin treated slices.
This experiment shows that the increase in mitochondrial dynamics in the
previous experiment, is not due to a secondary effect of lysolecithin, but due
to demyelination itself.
4.4.3 Future directions
As we only looked at the first part of the PC axon adjacent to the AIS, the
dynamics in the axon further away from the cell body could be completely
different. Most of the previous studies that were reporting about the ARMD
in demyelinated axons, were looking at axonal parts far away from the cell
body, mostly white matter tracts, in a different type of neurons and
mitochondrial dynamics might be different between cell types (Ohno et al.,
2011; Kiryu-Seo et al., 2010; Zhou et al., 2016; Misgeld et al., 2007; Misgeld,
Nikic, and Kerschensteiner, 2007). The in vivo situation might also be
different than in vitro and the dynamics might be different depending on the
demyelinating agent. In this case lysolecithin was used because its effect on
mitochondria is less pronounced than other commonly used agents,
furthermore, the shiverer experiment of this thesis showed no direct effect of
lysolecithin on mitochondrial dynamics (Birgbauer, Rao, and Webb, 2004;
Zhang et al., 2011; Komai, Hunter, and Takahashi, 1973; Keough, Jensen,
and Yong, 2015; Jeffery and Blakemore, 1995; Wallace et al., 2003; Yu et al.,
2007).
At this point it can only be speculated what the signal for this change in
mitochondrial dynamics in response to demyelination could be. Firstly, the
loss of the oligodendrocyte wrapped around the axon could either set a
signalling cascade in motion to respond to demyelination, since the trophic
support for the axon is lost, or it may be the other way around and the
oligodendrocyte is constantly signalling to the neuron and the loss of the
signalling pathway activates the ARMD (Nave, 2010;Morrison, Lee, and
Rothstein, 2013; Saab, Tzvetanova, and Nave, 2013). Another possibility
could be that the increase in energy demand of demyelination, the
subsequent change in the ADP/ATP ratio and change in ionic balance
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within the axon is enough to bring in more mitochondria from the cell body
and lead to a higher stopping probability in the axon (Trapp and Stys, 2009;
Mahad, Trapp, and Lassmann, 2015; Mohd, 2010; Albers and Siegel, 1998;
Lores Arnaiz and Ordieres, 2014). The increased mitochondrial content in
the shiverer mutant, which also shows similar changes in the mitochondrial
transport dynamics to the demyelinated axon, favours the latter hypothesis,
as in the shiverer mutant there is still some myelin wrapped around the axon
and it was shown that there is an increase in mitochondrial activity inside
the shiverer axons (Andrews et al., 2006). But since the myelin wrap around
the axon is not tight in the shiverer mutant, because the MBP is missing, it
could still be enough to signal a loss of myelin to the neuron (Barbarese,
Nielson, and Carson, 1983). To elucidate the mechanism behind the ARMD,
further experiments are necessary. Microfluidic chambers would offer the
possibility to separately manipulate and analyse the axonal and cell body
compartment, this would offer significant advantages over the cerebellar
slices for certain experiments, as every manipulations in the slice culture




Manipulations of the ARMD
5.1 Introduction
5.1.1 Manipulating mitochondrial dynamics
Some of the most widely studied neurodegenerative diseases, among them
Alzheimer’s, Huntington’s and Parkinson’s disease, display gene and
protein changes that imply that mitochondrial dynamics are involved,
namely fusion/fission and transport dynamics, which shows the
importance of the dynamic nature of these cellular organelles (Chan, 2006a;
Su et al., 2010; Bonda et al., 2011). The constant fusion and fission of
mitochondria leads, over time, to a complete mixing of mitochondrial lipids
and content, including the mtDNA (Chan, 2006a; Chan, 2006b; Chan, 2012a;
Chen et al., 2010). As every mitochondrion contains multiple nucleotids,
which contain mtDNA, a single mitochondrion can contain wild-type as
well as mutant DNA, called heteroplasmy (Chan, 2006b; Wallace, 2005;
Dimauro and Davidzon, 2005; DiMauro and Schon, 2003; Hayashi et al.,
1991; Nakada et al., 2001; Nakada, Inoue, and Hayashi, 2001). Via
mitochondrial fusion mutant mtDNA is diluted and via mitochondrial
fission, mitochondria containing only mutant mtDNA, called homoplasmy,
can be degraded via mitophagy (Chan, 2006b; Wallace, 2005; Dimauro and
Davidzon, 2005; DiMauro and Schon, 2003; Hayashi et al., 1991; Nakada
et al., 2001; Nakada, Inoue, and Hayashi, 2001; Bingo and Sheng, 2016;
McWilliams and Muqit, 2017; Whitworth and Pallanck, 2017). This is an
important part of mitochondrial quality control, as defective mitochondria
can be selectivity degraded via fission followed by mitophagy and if that is
not sufficient for maintaining mitochondrial health, fragmentation of
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mitochondria can also promote apoptosis (Bingo and Sheng, 2016;
McWilliams and Muqit, 2017; Whitworth and Pallanck, 2017; Wang, 2001;
Mao and Klionsky, 2013).
Another important part of mitochondrial dynamics is the mitochondrial
transport along microtubules, especially in neurons with their highly
polarized morphology mitochondrial transport is essential to supply distant
parts of the neuron with this vital organelle (Schwarz, 2013; Britt et al., 2016;
Sheng, 2014; Lin and Sheng, 2015; Cai and Sheng, 2009; Saxton and
Hollenbeck, 2012; Sheng and Cai, 2012). As described in chapter 1
mitochondria are coupled to the kinesin motor proteins via specific adapter
proteins, among them Miro1, which, with its EF hands, halts mitochondria
at sites with high Ca2+ concentration (Lin and Sheng, 2015; Cai and Sheng,
2009; Saxton and Hollenbeck, 2012; Sheng and Cai, 2012; Morris and
Hollenbeck, 1995; Stephen et al., 2015b; Guo et al., 2005). It is also reported
that disruption of Miro1 can greatly influence mitochondrial shape
(Yamaoka and Leaver, 2008). Furthermore, defects in dynein, which is
required for the retrograde transport of mitochondria, can lead to elongated
mitochondria in the perinuclear region, which shows that defects in the
mitochondrial transport machinery can affect mitochondrial fusion/fission
(Varadi et al., 2004; Chen and Chan, 2009a). Conversely, defects in
mitochondrial fusion and fission have been shown to affect mitochondrial
transport, showing that the different aspects of mitochondrial dynamics are
interconnected and interdependent (Chen and Chan, 2009a; Verstreken
et al., 2005; Li et al., 2004).
As mentioned above several neurodegenerative diseases are linked to
defects in mitochondrial dynamics. The inherited form of Parkinson’s
disease shows a defect in the Pink1 and Parkin genes, which have been
shown to be important for mitochondrial quality control (Bingo and Sheng,
2016; McWilliams and Muqit, 2017; Whitworth and Pallanck, 2017;
Winklhofer and Haass, 2010). Interestingly, overexpression of Drp1 or down
regulation of Marf/Mfn2 in drosophila pink1 or parkin mutants leads to an
amelioration of symptoms, which points to a connection to mitochondrial
fusion/fission dynamics (Chen and Chan, 2009a). Parkin has also been
implicated in mitochondrial turnover, by marking mitochondria with low
membrane potential for mitophagy (Chen and Chan, 2009a; Narendra et al.,
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2008). Apart from defects in mitochondrial fusion/fission, defects in
mitochondrial transport have been linked to many neurodegenerative
diseases and it was reported that genes affecting mitochondrial transport
can cause neurodegeneration (Chan, 2006a; Sheng and Cai, 2012; Sorbara
et al., 2014; Chang and Reynolds, 2006; Schon and Przedborski, 2011).
Furthermore, recently it was shown that mitochondrial transport deficits
precede axonal degeneration, which is the main correlate of clinical
disability, in mouse models of multiple sclerosis (Sorbara et al., 2014). These
mitochondrial transport deficits can be ameliorated by treatment with redox
scavengers or glucocorticoids, which suggests that inflammatory mediators
including ROS/RNS are the main mediators of these transport deficits
(Sorbara et al., 2014).
Manipulations of mitochondrial dynamics are possible through genetic
mutation of fusion/fission or transport proteins, leading to mutant lines
with different expression of the targeted mitochondrial proteins or
knock-out of the gene of interest (Ohno et al., 2014; Chen et al., 2003; Zhou
et al., 2016). Furthermore, genetic manipulations can be done by viral
transduction, either enhancing expression of a gene of interest or by a
targeted knock-down via shRNA (Zhou et al., 2016). It was recently shown
that syntaphilin-KO, which leads to enhanced mitochondrial transport in
axons, can aide axonal regeneration after axotomy in vitro and in vivo, this
effect was also replicated by overexpressing Miro1 in vitro (Zhou et al.,
2016). Another study reported that shiverer crossed with syntaphilin-KO
results in an increased lifespan compared to shiverer alone (Joshi et al., 2015).
The third possibility is manipulations via small compounds targeting
mitochondrial dynamics. The small molecular compound mdivi-1
(mitochondrial division inhibitor 1) is reported as being a specific inhibitor
of Drp1 and thus preventing mitochondrial fission, although a recent
publication claims that mdivi-1 does not have a specific effect on
mitochondrial fission and instead is a reversible complex I inhibitor
(Cassidy-Stone et al., 2008; Bordt et al., 2017). Another small molecule
compound available for manipulating mitochondrial dynamics is
oligomycin, which is an ATPase inhibitor and acts by blocking the
F0-subunit of the mitochondrial ATPase (Zala et al., 2013; Shchepina et al.,
2012). As mitochondrial transport is dependant on ATP production, the
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inhibition of the ATPase by oligomycin completely blocks mitochondrial
transport, while leaving the fast axonal transport of vesicles intact (Zala
et al., 2013). Pioglitazone, another small molecule compound, is a licensed
diabetes drug and was reported to increase mitochondrial biogenesis in vivo
and in vitro (Desouza and Shivaswamy, 2010; Skov et al., 2008; Bogacka
et al., 2005; Ghosh et al., 2007). Pioglitazone enhances mitochondrial
biogenesis by increasing the expression of peroxisome proliferator-activated
receptor (PPAR)-gamma coactivator-1alpha (PGC-1α) and mitochondrial
transcription factor A (TFAM), which are both regulators of mitochondrial
biogenesis (Corona and Duchena, 2016; Miglio et al., 2009). To manipulate
mitochondrial dynamics and test the effect on axonal health after
demyelination, the aim of this chapter was to test several small molecule
compounds in cerebellar slices after lysolecithin mediated demyelination.
5.2 Materials and methods
Animals
All procedures were performed according to the 1986 Animals Act
(scientific procedures) UK and were approved by the local ethics committee.
For all the experiments C57BL/6 mice were used. For the generation of
cerebellar organotypic slice cultures mice from P7 to P12 were used, because
slice generated at this age ensures a good survival of purkinje cells, while
already displaying many features of the adult structure of the cerebellum.
5.2.1 Demyelination with lysolecithin
For the demyelination of the slices 0.5mg/ml lysolecithin was added to the
slice culture medium for 17 hours before replacing it with normal medium.
Several different compounds were added to the slice culture medium
before, during and after lysolecithin mediated demyelination was
performed and the slices were then stained at 24 hours or 3 days after
removing the lysolecithin. For this the slices were fixed with
paraformaldehyde (PFA), after which antigen retrieval was performed. The
slices were then blocked before incubating them with the primary and
secondary antibody; for detailed IHC protocol see chapter 2.
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Oligomycin live imaging experiment
Because the increase of green fluorescence inside red fluorescence described
in chapter 3 & 4 could stem from the green protein being transported back
into the stationary red mitochondria, with no need for fusion events to
increase the green in red fluorescence. To address this issue oligomycin was
used to block all mitochondrial transport and check if the green in red
fluorescence would still increase over time (Zala et al., 2013). If the green
protein is transported back into the stationary red mitochondria over the
time observed, an increase in green in red fluorescence would be expected
despite there being no mitochondrial transport. If the increase of green in
red fluorescence is due to fusion of newly transported unconverted green
mitochondria with the stationary converted red mitochondria, no increase
of green in red fluorescence would be expected in the absence of
mitochondrial transport. For the live imaging experiment the slices were
injected with the lentivirus expressing mEOS2 (see chapter 3) and after 14
days in culture 20µM oligomycin was added to the slice culture 30 minutes
before imaging them on a Zeiss LSM 880 Airyscanner, with the oligomycin
solution staying on during the image acquisition. The 20µM concentration
of oligomycin was enough to bring mitochondrial movement to a complete
stop. For analysis the green in red ratio was measured at baseline and at 5
minutes, 10 minutes, 15 minutes and 20 minutes respectively. The green in
red ratio was measured by using ImageJ with the previously described
macro (chapter 2), with the addition of a macro for calculating the
percentage of green inside the red area.
5.2.2 Inhibiting mitochondrial transport with oligomycin
For inhibition of mitochondrial transport the ATPase inhibitor oligomycin
was used (Zala et al., 2013; Shchepina et al., 2012). Oligomycin works by
blocking the F0-subunit (proton channel) of the ATPase and thus inhibiting
oxidative phosphorylation (Shchepina et al., 2012). In 2013 it was shown by
Zala et al that by adding 20µM for 5 minutes was enough to completely block
mitochondrial transport, while vesicular fast axonal transport was still intact
due to having onboard glycolysis (Zala et al., 2013). In another publication
it was shown that a concentration of 0.25µM of oligomycin was the lowest
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dose that significantly inhibits oxidative phosphorylation in several cancer
cell lines (Hao et al., 2010). Therefore 0.25µM oligomycin was added to the
slices destined for treatment for either 6 hours or 24 hours. During that time
lysolecithin was added as well for 24 hours to achieve demyelination of the
slices and 24 hours after removing lysolecithin from the slices, all slices were
stained for neurofilament (NF), myelin basic protein (MBP) and complex IV
subunit (COXI). The stained slices were then imaged on a Zeiss LSM 710
confocal microscope using a 63x oil immersion objective with 2x zoom and
analysis was done in ImageJ by using the macro described in chapter 2.
5.2.3 Inhibiting mitochondrial fission with mdivi-1
For the inhibition of mitochondrial fission, the Drp1 (dynamin-related
protein 1) selective inhibitor mdivi-1 was used (Cassidy-Stone et al., 2008).
Slices were prepared and cultured as described in chapter 2 and kept in
culture at least seven days before any manipulations were done. After 7
days mdivi-1 was diluted in slice culture medium either 50µM or 100µM,
before removing the medium from the slices and replacing it with the
diluted mdivi-1 solution. After 2 days the mdivi-1 solution was renewed
with the appropriate concentration of mdivi-1 again diluted in slice culture
medium and lysolecithin was added to the solution at a concentation of
0.5mg/ml. The lysolecithin containing solution was then added to the slices
that were going to be demyelinated, while mdivi-1 solution without
lysolecithin was added to the myelinated treated slices and lysolecithin
without mdivi-1 to the demyelinated control slices. Furthermore, some
slices neither received mdivi-1 nor lysolecithin and were used as myelinated
control slices. After 17 hours lysolecithin was removed from the slices were
it was added before, while adding mdivi again. At 24 hours after removing
the lysolecithin, a final renewal of mdivi-1 was done and all slices were
stained 2 days later for neurofilament (NF), myelin basic protein (MBP) and
complex IV subunit (COXI). The stained slices were then imaged on a Zeiss
LSM 710 confocal microscope using a 63x oil immersion objective with 2x
zoom and analysis was done in ImageJ by using the macro described in
chapter 2.
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5.2.4 Increasing mitochondrial biogenesis with pioglitazone
To examine the effect of increased mitochondrial biogenesis on the ARMD
and on axonal health after demyelination with lysolecithin, the licensed
diabetes drug pioglitazone was used, which is an activator of
(PPAR)-gamma-coactivator-1-alpha (PGC-1α) and mitochondrial
transcription factor A (TFAM) and thus increases mitochondrial biogenesis.
Like with the other small molecule compounds the slices were prepared and
cultured as described in chapter 2 and kept in culture for a week, before
adding pioglitazone to the culture medium in either 10µM or 40µM
concentration. Two days later pioglitazone was renewed and lysolecithin
0.5mg/ml was added to the culture medium. After 17 hours the lysolecithin
was removed and pioglitazone added again until staining the slices 3 days
after the removal of lysolecithin. Pioglitazone was also added to slices that
did not receive lysolecithin and some slices were demyelinated without
pioglitazone treatment, and finally some slices received neither lysolecithin
nor pioglitazone. All slices were stained 3 days after removing lysolecithin
from the slices for neurofilament (NF), myelin basic protein (MBP) and
complex IV subunit (COXI) and subsequently imaged on a Zeiss LSM 710
confocal microscope using a 63x oil immersion objective with 2x zoom and
analysis was done in ImageJ by using the macro described in chapter 2.
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5.2.5 Immunohistochemistry





































For Immunohistochemistry protocol see methods section in chapter 2.
Reagents and Media
For slice culture reagents see methods section in chapter 2.
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5.3 Results
5.3.1 Live imaging after inhibition of mitochondrial
transport with oligomycin
To show that the increase of green in red fluorescence is not an effect of the
green protein simply being transported back into the stationary red
mitochondria over time, but real fusion events of newly transported
unconverted (green) mitochondria with converted stationary (red)
mitochondria, mitochondrial transport was inhibited by adding 20µM
oligomycin to the culture medium 30 minutes before imaging and left on
during image acquisition (Zala et al., 2013); see figure 5.1.
FIGURE 5.1: Impact of high dose oligomycin on mitochondrial
movement shown in a timelapse series, illustrating the stop
of mitochondrial movement and fading of green inside red
fluorescence over time. Scalebar=10µm
This concentration completely stopped mitochondrial transport, so if the
green fluorescence coming back in the converted red mitochondria is an
effect of the protein being transported back in, the green in red fluorescence
would still be expected to increase over time; see figure 5.1. But if the green
coming back in the red fluorescence is due to green mitochondria moving in
and fusing with the stationary red mitochondria, inhibition of
mitochondrial transport with oligomycin should get rid of this effect. After
inhibiting mitochondrial transport, the green in red was constantly
declining in comparison to the baseline, which suggest that there is no
transport back in of the green fluorescent protein and the bleaching of the
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green fluorescence constantly reduces the green in red fluorescence; see
figure 5.2.
FIGURE 5.2: Impact of high dose oligomycin on mitochondrial
movement and fusion, showing the decrease of the green in red
and total green fluorescence over the time imaged. There was
a significant decrease of green in red fluorescence, as well as
significantly decreased green overall in the oligomycin treated
slices compared to control. Each dot represents the average
of all mitochondria from one axon; the total n-number for the
untreated control axons is 16 slices from 12 different mice and
for the oligomycin treated slices 8 slices from 4 different mice.
***=p-value <0.001
FIGURE 5.3: Mitochondrial speed after high dose oligomycin
treatment shown on a kymograph and depicting the complete
stop of mitochondrial movement in the green in red channel
respectively. Above the kymograph the first images after
conversion, while below the kymograph the last frame of the
timeseries are placed, to illustrate the changes over time. The
black arrow is pointing in the anterograde direction.
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This decline of green in red was a constant decline over time, without
fusion or fission events in between, bleaching the green fluorescence during
the imaging process, due to the lack of transported of new mitochondria to
the axon; see figure 5.4.
FIGURE 5.4: Mitochondrial fusion dynamics after high dose
oligomycin treatment depicting the total stop of mitochondrial
transport and fusion and fission events, which leads to a
constant decline in green in red fluorescence over time without
any sharp increases or decreases in between shown by the
constant decrease of the bar graphs over time. Scalebar=10µm
The complete stop of mitochondrial movement was further examined by
creating the kymographs for green and red channels of the oligomycin
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treated axons with the Kymoclear 2.0 ImageJ plugin. Like expected neither
in green or red kymograph any significant movement was detected, apart
from a general drift of the axon over time; see figure 5.3.
5.3.2 Manipulation of mitochondrial transport by the
ATPase inhibitor oligomycin
By using the ATPase inhibitor oligomycin, which was shown to inhibit
mitochondrial transport, the effect of reducing mitochondrial transport after
demyelination was determined (Zala et al., 2013). Using a concentration of
0.25µM oligomycin, which was either added together with lysolecithin (for
a total of 24h) or 6 hours before the removal of lysolecithin (6h), the effect of
reduced mitochondrial transport on the ARMD was tested; see figures 5.5.
FIGURE 5.5: Effect of oligomycin on axonal mitochondria
shown in confocal images of untreated control (A), lysolecithin
demyelinated axon (B) and lysolecithin demyelinated axon
treated with 0.25µM oligomycin for 24h (C). Scalebar=5µm
For this experiment the total lysolecithin exposure was 24 hours and the
slices were stained at 24 hours after removing lysolecithin from the slice
culture medium. Already the shorter exposure time of 6 hours oligomycin
showed a trend towards decrease of the mitochondrial occupancy of the
axon, indicating that hindering transport of new mitochondria to the axon
potentially may diminish the ARMD, the same effect was observed by using
the longer exposure time of 24 hours of oligomycin; see figure 5.6.
Chapter 5. Manipulations of the ARMD 124
FIGURE 5.6: Impact of oligomycin on the mitochondrial
occupancy of the axon after demyelination with lysolecithin,
depicting the difference of mitochondrial occupancy (in
percent) with and without adding oligomycin and lysolecithin.
There was a significant increase of mitochondrial occopancy
of the axon in all demyelinated conditions compared
to the myelinated conditions. Although there was no
significant different between the demyelinated control and the
demyelinated oligomycin treated, there was a trend towards
decreased mitochondrial occupancy in the oligomycin treated
axons. Each dot represents one slice from one mouse and
includes 40 analysed axons. **=p-value <0.01
It must be noted that neither exposure time lead to a significant
reduction in mitochondrial occupancy, which could be due to the low
concentration of oligomycin used. But since oligomycin significantly
inhibits ATP production, exposure to high oligomycin concentrations was
not desired, as it would interfere with many cellular processes. There was
however a significant difference in mitochondrial occupancy of the axon
between the myelinated control and oligomycin untreated and treated
demyelinated slices. There was a trend to a decrease of mitochondrial area
and increase in mitochondrial numbers observed in the oligomycin treated
slices compared to the lysolecithin control without oligomycin treatment;
see figure 5.7.
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FIGURE 5.7: Impact of oligomycin treatment on mitochondrial
numbers and size after demyelination with lysolecithin. Left:
average mitochondrial area of single mitochondria in µm2.
Right: the mitochondrial number per µm2. There was
a significant increase of mitochondrial size of the axon
in the demyelinated control compared to the myelinated
control. Although there was no significant difference between
the demyelinated control and the demyelinated oligomycin
treated, there was a trend towards decreased mitochondrial
size in the oligomycin treated axons. There was a significant
increase of mitochondrial number in all the demyelinated
conditions compared to the myelinated condition. Although
there was no significant difference between the demyelinated
control and the demyelinated oligomycin treated, there was
a trend towards increased mitochondrial number in the
oligomycin treated axons. Each dot represents one slice from
one mouse and includes 40 analysed axons. **=p-value <0.01
This observation could indicate a fragmentation of the mitochondrial
networking inside the axon, which could be due to the blockage of
mitochondrial electron transport chain (ETC) by oligomycin, although not
used in high dose, is still able to inhibit the mitochondrial ATPase to a
significant proportion (Hao et al., 2010). There was a significant difference in
mitochondial numbers between the myelinated control and oligomycin
untreated and treated slices and also the mitochondrial area was
significantly different between the myelinated and demyelianted control.
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Effect of inhibition of mitochondrial transport on axonal health
To determine to effect of oligomycin on axonal health, the area of the axonal
bulbs was divided by the total axonal area to get the percentage of axonal
bulb area; see figure 5.8. Since oligomycin is an ATPase inhibitor, several
other detrimental possibilities on axonal health apart from inhibition of
mitochondrial transport are possible. Although a relatively low dose of
oligomycin was used, the inhibitory effect on the ATPase and subsequently
on the ETC function is still expected to be substantial (Hao et al., 2010).
FIGURE 5.8: Impact of oligomycin on axonal health judged
by confocal images of demyelinated axons stained for NF,
showing axonal bulbs in demyelinated slices without (A) and
with oligomycin treatment (B). Scalebar=50µm
The reduction of mitochondrial transport and ATPase activity in general,
lead to a significant increase of axonal bulbs with the 24 hours exposure to
oligomycin, indicating a detrimental effect on axonal health; see figure 5.9.
Already the 6 hour treatment of demyelinated axons with oligomycin
showed a trend towards an increased number of axonal bulbs; see figure 5.9.
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FIGURE 5.9: Effect of oligomycin treatment on axonal health
after demyelination, showing the area of axonal bulbs corrected
for the total axonal area in demyelinated slices with or without
oligomycin treatment. There was a significant increase of
axonal bulbs in the slices treated with oligomycin for 24
hours compared to control, there was however no difference
between the 6 hour oligomycin treatment and control. Each dot
represents one slice from one mouse and includes at least 40
analysed axons. *=p-value <0.05
5.3.3 Manipulation of the ARMD by blocking mitochondrial
fission
By using mdivi-1, a putative selective inhibitor of Drp1 and thus
mitochondrial fission, the effect of blocking mitochondrial fission during the
ARMD was examined (Cassidy-Stone et al., 2008). For this experiment, two
different concentrations of mdivi-1 (50µM and 100µM) were added to the
slice culture medium 2 days before demyelinating with lysolecithin for 17
hours or without adding lysolecithin at all, mdivi-1 was renewed when
adding lysolecithin and the slices were stained for Neurofilament (NF),
myelin basic protein (MBP) and complex IV subunit (COX-I) 3 days after
lysolecithin was removed from the slice culture medium; see figure 5.10. It
was reported previously that mdivi-1 can inhibit mitochondrial
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fragmentation and exert neuroprotective effects on hippocampal neurons
(Xie et al., 2013).
FIGURE 5.10: Impact of mdivi-1 treatment on mitochondria in
the axon with or without lysolecithin mediated demyelination,
showing the mitochondrial occupancy of axons in (from left to
right) myelinated control (A), lysolecithin (B), mdivi (C) and
lysolecithin+mdivi (D) treated slices. Scalebar=5µm
Mdivi-1 caused an increase in the mitochondrial occupancy of the
myelinated axons, while it increased the mitochondrial occupancy of the
axons even more in the demyelinated axons compared to demyelinated
axons without mdivi-1 treatment, with no difference between the 50µM and
100µM mdivi-1 concentration; see figure 5.11. There was a significant
difference in mitochondrial occupancy of the axon between the myelinated
control and mdivi-1 untreated/treated demyelinated slices.
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FIGURE 5.11: Effect of mdivi-1 on the mitochondrial occupancy,
showing the mitochondrial occupancy of the axons (in percent)
with and without adding mdivi and lysolecithin. There was
a significant increase in mitochondrial occupancy in the axon
with both concentrations of mdivi-1 compared to control, in the
myelinated as well as demyelinated axon. Each dot represents
one slice from one mouse and includes 40 analysed axons. *=p-
value <0.05 ;**=p-value <0.01
As a putative specific Drp1 inhibitor and therefore inhibitor of
mitochondrial fission, mdivi-1 was expected to enhance the average area of
single mitochondria and indeed the mitochondrial size was increased in
both the myelinated and demyelinated axons after mdivi-1 treatment, again
no significant difference between the 50µM and 100µM mdivi-1
concentration was observed; see figure 5.12. Furthermore, there was a
significant difference in mitochondrial size between the myelinated control
and mdivi untreated/treated demyelinated slices.
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FIGURE 5.12: Effect of mdivi-1 on the mitochondrial size and
number, showing a significant increase in mitochondrial size
with both concentrations of mdivi-1 compared to control, in
the myelinated as well as demyelinated axon. The number
of mitochondria was significantly increased in the myelinated
axon treated with mdivi-1 compared to myelinated control,
there was however no difference in the demyelinated axon.
Average mitochondrial area of single mitochondria in µm2;
number of mitochondria per µm2. Each dot represents one slice
from one mouse and includes 40 analysed axons. *=p-value
<0.05 ;**=p-value <0.01
An unexpected observation was the increase in mitochondrial number in
the myelinated axons treated with mdivi-1, there seemed to be a trend of
even further increase of mitochondrial numbers in the 100µM compared to
the 50µM mdivi-1 samples; see figure 5.12. In the demyelinated axons
mdivi-1 did not increase the mitochondrial number any further, compared
with the already increased numbers of mitochondria after demyelination
with lysolecithin alone; see figure 5.12. There also was a significant
difference in mitochondrial numbers between the myelinated control and
mdivi-1 untreated/treated demyelinated slices.
Effect of inhibition of mitochondrial fission on axonal health
To test whether the inhibition of mitochondrial fission with mdivi-1 is
promoting axonal health or is detrimental to it, the area of the axonal bulbs
was divided by the total axonal area to get the percentage of axonal bulb
area. In the 100µM mdivi-1 treated samples, a lot of axonal bulbs in the
neurofilament (NF) staining were observed; see figure 5.13.
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FIGURE 5.13: Impact of mdivi-1 on axonal health as judged
by confocal images of demyelinated axons stained for NF
and MBP, showing axonal bulbs in demyelinated slices
without (left) and with mdivi-1 100µM treatment (right).
Scalebar=50µm
FIGURE 5.14: Effect of mdivi-1 on axonal health, shown
by the axonal bulb area corrected for the total axonal area
in demyelinated slices with or without mdivi-1 treatment.
There was a significant increase of axonal bulbs in the 100µM
mdivi treatment compared to control, there was however no
difference between the 50µM concentration and control. Each
dot represents one slice from one mouse and includes at least
40 analysed axons. **=p-value <0.01
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The analysis of axonal bulb area as a fraction of total axonal area, showed
a slight trend in increasing axonal bulbs with 50µM concentration of mdivi-
1 in the demyelinated axons and a substantial increase of axonal bulbs at
100µM mdivi, compared to the axons demyelinated with lysolecithin alone;
see figure 5.14.
5.3.4 Manipulation of mitochondrial biogenesis with
pioglitazone
By using the licensed diabetes drug pioglitazone, which was shown to
increase mitochondrial biogenesis by increasing the expression of
peroxisome proliferator-activated receptor (PPAR)-gamma
coactivator-1alpha (PGC-1α) and mitochondrial transcription factor A
(TFAM), the effect of increasing mitochondrial biogenesis on the ARMD was
tested; see figure 5.15 (Desouza and Shivaswamy, 2010; Skov et al., 2008;
Bogacka et al., 2005; Ghosh et al., 2007). For this experiment two different
concentrations of pioglitazone were used (10µM and 40µM) and renewed
two days after the first addition together with the addition of lysolecithin
and a final renewal 24 hours after removing the lysolecithin. The total
lysolecithin exposure time was 18 hours and the slices were stained at 3
days after removing the lysolecithin from the culture. The ScoRe imaging
technique was used to determine the myelination status of the axons in this
experiment.
FIGURE 5.15: Effect of pioglitazone on axonal mitochondria,
depicted in fluorescent images of myelinated axons in slices
with (B) or without (A) pioglitazone treatment. Scalebar=5µm
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Although the n-number for this experiment was not high enough to
reach statistical significance, there was a clear trend towards increased
mitochondrial occupancy of myelinated axons in pioglitazone treated slices
without lysolecithin treatment compared to slices not treated with
pioglitazone; see figure 5.16.
FIGURE 5.16: Impact of pioglitazone treatment on the axonal
occupancy of mitochondria, showing a trend towards increased
occupancy in the myelinated axons. Although there was no
significant different between the myelinated control slices and
the pioglitazone treated slices, in both the myelinated and
demyelinated axons, there was a clear trend towards increased
mitochondrial occupancy of the axon in the pioglitazone
treated slices. A higher n-number would be needed to reach
statistical significance. Each dot represents one slice from one
mouse and includes 40 analysed axons.
There was a slight trend towards an increase in mitochondrial occupancy
in the lysolecithin-demyelinated slices treated with the 40µM pioglitazone
concentration, compared to the untreated demyelinated slices, but higher n-
number would be required to confirm a possible difference between the two;
see figure 5.16.
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FIGURE 5.17: Impact of pioglitazone on mitochondrial size and
number in axons. Like the occupancy, size and number, showed
an increasing trend in the myelinated axons. Although there
was no statistical significant difference between the myelinated
control slices and the pioglitazone treated slices, there was a
clear trend towards increased mitochondrial size and number
in the myelinated pioglitazone treated slices. A higher n-
number would be needed to reach statistical significance. There
was no difference in the demyelinated axons between control
and pioglitazone treated slices. Each dot represents one slice
from one mouse and includes 40 analysed axons.
Like the occupancy, the mitochondrial number in the axons and the area
of the average single mitochondrion showed an increasing trend in the
pioglitazone treated myelinated slices compared to myelinated control. In
the demyelinated slices, the number and average size of single
mitochondria did not differ between the pioglitazone treatment and the
control; see figure 5.17.
Effect of increasing mitochondrial biogenesis on axonal health
To check the effect of pioglitazone treatment on axonal health after
demyelination with lysolecithin, pioglitazone treated and untreated slices
were demyelinated with lysolecithin and stained 3 days after removing
lysolecithin. The slices were then stained for NF to compare the percentage
of axonal bulbs between the groups; see figure 5.18.
Chapter 5. Manipulations of the ARMD 135
FIGURE 5.18: Impact of pioglitazone on axonal health as shown
by fluorescent images of NF staining in demyelinated slices
with (B) or without (A) pioglitazone treatment. Scalebar=50µm
FIGURE 5.19: Effect of pioglitazone on axonal health as judged
by the percentage area of axonal bulbs of the total axonal area
in demyelinated slices with or without pioglitazone treatment.
There was a significant decrease of axonal bulbs, when the
size of bulbs was taken into account, in the 40µM pioglitazone
treated slices compared to demyelinated control. Each dot
represents one slice from one mouse and includes at least 40
analysed axons. *=p-value <0.05
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The analysis of the axonal bulb area as a percentage of the total axonal
area showed a significant reduction of axonal bulb area with the 40µM
pioglitazone concentration compared to the control; see figure 5.19. The
10µM as well showed a slight trend towards reduced axonal bulbs
compared to the control; see figure 5.19. This significant difference however
was lost when the total number of axonal bulbs, which was corrected for the
total axonal area, was measured; see figure 5.20.
FIGURE 5.20: Impact of pioglitazone treatment on axonal
health as judged by the number of axonal bulbs corrected for
the total axonal area in pioglitazone treated and untreated
slices after demyelination with lysolecithin. There was no
significant difference of axonal bulbs, when just counting the
numbers, between the pioglitazone treated slices compared to
demyelinated control. Each dot represents one slice from one
mouse and includes at least 40 analysed axons.
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5.4 Discussion
As several neurological diseases show protein alterations that imply
involvement of mitochondrial dynamics, either in fusion/fission dynamics
or mitochondrial transport dynamics, targeting mitochondrial dynamics is
of great interest to possibly modify the clinical outcomes of these diseases
(Chan, 2006a; Su et al., 2010; Bonda et al., 2011). Although genetic
manipulations of mitochondrial dynamics are widely used in experiments
in vitro as well as in vivo, genetic manipulations are not used in the clinical
setting, were small molecular compounds are warranted to target specific
molecular processes (Ohno et al., 2014; Chen et al., 2003; Zhou et al., 2016).
5.4.1 Manipulation of mitochondrial transport
The ATPase inhibitor oligomycin, which targets the F0-subunit of complex
V of the ETC, was reported to completely inhibit mitochondrial transport in
vitro (Zala et al., 2013; Shchepina et al., 2012). Two separate experiments
were done using oligomycin in specific concentrations for each experiment.
The first experiment was done to determine the effect of decreasing
mitochondrial transport, with a low dose of oligomycin, has on the ARMD
and subsequently on axonal health after demyelination with lysolecithin.
For this oligomycin was added together with lysolecithin, or 18 hours after
adding lysolecithin to the medium, while keeping it in the medium until
lysolecithin was removed, the slices were then stained 24 hours after
removing lysolecithin. This lead to a total oligomycin exposure time of 6 or
24 hours with a concentration of 0.25µM, which represents a relatively low
dose compared to the one used by Zala et al, which was shown to
completely inhibit mitochondrial transport (Zala et al., 2013). Compared to
the 24 hour timepoint after demyelination without treatment, the
oligomycin treatment lead to a trend in decreased mitochondrial occupancy
of the axon at 24 hours after removing lysolecithin from the medium,
although no statistical significant difference was observed.
The size of single mitochondria in the axon also showed a trend towards
decreased size in the oligomycin treated group compared to lysolecithin
alone, again no statistical significant difference was observed. At the same
time the number of mitochondria in the axon showed a trend towards an
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increase in mitochondrial numbers after treatment with oligomycin, with no
statistical difference. The increase in mitochondral numbers and decrease in
size of single mitochondria, although not significant, could point towards
mitochondrial fragmentation following oligomycin treatment. As
oligomycin is an inhibitor of the F0-subunit of complex V of the ETC and
thus inhibits ATP production, it would not surprising be to observe
mitochondrial fragmentation after oligomycin treatment (Shchepina et al.,
2012). Overall the trend towards a decrease in mitochondrial occupancy of
the axon and decrease in size of single mitochondria after demyelination,
points towards a disturbance of the ARMD after blocking mitochondrial
transport by oligomycin treatment. This decrease in the ARMD after
blocking mitochondrial transport, hints at the importance of mitochondrial
transport to the axon from other parts of the cell. Although is has to be
noted, that these findings were not statistical significant and oligomycin, as
an ATPase inhibitor, has many other effects on cellular health besides
blocking mitochondrial transport.
To check the effect of oligomycin treatment on axonal health after
demyelination, the area of axonal bulbs was measured and corrected for the
total axonal area. There was a significant increase in axonal bulbs with the
oligomycin treatment over 24 hours, with a trend of increase in axonal bulbs
after 6 hours of oligomycin exposure. This increase in axonal bulbs after
oligomycin and lysolecithin treatment indicates that mitochondrial
transport is an important part of the ARMD in protecting the axon from
degeneration. Again it has to be noted, that oligomycin has many other
effects on cellular health apart from blocking mitochondral transport, so it
can not be ruled out that some other effect of blocking ATP production lead
to the increase in axonal bulbs. As noted above the main caveat of this
oligomycin experiment, is that the blockage of the ATPase leads to many
different detrimental effects on cellular health besides inhibiting
mitochondrial transport, so a lower concentration of oligomycin was used
which did not lead to significant impact on the ARMD and instead blunted
the response. To further test the effect of oligomycin on the ARMD a
concentration titration of oligomycin should be done to determine the
optimal dose for inhibition of mitochondrial transport, while keeping the
cells alive. Another possibility to check the effect of mitochondrial transport
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on the ARMD, without affecting the ATP production, would be to use
genetic manipulations of the mitochondrial transport machinery. It was
already reported in the literature that overexpression of syntaphilin, a
mitochondrial docking protein in the axon, leads the decreased
mitochondrial transport, while a knock-out of syntaphilin leads to an
increase of mitochondrial transport in the axon (Ohno et al., 2014; Zhou
et al., 2016). Also overexpression of Miro1, an adapter protein that indirectly
links mitochondria the kinesin and dynein motor proteins, was reported to
increase mitochondrial transport significantly (Stephen et al., 2015b; Zhou
et al., 2016).
The second experiment with oligomycin, which was a live imaging
experiment, was done to exclude any transport of the unconverted green
mEOS2 protein back into the stationary converted red mitochondria. For
this a higher dose of oligomycin (20µM), which is reported in the literature
to completely block mitochondrial transport, was added to the slices 30
minutes before imaging and was left on during the imaging procedure (Zala
et al., 2013). This brought mitochondrial movement to a nearly complete
stop. The ROI was converted and imaged every minute for 20 minutes and
the overall movement as well as the green in red fluorescence was
measured. If the green protein would be transported back into the
stationary red mitochondria within the ROI, it would be expected to see an
increase of green in red fluorescence over the imaged time, on the other
hand if the green in red fluorescence only increase when fusion of newly
transported unconverted green mitochondria fuse with the stationary
converted red mitochondria, no increase of green in red fluorescence would
be expected. There was a significant decrease of green in red fluorescence
measured over time, which indicates that there is no transport back of the
green protein into the converted red mitochondria. That there was a
decrease of green in red fluorescence, instead of just stable levels, can be
explained by the bleaching of the green fluorescence over the imaged
period. This effect was also seen in the total green fluorescence, again a
significant decrease over the imaged 20 minutes. This clearly shows that the
increase of green in red fluorescence observed in chapter 3 and 4, is a
product of newly transported unconverted green mitochondria to the ROI
and subsequent fusion with the stationary converted red mitochondria.
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5.4.2 Manipulation of mitochondrial fission
To manipulate mitochondrial fission and to measure the effect on the
ARMD or axonal health after demyelination, the putative Drp1 specific
inhibitor mdivi-1 was used to inhibit mitochondrial fission in cerebellar
brain slices with or without lysolecithin (Cassidy-Stone et al., 2008). As
mentioned in chapter 1, mitochondrial fission is mediated by the GTPase
Drp1, which interacts with surface proteins on the mitochondrial outer
membrane, potential candidates are for example Mff (mitochondrial fission
factor) and Fis1 (mitochondrial fission 1 protein) (Liu and Chan, 2015; Losón
et al., 2013; Otera et al., 2010). A reduction in mitochondrial fission would
lead to enlarged mitochondria, emulating increased mitochondrial fusion,
which was reported to be protective under stress conditions, as elongated
mitochondria were shown to have increased ATP production and better
protection against ROS/RNS (Tondera et al., 2009; Redpath et al., 2013;
Chiang et al., 2015). Furthermore, mitochondrial fusion allows for
complementation of damaged mitochondria with healthy mitochondria,
thus diluting mitochondrial defects (DiMauro and Schon, 2003; Chan, 2012a;
Scott and Youle, 2010; Chan, 2012b; Nakada, Inoue, and Hayashi, 2001).
For this experiment two different concentrations of mdivi-1 were added
to the slices (50µM and 100µM) and the effect on the size and number of
mitochondria in the axon and subsequently on axonal health was measured
after demyelination with lysolecithin. Interestingly, mdivi-1 already
significantly increased mitochondrial content in the myelinated axons, with
both concentrations. Furthermore, mdivi-1 significantly increased the
mitochondrial occupancy in the lysolecithin treated axons even more than
with lysolecithin alone. The effect seen in the myelinated axons, can be
attributed to the increase in mitochondrial size, which was significantly
greater in the mdivi-1 treated axons compared to control. There was also an
increase in mitochondrial number, which was an unexpected finding, since
mdivi-1, as an inhibitor of mitochondrial fission, is expected to increase
mitochondrial size, but not numbers. On the contrary, it would be expected
that the bigger mitochondria, which are an effect of the decrease in fission,
are more difficult to transport to the axon. In the demyelinated axon there
was also an increase in mitochondrial occupancy of the axon with the
mdivi-1 treatment compared to the demyelinated axons treated with
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lysolecithin alone. This effect was significant with both used concentrations
of mdivi-1. In the case of the demyelinated axon this increase in
mitochondrial occupancy is not driven by the number of mitochondria in
the axon, as there was no increase in mitochondrial numbers compared to
the mdivi-1 untreated demyelinated axons. There was however an increase
in mitochondrial size, which was observed with both concentrations of
mdivi-1.
To check the effect of mdivi-1 treatment on axonal health after
demyelination, the area of axonal bulbs was calculated by using ImageJ and
was substracted from the total axonal area to correct for any differences in
axonal numbers between the images taken. There was no protective effect
on axons by treating the slices with 50µM mdivi-1 when demyelinating
them with lysolecithin. With the 100µM concentrations of mdivi-1 there was
even a significant increase of axonal bulbs compared with the mdivi-1
untreated slices. This detrimental effect of mdivi-1 on axonal health was
unexpected, since an increase in elongated mitochondria is supposed to be
protective in stress environments. Recently, it was reported that mdivi-1 is
not a specific inhibitor of Drp1 (and thus mitochondrial fission), since it only
poorly inhibits the GTPase activity (Ki > 1.2 mM), but a reversible NADH
Coenzyme Q oxidoreductase (complex I of the ETC) inhibitor; (Bordt et al.,
2017). This inhibitory effect on complex I could explain the detrimental
effect on axonal health, furthermore the increase in mitochondrial size,
despite being significant, was only marginal in terms of absolute size of
single mitochondria. If mdivi-1 was inhibiting mitochondrial fission
efficiently, the size of single mitochondrial would be expected to increase by
a substantial amount, which is not observed with the concentrations used,
in line with the report of mdivi-1 being a weak Drp1 inhibitor (Bordt et al.,
2017).
To really assess the effect of decreasing mitochondrial fission or
increasing mitochondrial fusion, a different approach should be used, either
by using different compound or by manipulating mitochondrial
fusion/fission dynamics by genetic manipulation. The peptide P110 was
reported to decrease mitochondrial fission efficiently in vitro by interacting
with Drp1, also under oxidative stress conditions (Qi et al., 2013; Filichia
et al., 2016). Furthermore, P110 was found to be neuroprotective in a model
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of Parkinson’s disease in vitro, by reducing excessive mitochondrial fission
and ROS production (Qi et al., 2013; Filichia et al., 2016). Dynasore is
another candidate to reduce mitochondrial fission, which was also reported
to be protective against ischemia/reperfusion injury in the mouse heart
(Reddy, 2014; Tanaka and Youle, 2008; Gao et al., 2013).
5.4.3 Manipulation of mitochondrial biogenesis
To measure the effect increasing mitochondrial biogenesis on the ARMD
and axonal health after demyelination, the licensed diabetes drug
pioglitazone was used to increase mitochondrial biogenesis in cerebellar
brain slices with or without lysolecithin treatment (Desouza and
Shivaswamy, 2010). Pioglitazone has been shown to increase expression of
PGC-1α and TFAM, two regulators of mitochondrial biogenesis (Skov et al.,
2008; Bogacka et al., 2005; Ghosh et al., 2007; Corona and Duchena, 2016).
While TFAM binds to mitochondrial promoters in the DNA and enhances
transcription of mitochondrial genes, PGC-1α is the master regulator of
mitochondrial biogenesis and is responsible for the activation of cAMP
response-element-binding-protein (CREB) and nuclear-respiraty-factor-1
and 2 (NRF1& 2), which in term increases the transcription of genes
responsible for mitochondrial biogenesis (Alam et al., 2003; Campbell,
Kolesar, and Kaufman, 2012; Liang and Ward, 2006). Increasing
mitochondrial biogenesis is reported to be neuroprotective and protects
neurons from mitochondrial insult (Stetler et al., 2012; Hasegawa et al.,
2016).
Two different concentrations of pioglitazone were used for this
experiment (10µM and 40µM) and the mitochondrial occupancy of the
axons, as well as the size and number of mitochondria in the axon was
analysed and compared between treated and untreated slices. Furthermore,
the effect of pioglitazone on axonal health was measured after
demyelination with lysolecithin. There was a trend towards increased
mitochondrial occupancy of myelinated axons in pioglitazone treated slices
compared to untreated slices. In the lysolecithin treated demyelinated slices,
pioglitazone did not increase the mitochondrial occupancy any further than
with lysolecithin treatment alone. The increase in mitochondrial occupancy
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in the myelinated axons, seemed to stem from the increase in mitochondrial
numbers, as well as the increase in the average size of the single
mitochondrion. In the demyelinated slices there was neither a change in
mitochondrial number nor size of the average mitochondrion compared to
slices only treated with lysolecithin. To confirm the trend seen in the
myelinated axons and examine the effect of pioglitazone on mitochondrial
parameters after demyelination in more detail a higher n-number is
warranted.
To determine the effect of pioglitazone treatment on axonal health after
demyelination, the area of each axonal bulb was calculated by using ImageJ,
added together and the percentage of axonal bulb area to the total axonal
area was calculated. There was already a slight trend toward a decrease in
percentage of axonal bulb with the 10µM pioglitazone concentration, while
the 40µM concentration lead to a significant decrease in axonal bulb area.
This effect however was not observable when measuring the number of bulbs
corrected for the total axonal area, which means that there is only a reduction
in size of the axonal bulbs, not in numbers.
5.4.4 Summary manipulating mitochondrial parameters
In summary, inhibition of mitochondrial fission, and possible inhibition of
complex I, with mdivi-1 leads to an increase in axonal bulbs compared to
untreated demyelinated axons (Cassidy-Stone et al., 2008; Bordt et al., 2017).
Also, the inhibition of mitochondrial transport, as well as the reduction of
ATP synthesis, with oligomycin has a detrimental effect on axonal health as
shown by the increase in axonal bulb area (Shchepina et al., 2012). The
increase of mitochondrial biogenesis with pioglitazone might have a
protective effect on axonal health after demyelination with lysolecithin,
although this protective effect was only significant when taking the bulb
size into account, while the total number of axonal bulbs was not
significantly lower than in untreated control slices. (Skov et al., 2008;






6.1.1 Mitochondrial deficiency in MS
The previous chapters were looking at mitochondrial dynamics after
demyelination with lysolecithin, to study the effect of demyelination, which
is a hallmark feature of multiple sclerosis, on this dynamic organelle
(Noseworthy et al., 2000; Ferguson et al., 1997; Fawcett and Asher, 1999;
Bitsch et al., 2000a; Stichel and Muller, 1998; Popescu, Pirko, and
Lucchinetti, 2013; Lassmann, 2013; Kutzelnigg and Lassmann, 2014). In all
these experiments, only wild-type neurons of the cerebellum were analysed,
but many neurons in multiple sclerosis show mitochondrial dysfunction
and DNA defects, as shown in MS autopsy cases. This defects can lead to
deficiency in one or more subunits of the ETC, which has negative
consequences for the neuronal mitochondria and is likely to contribute to
neurodegeneration seen in MS (Dutta et al., 2006; Campbell et al., 2011;
Broadwater et al., 2011; Witte et al., 2013; Kim et al., 2010; Hares et al., 2014;
Fischer et al., 2013; Haile et al., 2017a). To model the effect of this
mitochondrial deficiency on the ARMD and ultimately axonal health after
demyelination, slices from mutants with mitochondrial DNA deletions were
used. Because these mtDNA deletions lead to embryonic lethality, a Cre-lox
system with an ERt site was used to induce a conditional knock-out with
tamoxifen after the mice reached a certain age (Agostino et al., 2003). There
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are several transgenic mouse models used in the Mahad laboratory that
have distinct mitochondrial defects.
COX10fl/fl − Thy1− Cre− ERT2+−
The COX10fl/fl − Thy1 − Cre − ERT2+− mouse line is, after activation of
the Cre-recombinase with tamoxifen, lacking the mitochondrial scaffolding
protein COX10 in a subpopulation of neurons expressing the Thy1.2
promoter. Since COX10 is needed for the assembly of complex IV of the
mitochondrial respiratory chain, these mice completely lack complex IV; see
figure 6.1. This mouse line was generated by Graham Campbell in the
Mahad lab by crossing a mouse line in which the CreERT2 cassette is driven
by the Thy1.2 promoter (TCE) with a Cox10flox/flox mouse line (Zonta et al.,
2011; Fünfschilling et al., 2012).
FIGURE 6.1: Effects of different mitochondrial DNA defects.
The top panel shows the situation in MS, where an expansion
of mitochondrial DNA deletions over time is observed, which
leads to a reduction in complex IV activity. The bottom panel
show the effect of a COX10 deletion, which leads to a complete
loss of complex IV.
6.2 Timeline of COX10fl/fl−Thy1−Cre−ERT2+−
mouse
COX10fl/fl − Thy1− Cre− ERT2+− mice which were injected (by Graham
Campbell) on five consecutive days two weeks apart, show widespread
complex IV deficient neurons in the CNS four weeks after the last injection;
see figure 6.2. Six weeks later the mice present with severe clinical signs e.g.
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flat profile and severe hind limb disturbance; see figure 6.2. It was also
shown by Graham Campbell and other members of the Mahad lab, that the
ARMD is perturbed in the complex IV deficient axons, displaying an even
greater increase of mitochondrial occupancy compared to wild-type shortly
after demyelination, followed by a depletion over time. These mitochondria
appearing in the axon lack complex IV as opposed to wild type neurons
with are complex IV efficient. To determine any structural changes
following loss of mitochondrial complex IV in neurons, paraffin embedded
tissue of the mutant mice was stained for different cellular markers,
including synapses, and compared to litter mate control tissue
(COX10fl/fl − Thy1). Because any observed change will be most
pronounced at the end stage, every staining was first done at 10 weeks after
the last tamoxifen injection and thereafter earlier time points were stained.
This is done to determine the optimal time point for demyelination in vivo,
when there is no structural change but sufficient complex IV deficiency
found in the neurons.
FIGURE 6.2: Timeline of the COX10fl/fl − Thy1 − Cre −
ERT2+− transgenic mouse line, depicting the onset of
biochemical deficiency and late onset neurodegeneration.
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6.3 Materials and methods
6.3.1 Mutant mouse lines
All procedures were performed according to the 1986 Animals Act
(scientific procedures) UK and were approved by the local ethics committee.
The mutant mouse lines used for this experiments were created before my
arrival by Graham Campbell in the Mahad lab, with the
COX10fl/fl − Thy1 − Cre − ERT2+− being generated by crossing a mouse
line in which the CreERT2 cassette is driven by the Thy1.2 promoter (TCE)
with a Cox10flox/flox mouse line (Zonta et al., 2011; Fünfschilling et al.,
2012).
6.3.2 Immunohistochemistry
For Immunohistochemistry slice culture tissue and paraffin embedded
sections were used, the slides were labelled according to which antibodies,
dilution and antigen-retrieval method would be used, furthermore the date
of the beginning of the staining was indicated. For Immunohistochemistry
protocol see methods section in chapter 2.
6.3.3 Paraffin sections
For the paraffin sections four distinct steps followed, which are different
depending on the staining, 1. Deparaffination of the slides and blocking of
the endogenous peroxidase, 2. Antigen retrieval step, 3. Incubation with the
Antibodies and optional 4. development of the staining with DAB.
Reagents
For reagents see methods section in chapter 2.
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Antibody application





























































1. Frozen slides thawed on room temperature for 1 hour
2. DAB and Cytochrome C are thawed and combined
3. 1 Spatula of bovine catalase (Sigma) per thawed tube is added
4. Vortexed
5. Slides labelled accordingly PAP pen circle is drawn
6. Tissue is covered with DAB+Cytochrome C Solution
7. Slides/slices put into incubator for 30 minutes at 38 ◦C
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8. Slides/slices washed 2 times for 2 minutes with PBS
9. NBT, PMS (light sensitive), Succinate and Azide are thawed
10. 100µl of PMS and 100µl of Succinate added to NBT
11. 10µl of Azide added and vortexed
12. Tissue covered with SDH Solution
13. Slides/slices put into incubator for 30 minutes at 38 ◦C
14. Slides/slices washed 2 times for 2 minutes with PBS
15. Slides/slices put into 100% Ethanol for 10 minutes
16. Immersed into Histoclear 20 times
17. Mounted with DPX and glass coverslip
6.3.4 Imaging methods
VGlut1 synaptic staining
For the VGlut1 synaptic staining paraffin sections of different time points
after tamoxifen induction of complex IV deficiency were stained according
to the paraffin protocol and incubated over night at 4 ◦C with the VGlut1
antibody.
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FIGURE 6.3: Overview of the imaging method of VGlut1
positive synapses (red) and nuclei (blue), scalebar 20µm.
Images of the whole dorsal and ventral areas, as well as the
central (not analysed) region were taken with a 40x oil objective
on a Zeiss ApoTome2.
Anti-IgG1 coupled to Rhodamine-Red-X was used as the secondary
antibody. The imaging of the sections was done on a Zeiss ApoTome2 with
a 40x oil objective and 5.6ms exposure time for the Rhodamine and 1.6ms
for the DAPI. Pictures from the dorsal, central and ventral area were taken,
although the central area was not included in the following analysis; see
figure 6.3. For each area a z-stack of 6µm thickness was taken with 0.5µm
intervals between z-planes. After the imaging the pictures were converted
into 8-bit using ImageJ and adjusted for actual area of VGlut1 staining; see
figure 6.4. The quantification was done using the analyse particles tool in
ImageJ with a threshold of 8-255 and a selected pixel size of 10-500; see
figure 6.5.
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FIGURE 6.4: Conversion of images for quantitative analysis in
ImageJ. The pictures (A) had to be converted to 8-bit black and
white (B), this was done with ImageJ using the batch->convert
option. VGlut1 (red) and DAPI (blue), scalebar 20µm
FIGURE 6.5: Calculation of number of synapses was done in
ImageJ. To measure the number of VGlut1 positive synapses
the analyse particles tool in ImageJ was used. On the left (A)
a black and white 8-bit picture of VGlut1 positive synapses is
shown, on the right (B) the counted dots. Scalebar 20µm
Dendritic mitochondria (MAP2/Porin/COXI)
To determine the amount of deficient mitochondria in the dendrites a
fluorescent triple labelling with MAP2 (dendrites), Porin (mitochondrial
transmembrane protein present in all mitochondria) and COXI (subunit of
Complex IV, which is not present in COX10 knock-out cells) was done on
paraffin sections of controls and mutants at different timepoints after the
induction of deficiency with tamoxifen.
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FIGURE 6.6: Overview of the imaging method of dendritic
mitochondria, showing dendrites (red), mitochondria (green)
and mitochondrial COXI (blue; subunit of mitochondrial
complex IV). Images of the whole dorsal and ventral areas, as
well as the central region were taken with a 63x oil objective
with 1.5x zoom on a Zeiss LSM710 laser scanning confocal
microscope. Scalebar 10µm
For the MAP2/Porin/COXI staining paraffin sections of different time
points after tamoxifen injection were stained according to the paraffin
protocol and incubated for 1 hour and 30 minutes on room temperature
with the MAP2, Porin and COXI antibodies. For the secondary antibody,
anti-IgG1 Rhodamine, anti-IgG2b Alexa Fluor 488 and anti-IgG2a Alexa
Fluor 633 antibody was used. The analysis of the sections was done on a
Zeiss LSM 710 confocal scanning microscope using a 63x oil objective and
1.5x zoom. Pictures from the dorsal, central and ventral area were taken,
although the central area was not included in the following analysis; see
figure 6.6. For each area a z-stack of 4.29µm thickness was taken with
1.07µm intervals between z-planes.
Chapter 6. Modelling mitochondrial deficiency 153
FIGURE 6.7: Determining the amount of deficient mitochondria
in the dendrites. To assess the COXI deficiency of dendritic
mitochondria, non-dendritic mitochondria were cleared from
the images using Photoshop. The left panel (A) shows a control
(top) and mutant (bottom) with dendrites (red) and dendritic
COXI protein (blue), which is lacking in the mutant. The
right panel (B) shows a control (top) and mutant (bottom) with
dendrites (red) and all dendritic mitochondria (green). Scalebar
10µm
The images were then cleared of all non-dendritic mitochondria using
Photoshop; see figure 6.7. To clear non dendritic mitochondria, the red
channel (MAP2 for dendrites) was set to a threshold with no cell bodies but
most of the dendrites selected; see figure 6.7. The area outside of the
dendritic area was selected, the channel changed to the green (Porin for
mitochondria) and the selected area was cut out; see figure 6.7. The same
procedure was done for the blue channel (COXI for complex IV) and the
two separate channels were combined into one composite using ImageJ; see
figure 6.7. Dendritic area, percentage of dendritic area occupied by
mitochondria, average percentage of deficient mitochondria, mitochondrial
area, number of mitochondria and average area of single mitochondria were
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determined by using 3 different ImageJ macros (1. to measure dendritic
area, 2. area and number of Porin/CoxI signal as well as 3. overlap between
Porin and CoxI areas). An excel sheet was used to calculate the sums and
average of different values gained from the macros (see Chapter 2 methods
for the first 2 macros). After the first two macros have calculated the
mitochondrial occupancy of the dendrites and other mitochondrial
parameters, the two images depicting the porin staining for all
mitochondria and the COX-I staining for mitochondria with complex IV
were merged in ImageJ. After the images were merged the third macro was
activated by pressing ’3’, which subsequently measured the percentage of
blue (COXI) in green (Porin) staining and thus calculated the complex IV
deficiency. This data was also inserted into the excel sheet, were the mean of
all analysed dendrites was calculated, giving the total mean deficiency for
the mitochondria in the dendrites from a specific region.
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6.4 Results
6.4.1 Induction of COX10 deficiency in slices
To induce complex IV deficiency in cerebellar purkinje cells in COX10fl/fl −
Thy1− Cre− ERT2+− slices, 10µM tamoxifen or 1µM 4-OHT was added to
the slice culture medium and left on for 4 days, with one renewal at 2 days.
FIGURE 6.8: Mitochondrial complex IV deficiency in cerebellar
slices. Bright field image showing cells that are deficient for
mitochondrial complex IV in blue, while cells with complex IV
activity are brown. Scalebar 100µm
After the induction with tamoxifen or 4-OHT the slices were left in culture
for another 3-4 weeks to allow sufficient time for the deletion to take effect.
After this 3-4 week period a COX/SDH assay was performed on the slices
to determine if there was successful COX10 deletion within the cerebellar
purkinje cells; see figure 6.8. Although blue cells were visible in the slices,
which is an indicator that complex II (completely nuclear-encoded) is active,
but complex IV is not, non of these cells appeared to be purkinje cells as
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judged by visual appearance; see figure 6.8. 4-OHT treatment lead to more
deficient cells compared to tamoxifen, but no deficient PC could be observed
by morphological features even 4 weeks after the induction with 4-OHT; see
figure 6.9.
FIGURE 6.9: Mitochondrial complex IV deficiency in cerebellar
slices. Bright field image showing complex IV deficient cells 4
weeks after treatment with either Tamoxifen (A) or 4-OHT (B).
Scalebar 40µm
Deficient PC in slices
To determine if the PC in the slices still have complex IV activity an IHC
staining for calbindin with subsequent COX assay was performed and the
appropriate regions were overlapped in Photoshop to determine complex IV
activity in purkinje cells; see figure 6.10.
FIGURE 6.10: Mitochondrial complex IV deficiency in
cerebellar slices. Fluorescence image of calbindin antibody
(B) mediated fluorescence IHC and bright field image of COX
assay (A) in a cerebellar slice overlapped to show the activity of
mitochondrial complex IV in purkinje cells. Scalebar 20µm
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Furthermore, a triple staining for calbindin, porin (a mitochondrial outer
membrane protein on all mitochondria) and COXI (complex IV subunit) was
performed to determine the presence of complex IV in PC mitochondria; see
figure 6.11.
FIGURE 6.11: Mitochondrial complex IV deficiency in
cerebellar slices. Fluorescence image of calbindin (A), porin
(B) and COXI (C) triple-staining, to determine the presence of
complex IV in purkinje cells in cerebellar slices. Scalebar 50µm
The COX assay combined with IHC, as well as the triple
immunofluorescence staining, both showed that the PC mitochondria in the
mutant slices still contain complex IV and maintain complex IV activity; see
figure 6.10 and figure 6.11. A possible explanation for this lack of deficient
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mitochondria after the induction with 4-OHT or tamoxifen, could be that
the turnover for mitochondria in purkinje cells is too slow, so that the
lifetime of healthy slices is too short to successfully get deficient PC in slice
culture.
6.4.2 In vivo model COX10fl/fl − Thy1− Cre− ERT2+−
Because it was not possible to get deficient PC in the slice culture system
during this experiment, the determination of the effect of a mitochondrial
complex IV defect on the ARMD had to be tested in vivo, where complex IV
deficient cells can be found at 4 weeks after induction with tamoxifen.
FIGURE 6.12: Complex IV deficient Purkinje cells in the
cerebellum of COX10fl/fl − Thy1 − Cre − ERT2+− mice 4
weeks after induction with tamoxifen. COX/SDH assay was
done to visualize complex IV deficient cells in blue, while
complex IV efficient cells are stained brown. Scalebar 100µm
While the greatest part of this experiment was done by Graham
Campbell, at the time post-doc in the Mahad lab, my contribution was to
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determine the optimal timepoint for demyelination, where there is
significant complex IV deficiency in the neurons, but no structural change.
For this experiment IHC stainings for several different cellular markers
were performed on paraffin emdedded sections at different timepoints after
the induction of deficiency with tamoxifen.
VGlut1 in the spinal cord of COX10fl/fl − Thy1− Cre− ERT2+− mutants
Previous data from the lab has indicated that there is no neuronal loss or
structural change at the neuromuscular junction, despite a strong motor
function related phenotype in the mutant mice. It has been shown that
glutamatergic synapses of neurons lacking complex IV in the hippocampus
show signs of dysfunction (Booker et al., 2017). After testing several
different cellular markers by doing IHC stainings, VGlut1 in the spinal cord
turned out to be the marker most affected by the complex IV deficiency; see
figure 6.13. Therefore, VGlut1 synapses were used as a marker to determine
the earliest timepoint, with overt deficiency of complex IV, where there is no
structural change in the ventral or dorsal spinal cord of the mutant mice.
FIGURE 6.13: Loss of VGlut1 positive synapses in the ventral
horn of COX10fl/fl − Thy1 − Cre − ERT2+− mutants (B)
compared to control (A), shown by IHC staining for VGlut1 in
the ventral horn of control mice and mutant mice with complex
IV deficiency 10 weeks after induction with tamoxifen. Scalebar
20µm
At 10 weeks post induction of deficiency with tamoxifen theCOX10fl/fl−
Thy1 − Cre − ERT2+− mutant mice showed a significant loss of VGlut1 in
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the ventral horn of the cervical, thoracic and lumbar region of the spinal cord;
see figure 6.13 and figure 6.14.
FIGURE 6.14: Impact of complex IV deficiency on the integrity
of VGlut1 positive synapses, showing a significant synapse loss
in the ventral horn of the cervical, thoracic and lumbar region
of the spinal cord at 10 weeks post induction with tamoxifen.
All other areas and timepoints were not significantly different,
although there was a decreasing trend in several. Each dot
represents the mean value from at least 4 different slides from
one mouse. *=p-value <0.05
To check the VGlut1 loss at earlier timepoints, IHC staining for VGlut1
were done at 4, 6 and 8 weeks past induction with tamoxifen; see figure 6.14.
Although at none of the other timepoints showed a significant loss of
VGlut1 in the ventral horn either in the cervical, thoracic or lumbar region
of the spinal cord, there was a slight trend towards decreasing synapse
number at 6 and 8 weeks, while at 4 weeks post induction there was no
indication of a possible VGlut1 reduction in the ventral horn of the spinal
cord in COX10fl/fl − Thy1− Cre− ERT2+− mutant mice; see figure 6.14.
Mitochondrial deficiency in the dendrites of COX10fl/fl − Thy1 − Cre −
ERT2+− mutants
To determine the mitochondrial deficiency in the dendrites of
COX10fl/fl − Thy1 − Cre − ERT2+− mutants at different timepoints after
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the induction of deficiency, a triple IHC staining for MAP2 (for neuronal
dendrites), porin (labelling all mitochondria) and COXI (labelling
mitochondrial complex IV) was performed. It was previously shown in the
Mahad lab (unpublished data), that the complex IV deficiency is already
present at 4 weeks post induction in the cell body, but takes much longer to
manifest inside the axon. As with the VGlut1 staining the timepoint 10
weeks post tamoxifen induction was stained first, as this stage is near the
end stage and the biggest effect is to be expected. The IHC triple staining at
10 weeks post induction revealed a significant amount of complex IV
deficient mitochondria in the mutant compared to the control; see figure
6.15.
FIGURE 6.15: Loss of complex IV in dendrites of COX10fl/fl −
Thy1 − Cre − ERT2+− mutants (B) compared to control
(A), shown in a IHC fluorescence triple staining at 10
weeks post tamoxifen. Depicted are the dendrites (red), all
mitochondria stained by porin antibody (green), and complex
IV efficient mitochondria stained with COXI antibody (blue),
while complex IV deficient mitochondria are lacking COXI
staining. Scalebar 10µm
In the dorsal as well in the ventral horn of the spinal cord a significant
higher percentage of mitochondria were deficient in the mutant compared
to the control at 10 weeks post induction; see figure 6.16 and figure 6.17.
Furthermore, there was a trend towards decreased mitochondrial and
dendritic area, although not significant.
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FIGURE 6.16: Loss of complex IV in dendrites of COX10fl/fl −
Thy1 − Cre − ERT2+− mutants, showing the significant
increase in mitochondrial complex IV deficiency in the mutant
ventral horn 10 weeks after induction with tamoxifen. Each dot
represents the mean value from 2-4 different slides from one
mouse. *=p-value <0.05
FIGURE 6.17: Loss of complex IV in dendrites of COX10fl/fl −
Thy1 − Cre − ERT2+− mutants, showing the significant
increase in mitochondrial complex IV deficiency in the mutant
dorsal horn 10 weeks after induction with tamoxifen. Each dot
represents the mean value from 2-4 different slides from one
mouse. *=p-value <0.05
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The earliest timepoint stained for MAP2 was 4 weeks post induction
with tamoxifen and at this time the dendrites in the cervical ventral spinal
cord already showed a significant increase of complex IV deficiency
compared with non-induced control cases; see figure 6.18. This determines 4
weeks after induction of deficiency as the earliest timepoint with significant
deficiency and no structural change in the spinal cord of
COX10fl/fl − Thy1− Cre− ERT2+− mutant mice.
FIGURE 6.18: Loss of complex IV in dendrites of COX10fl/fl −
Thy1 − Cre − ERT2+− mutants, showing the increase in
mitochondrial complex IV deficiency in the mutant cervical
ventral horn 4 weeks after induction with tamoxifen. Other
parameters show a slight decreasing trend in the mutant,
although non of them are significant. Each dot represents the
mean value from 2-4 different slides from one mouse. *=p-
value <0.05
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6.5 Discussion
Recently it was shown by several independant research groups that many
neurons in multiple sclerosis show a deficiency in at least one of the
complexes of the mitochondrial electron transport chain. These deficiencies
are a consequence of mitochondrial DNA deletions, which have also been
shown in multiple sclerosis autopsies (Dutta et al., 2006; Campbell et al.,
2011; Broadwater et al., 2011; Witte et al., 2013; Kim et al., 2010; Hares et al.,
2014; Fischer et al., 2013; Haile et al., 2017a). Data from the Mahad lab
(unpublished data) shows that none of the currently used animals models of
multiple sclerosis harbour these mitochondrial DNA deletions, so there is a
need to model this MS phenomenon in vivo and in vitro. These models
would allow test the effect of mitochondrial DNA deficiencies on
demyelinated axons and to test different treatment strategies for this
mitochondrial deficiencies. Ultimately these models may be useful in
finding a treatment for progressive multiple sclerosis, which only has one
licensed treatment thus far (Montalban et al., 2017). For this purpose several
different mouse mutant lines have been established in the Mahad lab over
the past years. For this thesis, the COX10fl/fl − Thy1 − Cre − ERT2+−
mutant line was used, firstly to make cerebellar slices and induce complex
IV deficiency by using Tamoxifen or 4-OHT, and secondly to determine to
optimal timepoint for demyelination in vivo, which is characterized by a
significant complex IV deficiency without structural changes of cellular
markers.
6.5.1 Induction of mitochondrial deficiency in cerebellar
slices
To determine the effect of mitochondrial DNA deletions on the ARMD,
cerebellar brain slices from COX10fl/fl − Thy1 − Cre − ERT2+− mice were
created and the Cre-recombinase was induced by adding either 10µM of
Tamoxifen or 1µM of 4-OHT to the slice culture medium and left on for 4
days. After leaving the slices in culture for 3 to 4 weeks, either a COX/SDH
assay or IHC triple staining for COXI, a complex IV subunit, was performed
to check for complex IV deficiency. The COX/SDH assay, which tests for
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complex II (blue) and complex IV activity (brown), showed complex IV
deficient cells in the slices after 4 weeks of induction with
tamoxifen/4-OHT. These blue cells were however, judging by morphology
and confirmed by IHC staining for calbindin, not purkinje cells. Because the
cerebellar brain slice health began to deteriorate after 3 to 4 weeks it was not
possible to keep the slice culture long enough to obtain complex IV deficient
purkinje cells with the induction of tamoxifen or 4-OHT. An alternative
approach would be to use a lentivirus expressing Cre-recombinase and
inject it into the slices right after making the slice culture, which might be a
more effective way of inducing complex IV deficiency.
FIGURE 6.19: Complex IV deficient cells in DRG culture,
depicted by the COX/SDH assay which labels complex IV
deficient cells in blue, while complex IV efficient cells are
stained brown.
Another possibility to model mitochondrial deficiency in vitro would be
to use neuronal culture, for example dorsal root ganglia culture. In DRG
culture it is possible to get mitochondrial complex IV deficient cells around
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14 days after adding a lentivirus expressing Cre-recombinase into the
culture medium. DRG culture can also be used in microfluidic chambers,
which would allow the assessment of directionality of mitochondrial
movement and the possibility to treat cell body and axon separately, to
study the effects different drugs might have on the mitochondrial deficiency
(Taylor et al., 2005).
6.5.2 Structural changes and mitochondrial deficiency in the
COX10fl/fl − Thy1− Cre− ERT2+− mutant
The mitochondrial complex IV deficiency can also be modelled in vivo, where
it is much easier to get complex IV deficient neurons. Another advantage
of the in vivo approach is that the phenotype of the mitochondrial defect in
question can be studied and different drugs can be tested to determine if they
ameliorate the phenotype. The phenotype analysis, different drug treatments
and injection of lysolecithin for demyelination in vivo was done by Graham
Campbell and other members of the Mahad lab.
For this thesis, the structural integrity of several different cellular
markers was tested to find the earliest timepoint where there is no structural
change, but significant mitochondrial complex IV deficiency. For this,
paraffin embedded sections of induced mutants were first stained near the
endstage to ensure that any possible change in markers would be significant
enough to observe. Most of the cellular markers tested (not shown), did not
show a significant change in the induced
COX10fl/fl − Thy1 − Cre − ERT2+− mutant compared to the control, only
the VGlut1 synapses did show a reliable marker of structural change after
induction of deficiency. In general the loss of synapses was strongest in the
cervical area, followed by the thoracic region of the spinal cord, while the
lumbar region had the least dramatic reduction. At 10 weeks post induction
of deficiency with tamoxifen, there was a significant reduction of VGlut1
positive synapses in the cervical, thoracic and lumbar ventral horn of the
COX10fl/fl − Thy1 − Cre − ERT2+− mutant spinal cord. This significant
reduction was not observed at any earlier timepoint tested, although there
was a trend towards a reduction of synapses at 8 weeks and a slight trend at
6 weeks post induction, only in the cervical region. At 4 weeks after
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induction of deficiency, none of the regions analysed showed any reduction
in VGlut1 positive synapses in the COX10fl/fl − Thy1 − Cre − ERT2+−
mutant. The conclusion from this experiment was that 4 weeks after
induction of deficiency was the earliest timepoint with no structural change.
To determine the earliest timepoint with significant complex IV
deficiency in the dendrites of the spinal cord a IHC triple staining with
MAP2 for dendrites, porin for all mitochondria and COXI for complex IV
efficient mitochondria was performed on paraffin embedded section of the
COX10fl/fl − Thy1 − Cre − ERT2+− mutant at different timepoints after
induction of deficiency. Near the end-stage at 10 weeks post induction of
deficiency there was a significant percentage of mitochondria deficient of
complex IV in the mutant in the cervical region of the spinal cord. In the
thoracic and lumbar region there was significant tissue damage in some of
the cases, so the n-number in this regions was not high enough to reach
statistical significance, but a clear trend was observable. As the earliest
timepoint analysed, because there was no structural change found at this
timepoint, 4 weeks post induction already showed a significant increase in
mitochondrial complex IV deficiency in the dendrites of the cervical ventral
horn. All the other parameters analysed, as well as VGlut1, did not show
any significant change at this stage. Therefore, 4 weeks post-induction of
deficiency was determined as the earliest timepoint with significant




7.1 Recap of the literature review and aims
The brain is the most energy demanding organ of the human body, using
about 20% of the bodies energy reserves, while representing only about 2%
of the total body mass (Raichle and Gusnard, 2002). The brain in turn uses
about half of its energy budget for maintaining a transmembrane ionic
balance of sodium and potassium with ATP powered ion-pumps (Fei et al.,
2008). The myelination of axons, besides enhancing the signal transmission
speed, is improving the energy efficiency of maintaining this ionic balance,
with the ion channel and pumps being concentrated at the nodes of Ranvier
between the myelinated segments of the axon (Neishabouri and Faisal, 2011;
Saab, Tzvetanova, and Nave, 2013). At these nodes of Ranvier stationary
sites of mitochondria supply the ATP necessary to maintain this ionic
balance (Ohno et al., 2011; Chiu, 2011). Demyelinating diseases of the CNS
and PNS destroy this energy efficiency by disrupting the ordered ion
channel distribution, followed by a diffuse ion channel redistribution along
the demyelinated axon (Craner et al., 2004b; Waxman, 1992; Craner et al.,
2004a). To meet this increase in energy demand, mitochondria respond with
an increase in numbers, speed and size in the demyelinated axon, termed
the axonal response of mitochondria to demyelination (ARMD).
The phenomenon of the ARMD is described in the literature and
observed in demyelinated axons in MS autopsy tissue as well as in vitro
neuronal cell culture (Mahad et al., 2009; Witte et al., 2009; Zambonin et al.,
2011; Ohno et al., 2011; Kiryu-Seo et al., 2010; Ohno et al., 2014). This
increase in mitochondrial parameters seems to be a compensatory
mechanism to deal with the increase in energy demand in the demyelinated
Chapter 7. Discussion 169
axon, which stems from the loss of trophic support from the
oligodendrocyte and increased sodium influx caused by the redistribution
of Nav1.2 and Nav1.6 along the axon (Craner et al., 2004b; Waxman, 2006;
Mohd, 2010; Albers and Siegel, 1998; Lores Arnaiz and Ordieres, 2014). The
literature on the details of mitochondrial dynamics in the context of
demyelination is limited, with only the increase in the speed of
mitochondrial transport after demyelination being reported so far
(Kiryu-Seo et al., 2010). Where these additional mitochondria in the
demyelinated axon come from, whether it is by transport from the cell body,
biogenesis directly in the axon or transport from another part of the axon to
the demyelinated site, has not been studied. Furthermore, the dynamics of
mitochondrial fusion, which can be assumed to be different, judging from
the change in mitochondrial morphology in demyelinated axons, has not
been studied so far (Mahad et al., 2009; Witte et al., 2009; Zambonin et al.,
2011; Ohno et al., 2011; Kiryu-Seo et al., 2010).
Another important aspect of neuronal mitochondria in multiple sclerosis
is that they harbour mtDNA deletions, which lead to changes in the activity
of the complexes of the mitochondrial electron-transport-chain (ETC) (Dutta
et al., 2006; Campbell et al., 2011; Broadwater et al., 2011; Witte et al., 2013;
Kim et al., 2010; Hares et al., 2014; Fischer et al., 2013; Haile et al., 2017a).
These mtDNA deletions were found in the cell bodies of neurons in the
cortex of MS autopsy tissue, which were also deficient for complex IV
activity (Campbell et al., 2011). Furthermore, it has been reported, that
neurons in the MS cortex display a decrease in expression of genes
responsible for mitochondrial upkeep (Witte et al., 2013). As dysfunctional
mitochondria display an increase in ROS production and are not able to
efficiently generate ATP to meet the required energy demands, the question
is raised what consequence it might have on the demyelinated axon if these
deficient mitochondria from the cell body would be transported to the site
of demyelination (Brand and Nicholls, 2011; Wang et al., 2013). To study the
effect of mitochondrial DNA deletions and complex IV deficiency, mouse
models with complex IV knock-out were created in the Mahad lab.
Preliminary data shows, that there is a decrease of mitochondrial content in
myelinated axons in these mutants, and that mitochondria deficient in
complex IV activity appear in the axon following demyelination with
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lysolecithin.
For the determination of the timecourse of the ARMD, how it develops
over time after demyelination, a cerebellar slice culture system with
lysolecithin mediated demyelination was used in this study. These
cerebellar slices were then stained with IHC to determine mitochondrial
occupancy, size and numbers at different timepoints after demyelination. To
study the transport and fusion dynamics of mitochondria after
demyelination and to determine where these additional mitochondria after
demyelination come from, a lentivirus expressing a green-to-red
photoconvertible protein was used, which allowed to differentiate between
mitochondria being transported from either direction and to study the
amount of fusion in the demyelinated axons of PC in cerebellar slices.
Furthermore, different small molecule compounds that are able to
manipulate mitochondrial dynamics were to used to study their effect on
the ARMD and axonal health following demyelination (Cassidy-Stone et al.,
2008; Bordt et al., 2017; Shchepina et al., 2012; Desouza and Shivaswamy,
2010; Skov et al., 2008; Bogacka et al., 2005; Ghosh et al., 2007; Corona and
Duchena, 2016; Miglio et al., 2009; Hao et al., 2010). To model the
mitochondrial deficiency found in MS neurons, cerebellar brain slices from
COX10fl/fl-Thy1 − Cre − ERT2+− mutant mice were used, to study the
impact of a COX10 deletion, which leads to complex IV deficiency, has on
the ARMD in vitro. The effect of the COX10 deletion on the ARMD in vivo
was studied in parallel by Graham Campbell and other members of the
Mahad lab, my contribution to this was to determine to earliest timepoint
after the induction of deficiency with tamoxifen, where there is significant
deficiency, but no structural change within the neurons of the
COX10fl/fl − Thy1− Cre− ERT2+− mutant mice.
7.2 Major findings of this thesis
7.2.1 Timecourse of the ARMD
The timecourse experiment of the ARMD after demyelination with
lysolecithin and IHC staining at different timepoints after demyelination,
showed a bell shaped curve of increase and decrease of mitochondrial
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parameters over the time analysed. The mitochondrial occupancy of the
axon in percent increased sharply 24 hours after demyelination and
continued to rice until reaching a peak at 4 days after lysolecithin was
removed from the slice culture medium. After the peak the mitochondrial
occupancy decreased again at 7 and 12 days after demyelination, while
never reaching the control level of myelinated axons. The mitochondrial
number in the axon after demyelination already reached its peak at 24 hours
after removing lysolecithin, with only marginal but non-significant increase
at 5 days after demyelination. Like the mitochondrial occupancy, the
mitochondrial number in the axon decreased again at 7 and 12 days after
removing lysolecithin. The average size of the single mitochondrion
followed a similar change after demyelination, with significant increase at
24 hours after demyelination and reaching its peak at 4 days, and finally
decrease again at 7 and 12 days after removing lysolecithin. These
observations hint at either a transport of mitochondria from the cell body to
the demyelinated axon, or local biogenesis in the axon, following
demyelination. The second conclusion that can be drawn from this data set
is that the ARMD is mounted soon after demyelination by enhancing
mitochondrial numbers and there is an increase in mitochondrial fusion
over the days following demyelination.
This bell shape curved increase and decrease of mitochondrial
parameters in the demyelinated axon, shows that the mitochondria in the
cell need a certain amount of time to adequately respond to the increase in
energy demand after the loss of myelin. This leaves the axon in a vulnerable
state until the ARMD is fully mounted and possibly beyond that point. In
MS there is the additional component of inflammation, which most likely
damages the axons in this vulnerable state even more than axons that have
already mounted a sufficient response to the increase in energy demand
after demyelination. This means that the ARMD can potentially be
enhanced or sped up to decrease the timespan during which the
demyelinated axons are in this vulnerable state and possibly lead to axonal
protection. Another observation that can be made from this bell shaped
curve is that the mitochondrial occupancy goes down again after a certain
amount of time, which could indicate remyelination of the axons leading to
a decrease in energy demand. The mitochondrial occupancy however does
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not return to the baseline level during the timepoints measured, indicating
that the energy demand is not (yet) in a normal range, this observation was
also reported in a study of remyelinated axons in MS autopsy tissue
(Zambonin et al., 2011). To determine where this additional mitochondria
seen in the ARMD come from and how much greater the fusion rate in the
demyelinated axon is compared to the myelinated axon, a lentivirus with
photoconvertible protein was used in the following experiments.
7.2.2 Mitochondrial dynamics in myelinated axons
For the mitochondrial dynamics experiment first myelinated and
unmyelinated axons of Purkinje cells in cerebellar slices were analysed. For
this a lentivirus expressing mEOS2, a photoconvertible protein with
attached mitochondrial targeting sequence, was injected into the Purkinje
cell layer using a picospritzer 1 hour after the slicing procedure (McKinney
et al., 2009). At 14 days after injection of the virus, the slices were used for
living imaging on a Zeiss LSM 880 with airyscan module, mitochondrial
transport speed and direction of transport as well as fusion dynamics were
analysed by using ImageJ. Unmyelinated axons did either not myelinate
during the 14 days until live microscopy or were demyelinated by an
unknown event after the slicing procedure. In the unmyelinated axons a
trend of increased anterograde transport of mitochondria and a significant
increase in retrograde transport was found. There was also a significant
increase of mitochondrial transport speed both in anterograde and
retrograde direction in the unmyelinated compared to the myelinated
axons, as well as a significant increase in fusion rate in the unmyelinated
axons of PC. Apart from comparing the mitochondrial fusion and transport
dynamics in unmyelinated and myelinated axons, this experiment set out to
determine the ’baseline’ mitochondrial dynamics in myelinated PC axons in
cerebellar slices to compare it with axons demyelinated with lysolecithin in
the next experiment.
7.2.3 Mitochondrial dynamics in demyelinated axons
The main aim of this thesis was to determine the transport and fusion
dynamics in demyelinated PC axons and to determine if the additional
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mitochondria in the demyelinated axon are transported from the cell body
or another part of the axon to the demyelinated site. For this experiment the
same experimental procedure as in the analysis of mitochondrial dynamics
in myelinated PC axons was used, except that demyelination with
lysolecithin was done for 17 hours at 13 days after the slicing procedure and
imaging was done right after removing the lysolecithin. The analysis of the
demyelinated axons show a significant increase of mitochondrial
anterograde transport, as well as a significant increase of anterograde
transport speed. Retrograde mitochondrial transport was also significantly
enhanced in the demyelinated compared to the myelinated axons, while the
retrograde speed not was different between the two groups. There was also
significantly more fusion taking place in the demyelinated axons compared
to control. Because the axon area converted was right next to the AIS, it was
possible to show that the newly transported mitochondria coming in from
the anterograde direction are being transported from the cell body.
Another part of this experiment was to determine if this observed
increase in mitochondrial transport and fusion is caused by the process of
demyelination and not some other effect of lysolecithin on the neurons. For
this experiment cerebellar brain slices of the shiverer mutant were used, as it
is reported in the literature that there is an increase of mitochondrial
number and activity in this dysmyelination mutant (Andrews et al., 2006).
Shiverer slices were cultured for 14 days until imaging and lysolecithin was
either added the day before imaging or not. None of the parameters
measured showed a significant difference between the shiverer with or
without lysolecithin treatment, suggesting that the increase in
mitochondrial parameters after lysolecithin is an effect of the demyelination
rather than a secondary effect of the lysolecithin on the neurons. The
number of mitochondria transported in anterograde direction as well as the
anterograde mitochondrial speed of the shiverer slices without lysolecithin
was very similar to the wild-type demyelinated slices, while the fusion rate
and number of mitochondria being transported in retrograde direction was
more similar to the myelinated axons. The shiverer with lysolecithin
treatment showed slightly, although not significantly, lower movement
speed of mitochondria, but otherwise no difference to the shiverer without
lysolecithin treatment.
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In summary this experiment showed that there is a significantly
increased anterograde transport of mitochondria from the cell body to the
demyelinated part of the axon, with an increase in transport speed and
enhanced fusion of the newly transported mitochondria with the stationary
mitochondrial sites within the axon. The mitochondrial dynamics in the
shiverer were not increased with lysolecithin treatment, which suggests that
this effect was due to demyelination itself and not some other effect of
lysolecithin on the axons. This finding implies that the mitochondria
deficient for complex IV found in neuronal cell bodies in the MS cortex, will
be transported to the demyelinated axon upon demyelination. The already
injured axon might not be able to cope with the increased energy demand,
since the dysfunctional mitochondria are not able to produce ATP efficiently
and might increase the ROS mediated damage to the axon.
7.2.4 Manipulations of the ARMD
Manipulation of mitochondrial dynamics has been reported to be
neuroprotective, as it was shown that enhancing mitochondrial transport
aides in the regeneration of axons after axotomy, inhibition of mitochondrial
fission ameliorates axonal damage after capsaicin treatment and increasing
mitochondrial biogenesis was shown to be protective in a model of
parkinson’s disease (Zhou et al., 2016; Chiang et al., 2015; Scholpa et al.,
2018a). To test the effect that manipulating several mitochondrial
parameters has on the axonal health after demyelination with lysolecithin,
different compounds were added to the slice culture medium before
demyelination (Cassidy-Stone et al., 2008; Bordt et al., 2017; Shchepina et al.,
2012; Desouza and Shivaswamy, 2010; Skov et al., 2008; Bogacka et al., 2005;
Ghosh et al., 2007; Corona and Duchena, 2016; Miglio et al., 2009; Hao et al.,
2010).
The first experiment was the inhibition of of mitochondrial transport
with the ATPase inhibitor oligomycin, which is reported to completely
inhibit mitochondrial transport at a concentration of 20µM (Zala et al., 2013).
To not cause too severe ATPase inhibition, as this would be detrimental on
axonal health in itself, a lower concentration of 0.25µM was used for the
axonal health experiment. This lower concentration already decreased the
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mitochondrial occupancy of the axons after demyelination compared to
lysolecithin treatment alone, although not significantly. The average size of
an mitochondrion was decreased after treatment with oligomycin and the
number of mitochondria increased, again no statistical significance in both
cases. The greater number of smaller mitochondria after ATPase inhibition
could be explained by the fragmentation and subsequent degradation of
mitochondria, which is to be expected after ATP depletion. The effect of
oligomycin treatment after demyelination on axonal health was detrimental,
as the axonal bulb area increase significantly 24 hours after treatment. This
negative effect can be explained by both inhibition of mitochondrial
transport, shown by the decrease of mitochondrial occupancy, as well as the
expected reduced ATP production after oligomycin treatment. Oligomycin
was also used for a live imaging experiment, to determine if the increase of
green in red fluorescence over time is really a consequence of mitochondrial
fusion rather than transport back of the green mEOS2 protein into the
stationary red mitochondria. For this a 20µM concentration of oligomycin
was used to completely block mitochondrial transport and assess the green
in red fluorescence change over 20 minutes. This experiment showed that
without mitochondrial transport there is a constant decrease of the green in
red fluorescence, which demonstrates that the green in red increase
observed in the mitochondrial dynamics experiments is really a
consequence of ongoing mitochondrial fusion, rather than transport back of
green mEOS2 protein into the stationary red mitochondria.
The second manipulation was the inhibition of mitochondrial fission
with the supposedly Drp-1 specific inhibitor mdivi-1 lead to a significant
increase of mitochondrial occupancy, already in the myelinated axon and an
even further increase of mitochondria in the demyelinated axons
(Cassidy-Stone et al., 2008; Bordt et al., 2017). The size of an average
mitochondrion was significantly increased as well in both myelinated and
demyelinated slices. A curious observation was the increase in
mitochondrial number in the myelinated slices, which is not expected after
treatment with an inhibitor of mitochondrial fission. Another unexpected
observation was the increase of axonal bulbs in the mdivi-1 treated slices
compared to the untreated control, as it was expected for the inhibition of
mitochondrial fission to be protective, or at least not detrimental, to axonal
Chapter 7. Discussion 176
health. Recently however, it was reported that mdivi-1 is not a very good
inhibitor of mdivi-1, but instead a very efficient inhibitor of complex I of the
ETC (Bordt et al., 2017). This could explain the negative effect on axonal
health, as inhibition of complex I decreases the ATP production of
mitochondria as well increased production of ROS, as well as the mediocre
effect on mitochondrial area. The increased occupancy in the myelinated
axons, could be a consequence of the decrease in energy production of the
inhibited mitochondria and compensatory reaction in form of transport of
additional mitochondria to the axon, as well as the subtle but significant
increase in mitochondrial area due to the (unspecific) inhibition of drp1.
Lastly the effect of increased mitochondrial biogenesis on axonal health
after demyelination with lysolecithin was tested. Pioglitazone, which was
used in this experiment, was shown to increase mitochondrial biogenesis by
enhance the expression of PGC-1α and TFAM (Desouza and Shivaswamy,
2010; Skov et al., 2008; Bogacka et al., 2005; Ghosh et al., 2007; Corona and
Duchena, 2016; Miglio et al., 2009). Similar to mdivi-1 pioglitazone
increased the mitochondrial occupancy, number and size in the myelinated
axons compared to control, although the n-number used was too low to
reach significance. In the demyelinated axons the mitochondrial parameters
only showed a slight trend towards an increase with pioglitazone treatment
compared to demyelinated control. The axonal health after pioglitazone
demyelinated slices was significantly better when taking into account the
bulb size, but lost significance when only comparing total bulb number,
both values were corrected for total axonal area. Increasing mitochondrial
biogenesis seems to be the most promising manipulation tested during this
thesis, as it was the only manipulation showing a significant reduction of
axonal bulbs after treatment. Increasing mitochondrial transport is another
neuroprotective treatment, which was not tested within this thesis and
could be a promising target, as it was reported to be protective in models of
axonal damage (Zhou et al., 2016).
7.2.5 Modelling mitochondrial deficiency
Previous research from the Mahad lab, as well as several other independent
research groups around the world, showed that neurons in MS harbour
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mtDNA defects and display a down regulation of important mitochondrial
genes, which subsequently lead to deficiencies of the ETC (Dutta et al., 2006;
Campbell et al., 2011; Broadwater et al., 2011; Witte et al., 2013; Kim et al.,
2010; Hares et al., 2014; Fischer et al., 2013; Haile et al., 2017a). As the
experiment of this thesis were done on wild-type neurons of the cerebellum,
the aim of this experiment was to model mitochondrial complex IV
deficiency in cerebellar slices. For this cerebellar slices of
COX10fl/fl − Thy1 − Cre − ERT2+− mutant mice were generated and
mitochondrial complex IV deficiency was induced by the addition of
tamoxifen or 4-OHT to the slice culture medium. Even after 4 weeks in
culture PC in the slices did not show any deficiency of mitochondrial
complex IV. A possible explanation for this finding could be that the
mitochondrial turnover in PC is too slow to induce any significant
deficiency in that time frame, but since the health of the slices started to
deteriorate after 3 to 4 weeks, it was not possible to produce complex IV
deficient PC in cerebellar slices during this thesis.
In parallel to the experiments conducted for this thesis, Graham
Campbell and other members of the Mahad lab performed in vivo
experiments with the COX10fl/fl − Thy1 − Cre − ERT2+− mutant mice.
My contribution to this set of experiments was to determine the earliest
timepoint where significant deficiency can be found in the neurons, but no
structural change has occurred yet, as this would be the optimal timepoint
for demyelination. The analysis of several different cellular markers
determined VGlut1 positive synapses as the most sensitive marker for
structural change after the induction of deficiency. Subsequently different
timepoints after the induction of deficiency with tamoxifen were analysed
by IHC staining for VGlut1 and showed a significant decrease of VGlut1
positive synapses in the ventral horn of the spinal cord at 10 weeks post
induction of deficiency. There was still a trend to decreased number of
VGlut1 synapses at 8 weeks and a slight trend at 6 weeks post induction of
deficiency. As the earliest timepoint stained,
COX10fl/fl − Thy1 − Cre − ERT2+− mutant mice 4 weeks after tamoxifen
injection, no loss of VGlut1 positive synapses was observed. The second
part of this in vivo analysis, was to determine the mitochondrial complex IV
deficiency in the dendrites of neurons in the spinal cord at 10 weeks and 4
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weeks after induction of mitochondrial complex IV deficiency. At 10 weeks
post tamoxifen injection there was significant increase in mitochondrial
deficiency in the cervical ventral horn, while the n-number in other regions,
due to significant tissue damage in the paraffin sections, was not high
enough to reach statistical significance. Other mitochondrial parameters
measured were not significantly different between mutant and control, only
the mitochondria area showed a trend towards reduced area in the mutant.
This observation, altough not signifcant, was similiar in another model of
mitochondrial deficiency used in the Mahad lab, which showed a reduction
of mitochondrial mass in the myelinated axons over time. Already at 4
weeks post induction of deficiency the complex IV deficiency in the cervical
ventral horn could be observed, while other parameters measured were not
different between mutant and control. These findings indicate week 4 after
the induction of deficiency with tamoxifen as the earliest timepoint were
there is significant deficiency in the neurons of the cervical ventral horn,
while there is no significant structural change in the VGlut1 positive
synapses. Therefore, 4 weeks after injection of tamoxifen would be the ideal
timepoint for demyelination with lyoslecithin to study the effect of
demyelination on neurons with complex IV deficiency.
7.3 Conclusion
MS was long regarded primarily as a white matter disease, although the
involvement of the grey matter in the pathology of MS is known for well
over a century, only in recent decades the interest in the grey matter came
more into focus (Love, 2006; Popescu and Lucchinetti, 2012a). Now it is
widely accepted that MS is a multi focal disease affecting both white matter
and grey matter in varying amount, but are mostly dealt with like they are
separate aspects of this disease (Love, 2006; Popescu and Lucchinetti, 2012a;
Mahad, Trapp, and Lassmann, 2015). The neuron however connects these
two aspects as it is affected both at the soma in the grey matter, as well as in
the distal axon residing in the white matter and damage to the neuronal cell
body affects the health status of the axon and vice versa. The axons in MS
are compromised by inflammation, which affect axonal transport and
energy production (Sorbara et al., 2014; Mahad, Trapp, and Lassmann,
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2015). Demyelination of the axon further worsens the situation by
increasing the energy demand in the axon via the redistribution of sodium
channels along the axon and the excess sodium that has to be pumped out
of the axolemma (Craner et al., 2004b; Waxman, 2006; Mohd, 2010; Albers
and Siegel, 1998; Lores Arnaiz and Ordieres, 2014). To combat this increase
in energy demand and decrease in local energy production, the amount of
mitochondria in the axon is increased in demyelinated axons in MS (Mahad
et al., 2009; Witte et al., 2009; Zambonin et al., 2011; Ohno et al., 2011). It is
not known how this ARMD comes about or where these additional
mitochondria observed in the demyelinated axons come from.
The aim of this thesis was to determine the mitochondrial dynamics in
cerebellar brain slices after demyelination with lysolecithin, manipulate
mitochondrial dynamics to preserve axonal health and to model
mitochondrial deficiency in vitro. The timecourse experiment of the AMRD,
revealed a bell shaped curve of mitochondrial occupancy of the axon over
time, with sharp increase until reaching a plateau, before decreasing again.
This response is mediated by fast transport of mitochondria into the axon
and fusion of newly transported mitochondria with stationary mitochondria
over time. These newly transported mitochondria are coming from the cell
body and their movement speed is increased compared to the myelinated
axon, while fusion rate within the demyelinated axon is also enhanced.
Blocking mitochondrial transport with oligomycin showed that the increase
of green-in-red fluorescence is truly an effect of fusion and not mediated by
the transport back into the stationary mitochonria of the mEOS2 protein.
The fact that the additional mitochondria, observed after demyelination, are
coming into the axon from the cell body further stresses the important
connection between cell body and axon, as the health status of the
mitochondria in the cell body is of vital importance for the future health
status of the axon, which with inflammation and demyelination is already
in a state of virtual hypoxia (Trapp and Stys, 2009). The increased energy
demand in the axon also puts stress on the cell body as increased transport
of mitochondria from the cell body to the axon is needed to meet this
increase in demand. Furthermore, it was shown that in models of MS the
transport of mitochondria is already affected in non-demyelinated axons,
leading to axonal structural changes and sparsity of mitochondria in the
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distal part of the axon, stressing the importance of mitochondrial transport
in MS (Sorbara et al., 2014). This sparsity of mitochondria in the distal
axonal part, along with the increase in syntaphilin along the axon, which
stops the newly transported mitochondria in the axon, could potential lead
to drastic reduction in mitochondria in the synapses and consequently
synapse loss, which was shown to be widespread in MS.
To determine if this increase of mitochondrial dynamics seen in the
demyelinated axons is not an effect of the lysolecithin shiverer mutant slices
with or without lysolecithin treatment were used, as it was reported that
there is an increase of mitochodnrial content in the shiverer mutant.
Lysolecithin treatment of shiverer mutant slices showed that the effect seen
in the wild-type demyelinated slices is not a secondary effect of lysolecithin,
but a consequence of demyelination, as the mitochondrial dynamics did not
differ between treated and untreated shiverer mutant slices. Proper
myelination seems to ’put the brakes on’ mitochondrial dynamics as it not
only increases the speed in propagation of action potentials, but also
decreases the amount of energy needed to keep up neuronal communication
and therefore decreases the need for an increase in mitochondrial dynamics
(Neishabouri and Faisal, 2011; Saab, Tzvetanova, and Nave, 2013).
Several experiments with different small molecule compound
demonstrated that the inhibition of mitochondrial fission, with mdivi-1
increases mitochondrial content of the axon and is detrimental to axonal
health, but it is more likely that the detrimental effect on axonal health is
caused by the inhibition of complex I which is supposed to be significant
with mdivi-1 treatment (Cassidy-Stone et al., 2008; Bordt et al., 2017). It was
reported earlier that decreasing excessive mitochondrial fission is protective
in an in vitro model of Parkinson’s disease, but a different compound, which
is a specific inhibitor of mitochondrial fission (P110) without effect on
complex I, was used, which could explain the different findings (Qi et al.,
2013). Similarly to the inhibition of mitochondrial fission, the blockage of
mitochondrial transport, and reduction of ATP synthesis, with oligomycin
was found to be detrimental on axonal health, while decreasing the
mitochondrial content in the treated axons (Zala et al., 2013; Shchepina
et al., 2012). This detrimental effect on axonal health however was expected
and confirms the importance of mitochondrial transport for the axon. Only
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the increase of mitochondrial biogenesis with pioglitazone showed a
significant improvement of axonal health after demyelination, when taking
the size of axonal bulbs into account (Desouza and Shivaswamy, 2010; Skov
et al., 2008; Bogacka et al., 2005; Ghosh et al., 2007; Corona and Duchena,
2016). Increasing mitochondrial biogenesis, as the decrease of mitochondrial
fission, was shown to be protective in an in vitro model of Parkinson’s
disease, but none of these substances was used in the context of
demyelination or MS (Scholpa et al., 2018b). Another possible manipulation
for rescuing axonal health after demyelination is the acceleration of
mitochondrial transport, which was shown to enhance axonal regeneration
after transection, but was not used in a model of demyelination thus far
(Zhou et al., 2016). The hypothesis for this experiment would be that the
ARMD is accelerated and would reach its peak earlier than the 4 days after
demyelination observed. This acceleration of ARMD potentially is also
taking place in the pioglitazone experiment as the increase in mitochondrial
biogenesis supplies more mitochondria to be transported into the
demyelinated axon. But further investigation of the pioglitazone treatment
as well as experiments involving increased mitochondrial transport are
needed to test this hypothesis.
The experiments conducted for this thesis demonstrate that the health
status of mitochondria in the cell body is important for the fate of the axon
after demyelination, since the mitochondria from the cell body are the ones
supplying the additional organelles after demyelination. If the cell body
harbours dysfunctional mitochondria, which was demonstrated in the MS
cortex, demyelination leads to an influx of dysfunctional mitochondria into
the already damaged axon and subsequently will lead to energy deficiency,
enhanced oxidative damage and eventual death of the axon (Dutta et al.,
2006; Campbell et al., 2011; Broadwater et al., 2011; Witte et al., 2013; Kim
et al., 2010; Hares et al., 2014; Fischer et al., 2013; Haile et al., 2017a). This
deficiency of cell body mitochondria has to be modelled in a disease
relevant model and needs to be addressed in potential therapies. Although
mitochondrial deficiency is difficult to target, it was recently shown that
deficiency in different complexes of the ETC, can be treated by hypoxia and
compounds activating the hypoxia responsive pathways (Jain et al., 2016;
Russell, Lightowlers, and Turnbull, 2016). Although contra intuitive at first
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sight, the decrease of dependence, maybe via an increase of glycolosis, on
these deficient mitochondria could lead to decreased ROS and subsequently
improved cellular health (Jain et al., 2016; Russell, Lightowlers, and
Turnbull, 2016). The artificial upregulation of hypoxia induced pathways,
could be even more relevant to MS as it was shown that mitochondrial
deficiency impairs the ability of up regulation of the hypoxia involving
pathways (Jain et al., 2016; Russell, Lightowlers, and Turnbull, 2016).
However, if this principal is of use in the treatment of MS and relevant
disease models, where a state of virtual hypoxia is present, has yet to be
investigated. One of the caveats of this thesis is that the model and methods
used represent a reductionist view of the problem on hand, as there are
many more components playing a role in MS, which include inflammation
and various types immune cells that are present in the MS lesions, focal
instead of total demyelination, as well as mitochondrial deficiencies in the
neurons, which all play a significant part in MS pathology and were not
addressed in the experiments conducted for this thesis. There is also chronic
demyelination going on in MS, especially in the progressive phase of the
disease, as opposed to the acute demyelination used for the experiments of
this thesis.
The next step would be to determine if interventions that already
showed a protective effect in wild type demyelinated axons, can also rescue
demyelinated axons of neurons that contain a significant number of
dysfunctional mitochondria. The ideal experimental setup for this would be
a microfluidic chamber system, which not only allows to have a pre
determined directionality of axons, but also offers the possibility to treat the
cell body and axon separately. This enables to inhibit different complexes of
the ETC in the cell body compartment and demyelinate the axonal chamber
with lysolecithin to determine the effect of mitochondrial dysfunction on
demyelinated axons and to test if different treatments of the cell body have
an effect on axonal health. It was shown that there is only around 20%
neuronal loss even at later stages of MS, while axonal loss very profound
with 60-70% and there is also a very significant loss of synapses (Magliozzi
et al., 2010; Papadopoulos, Pham-Dinh, and Reynolds, 2006; Peterson et al.,
2001; Bitsch et al., 2000b; Jürgens et al., 2016; Trapp et al., 1998). This makes
MS a very good target disease for neuroprotective therapies, as there is very
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little neuron cell body loss for a long time, as opposed to other
neurodegenerative diseases. There is still a relatively low rate of neuronal
cell loss even when the disease becomes symptomatic, because the
symptoms are not necessarily caused by neuronal death, but rather by the
loss of synapses, myelin, axon connection disturbances and inflammation.
This leaves a long window of opportunity in treating the neuronal cell
bodies and disease progression.
One future difficulty will be to translate the findings into the clinical use,
as these experiments are done on a very basic level without taking into
account that treatment can have effects on many different part of the
patients body, on different tissue types and finally on different cell types
within the tissue, because mitochondria play a vital role in every part of the
human body. Nevertheless, trying to manipulate and subsequently improve
mitochondrial dynamics in MS and other diseases of the CNS is a promising
target to modify disease course, especially in patients that are at an
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